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Abstract 
 
Oncolytic viruses are a group of viruses that preferentially replicate in cancer 
cells and are a promising cancer treatment. However, how these oncolytic 
adenoviruses kill cancer cells is not fully understood. It was long thought that 
DNA viruses utilize apoptosis to induce cell death but there is now evidence that 
adenovirus and vaccinia cytotoxicity displays features of necrosis-like 
programmed cell death.  
 
In order to investigate the role of necrosis in cell death as a result of oncolytic 
adenovirus infection, a panel of ovarian cancer cells with varying sensitivities to 
the oncolytic adenoviral mutant dl922-947 was used. Cells infected with dl922-
947 displayed key features of necrotic death. Using necrosis inhibitors 
necrostatin-1, necrosulfonamide, GSK2791840B, GSK2399872B and GSK2393843A, 
as well as RNAi-mediated knockdown of RIPK1, RIPK3 or MLKL, I showed that 
cells undergo RIPK3-dependent necrosis and that blockage of the downstream 
effector mixed lineage kinase domain-like (MLKL) attenuated cell death.  
 
While Tumour necrosis factor-α (TNF-α)-induced programmed necrosis(Laster, 
Wood and Gooding 1988) relies on the (RHIM)-dependent interaction of RIPK1 
and RIPK3  (Li et al. 2012, Wu et al. 2014), RIPK1 seems to be redundant for 
adenovirus-induced death. Further, the addition of TNF-α blocking antibody to 
virus-infected cells showed no effect on either cell death. 
 
Using a RIPK3 overexpression model, I showed that the amount adenovirus-
induced cell death correlated with the amount of RIPK3 expression and that 
RIPK3 expression did not affect virus production, infectivity or the expression of 
viral proteins. 
 
Further, in vivo experiments using human xenografts showed that expression of 
RIPK3 significantly improved anti-tumour activity following intra-tumoural 
injection of dl922-947. 
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PPP2R1α Protein phosphatase 2 regulatory subunit alpha 
pRB  Retinoblastoma protein 
PTEN  Phosphatase and tensin homologue 
qRT-PCR Quantitative real time polymerase chain reaction 
RGD  Arg-Gly-Asp 
RID  Receptor internalization and degradation 
RIPK1  Receptor interacting protein kinase 1 
RIPK3  Receptor interacting protein kinase 3 
RNA  Ribonucleic acid 
ROS  Reactive oxygen species  
SDS  Sodium dodecyl sulphate 
s   Second 
SEM  Standard error of mean 
siRNA  Small interfering RNA 
SMAC  Second mitochondrial-derived activator of caspases 
SSC  Side scatter 
		
18	
STDEV  Standard deviation 
TAA  Tumour-associated antigens 
TSA  Tumour-specific antigens 
TBS  Tris-buffered saline 
TBST  Tris-buffered saline tween-20 
TBT  Tris-buffered Tween 
TBTB  Thiazolyl Blue Tetrazolium Bromide 
TCID50  Tissue culture inhibitory dose 50% 
TCR  T cell receptor 
TEMED Tetramethylethylenediamine 
TERT  Telomerase reverse transcriptase 
TK  Thymidine kinase 
TLR  Toll-like receptor 
TNFR  Tumour necrosis factor receptor 
TNF-α  Tumour necrosis factor α 
TP53  Tumour protein p53 
TRADD Tumour necrosis factor receptor type 1-associated death domain 
TRAF TNF receptor associated factor 
TRAIL TNF-related apoptosis-inducing ligand 
TRIF TIR-domain-containing adapter-inducing interferon-β 
TZM Temozolomide 
TSZ Tnf-α, smac mimetic and zVAD-fmk 
TWEAK TNF-like weak inducer of apoptosis 
UK United Kingdom 
UMFIX Universal Molecular FIXative 
USA United States of America 
V  Volt 
VEGF Vascular endothelial growth factor 
vIRA Viral inhibitor of RIP activation 
VSV Vesicular stomatitis virus 
VV Vaccinia virus 
WT Wild-type 
XIAP X-linked inhibitor of apoptosis proteins 
Z.VAD.fmk N-Benzloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone 
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1 Introduction 
Maintaining the balance between cell death and cell division is of great 
importance in multicellular organisms (Fuchs and Steller 2015). Cancer is 
characterized by an imbalance in overall cell number, where cell division 
exceeds cell death due to mutations that can drive uncontrolled cell-cycle 
progression (Beltrami et al. 2004). Normally events like these would be expected 
to trigger a variety of tumour suppressive mechanisms that would drive the cell 
into apoptosis or cellular senescence, yet still cancer cells do not die, due to 
acquired mechanisms that promote tumour growth. In 2000, Hanahan and 
Weinberg published a paper describing those traits (Hanahan and Weinberg 2000) 
calling them the “Hallmarks of Cancer”. In 2011 the same authors wrote a newer 
version including several new hallmarks (Hanahan and Weinberg 2011). Figure 1-
1 shows defects in signalling pathways that counteract tumour growth and are 
abnormally regulated in tumours. 
 
Figure 1-1: Hallmarks of cancer                                                                                                  
Figure shows pathways that can be abnormally regulated in cancer. Figure adapted from: Cell 
2011 144, 646-674DOI: (10.1016/j.cell.2011.02.013)  
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1.1 Ovarian Cancer 
1.1.1 Epidemiology of ovarian cancer 
Ovarian cancer is the general term for non-uterine cancers arising from the 
pelvic and peritoneal area. It is the 15th most common cancer in the UK and 6th 
most common cancer in females with 7300 new cases diagnosed in the UK in 
2013 (Weblinks 1-4). Ovarian cancer is typically found in post-menopausal 
women. Figure 1-2A shows the average number of ovarian cancer cases at the 
age of diagnosis indicating that women at the ages of 65-69 have the highest 
incidence for the disease. 
 
Early detection of the disease has proved to be difficult since it often presents 
with non-specific symptoms, such as persistent abdominal pain and/ or bloating, 
back pain and loss of appetite (CRUK, 2016) and the non-availability of efficient 
and effective early screening methods (Jacobs et al. 2016, Buys et al. 2011). 
Therefore, the majority of ovarian cancers fall into the advanced stage of the 
disease (Figure 1-2B), which has only a 52.8% chance of one-year relative 
survival for women diagnosed with stage IV and only a 3% chance of five-year 
relative survival (Figure 1-2D). 
 
Overall survival rates have improved since the introduction of platinum-based 
chemotherapy in the 1980s and the introduction of paclitaxel in the 1990s, but 
survival rates have stagnated for the past 20 years (Coleman et al. 2011) as 
shown in figure 1-2C. Especially survival rates for women diagnosed with late 
stages of the disease have barely improved since they will often develop 
relapsed disease leading to chemoresistance and death. 
 
 
 
 
 
 
 
		
22	
 
Figure 1-2: Ovarian cancer statistics                                                                                                
A) Average number of ovarian cancer cases and rate per 100,000 at age of diagnosis.                       
B) Proportion of cases diagnosed at each stage in England in 2014. Data derived from Cancer 
Research UK.                                                                                                                                       
C) 2016 Ovarian cancer survival trends over time. Graph shows one and five age-standardised 
net-survival over a time frame from 1995 until 2007 for women aged 15-99 years in Australia, 
Canada, Norway, Denmark and UK.                                                                                                                 
D) One- and five-year relative survival by stage in women aged 15-99 years in England in 2012. 
Graph A, C and D adapted from Cancer Research UK, (Weblinks 1-4) Graph C taken from M P 
Coleman et al. 2011. 
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1.1.2 Origins of ovarian cancer 
As mentioned before, ovarian cancer is the general term for cancers arising from 
the pelvic and peritoneal area that share the same anatomical location; the 
ovaries. Ovarian cancer can be categorized in two main groups; epithelial 
derived tumours and non-epithelial derived tumours (Chen et al. 2003), with 
non-epithelial derived tumours being further divided into sex cord-stromal and 
germ cell tumours. Epithelial tumours are the most common type of ovarian 
cancer and can be further divided into the following subtypes: High-grade 
serous, low-grade serous, endometrioid, clear cell and mucinous cancers. 
Interestingly, some of these subtypes may be derived from non-ovarian tissues 
(Vaughan et al. 2011). For example, most mucinous invasive ovarian cancers may 
represent metastases to the ovaries, which have been derived from another solid 
cancer originating in the stomach, colon or appendix (Gastrointestinal area), 
while clear cell and endometrioid ovarian cancers are associated with 
embedding of cells of the endometrium into other organs like the ovaries, 
fallopian tubes, the lining of the abdomen, intestines or bladder, a condition 
known as endometriosis. Many high-grade serous ovarian cancers originate from 
secretory cells in the fimbriae of the fallopian tube, while low-grade serous 
ovarian cancers may originate from the cortical inclusion cysts derived from 
invaginated ovarian epithelial cells. Figure 1-3 shows where ovarian cancer can 
originate from within the pelvic and peritoneal area. 
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Figure 1-3: Origins of ovarian cancer from within the pelvic and peritoneal area          
Mucinous invasive ovarian cancers are often metastasis arising in the gastrointestinal tract but 
localise in the ovaries. Endometrioid and clear cell ovarian cancer are cancers associated and 
originating from endometriosis, while many high-grade serous ovarian cancers originate from 
secretory cells from the fallopian tube. Nature Reviews Cancer 11, 719-725 (October 2011). 
 
1.1.3 Mutations associated with ovarian cancer 
As described earlier, epithelial ovarian cancers can be categorised into four 
subgroups with each of the subgroups being associated with the occurrence of 
certain mutations. High-grade serous ovarian cancer is characterised by near 
universal TP53 abnormalities, genomic instability and abnormalities in the DNA 
copy number. They also contain low prevalence somatic mutations in NF1, 
BRCA1/2, RB1 and CDK12 (Cancer Genome Atlas Research 2011). Low-grade 
serous ovarian cancers most commonly contain mutations in BRAF or KRAS 
leading to the activation of the mitogen-activated protein kinase (MAPK) 
signalling pathway (Singer et al. 2003). About 30% of endometrioid and clear cell 
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ovarian cancers carry mutations in PI3KCA and AKT leading to the activation of 
the PI3K pathway (Banerjee and Kaye 2013). They also have frequent mutations 
in ARID1A. Mucinous ovarian cancers contain nearly universal mutations in KRAS 
and show in about 18% of all cases amplification or overexpression of HER2 
(Banerjee 2013, Anglesio et al. 2013). Table 1 shows mutations associated with 
each subtype. 
 
Table 1: Mutations associated with each epithelial ovarian cancer subtype.                         
Table adapted from G C Jayson et al. 2014. 
 High-grade 
serous 
Low-grade 
serous 
Endometrioid Clear 
cell 
Mucinous 
Mutations TP53 BRAF ARID1A ARID1A KRAS 
BRCA1/2 KRAS PI3KCA PI3KCA HER2 
ampl. 
NF1 NRAS PTEN PTEN  
CDK12 ERBB2 PPP2R1α CTNNB1  
Defective 
homologous 
recombination 
 mismatch 
repair 
deficiency 
PP2R1A  
RB1     
Alterations in 
PI3K/Ras/Notch/ 
FoxM1 pathway 
    
 
1.1.4 Treatment of ovarian cancer 
First line treatment for ovarian cancer consists of primary debulking surgery. 
However, in cases where surgery is not feasible due to patient health or 
dissemination of the tumour, neoadjuvant platinum- and taxane-based 
chemotherapy is given. In neoadjuvant chemotherapy, the patient is treated 
with chemotherapy prior to debulking surgery. Whether a patient is treated with 
debulking surgery or neoadjuvant chemotherapy first can also depend upon the 
hospital site and the approach of the gynaecological oncology surgeon. When 
patients receive neoadjuvant chemotherapy, they undergo interval debulking, 
where the debulking surgery is performed after 3-4 cycles of chemotherapy. 
Platinum-based chemotherapy, has been the standard treatment for ovarian 
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cancer for the last 40 years (Jayson et al. 2014). For the treatment of ovarian 
cancer, platinum-based chemotherapeutics like carboplatin and cisplatin are 
usually given in combination with a taxane (Usually paclitaxel but docetaxel is 
equally effective (Vasey et al. 2004)).  
 
In recent years, new treatment strategies have evolved since many women 
treated with platinum-based chemotherapy become resistant over time. One of 
those treatments involves the use of poly (ADP-ribose) polymerase (PARP) 
inhibitors for patients with mutations in BRCA1 or BRCA2. BRCA1 and BRCA2 are 
involved in the repair of DNA double strand breaks making cancers carrying these 
mutations rely on the non-homologous end joining pathway to repair DNA 
damage. Clinical trials using the PARP inhibitors olaparib, niraparib and 
rucaparib in patients carrying these mutations showed impressive anti-tumour 
responses (Fong et al. 2009, Kaye et al. 2012).  
 
Another treatment involves targeting the growth and spread of tumour blood 
vessels, a term called angiogenesis. Vascular endothelial growth factor (VEGF) is 
a signal protein that stimulates the production of blood vessels. It has been 
shown that VEGF is secreted by malignant ovarian epithelial cells (Olson et al. 
1994, Premalata et al. 2016). Bevacizumab, a monoclonal anti-VEGF antibody, 
has shown in first line trials that its addition to chemotherapy followed by single 
agent maintenance treatment improves progression-free and overall survival in 
patients (Burger et al. 2011, Perren et al. 2011). 
 
In recent years research has shown an increasing interest in the role of immunity 
in cancer progression, since it has been demonstrated that immune cells can 
recognise and kill tumour cells through the expression of tumour-associated 
antigens (TAA) and tumour-specific antigens (TSA) (Koebel et al. 2007).  The 
expression of immune checkpoint proteins on effector T-cells can contribute 
towards immune evasion of cancer cells.  Especially the immune checkpoint 
proteins cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed 
cell death protein 1 (PD-1) have drawn great attention, since their ligation can 
inhibit T-cell priming and activation or the lytic activity of effector T-cells. 
Ipilimumab a CTLA-4 targeting antibody, showed in a phase I/II trial a 11% 
response rate for ovarian cancer (1 out of 9 patients; NCT01611558). In a Phase-
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1b study treatment with with pembrolizumab (PD-1 antibody) resulted in 1 
complete response, 2 partial responses and 6 patients with stable disease from a 
cohort of 26 patients with PD-L1 positive advanced ovarian cancer (Varga A 
2015).  
 
Despite these advances in the treatment of ovarian cancer, less than 50% of all 
patients survive their disease for more than five years making it important to 
search for new therapies and treatment options. 
 
1.2 Oncolytic Virotherapy 
Oncolytic viruses are viruses that replicate selectively in tumours cells. These 
viruses specifically exploit the mechanisms that aid tumour growth, therefore 
making them selective for cancerous cells, while not affecting healthy tissues. In 
addition to their ability to infect and lyse tumour cells, virus-induced cell lysis is 
often associated with the induction of inflammation and release of damage-
associated molecular patterns (DAMPS) as well as pathogen-associated patterns 
(PAMPS) leading to a type of cell death known as immunogenic cell death (ICD). 
This in turn can stimulate an adaptive immune response enabling the immune 
system to recognize the tumour, potentially leading to anti-tumour immunity. 
Oncolytic viruses can be classed into three broad categories consisting of 1) 
native viruses, which preferentially replicate in tumour cells, 2) genetically-
modified viruses, which have can have deletions within the viral genome or 
tropism modifications and 3) genetic modified viruses that express therapeutic 
transgenes. 
 
Many pre-clinical studies have successfully demonstrated the efficacy and high 
selectivity of oncolytic viruses in vitro and vivo, with numerous making it into 
phase I/II clinical trials although only fewer into phase II or III trials.  
 
Accumulating evidence suggests that the host immune response is a critical 
factor for assessing the efficacy of oncolytic viruses (Taipale et al. 2016, Cerullo 
et al. 2012). Natural resistance from pre-existing immunity can lead to the 
production of neutralizing antibodies and can therefore lead to the elimination 
of the virus rather than the development of an adaptive immune response 
towards the tumour. Even the route of virus administration can pose challenges 
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in treatment. For systemic treatment, agents must have a high tumour tropism 
to ensure that no healthy cells are being targeted and clinical studies 
investigating virus-tumour tropism (Green et al. 2012) have been already been 
undertaken.  
 
1.2.1 Naturally oncolytic viruses 
Native or naturally occurring oncolytic viruses are replication-competent viruses 
that selectively infect and kill tumour cells without requiring any genomic 
alteration. Observations in the early 1900s showed that patients with leukaemia 
who contracted influenza, underwent periods of remission, which produced 
beneficial effects for the patients (Dock 1904, Pelner, Fowler and Nauts 1958). 
In 1950 Pack et al. described the use of a virus for the treatment of cancer. He 
observed that a patient with malignant melanoma was cleared of her tumour 
after receiving the rabies vaccine following a dog bite. Following his 
observation, he performed a small controlled study in 12 patients with 
melanoma using the Harris rabies vaccine. Two of his 12 patients showed tumour 
reduction following treatment (Pack 1950).  
1.2.1.1  Reovirus 
Reoviruses are non-enveloped double-stranded RNA viruses that naturally occur 
in the human respiratory and gastrointestinal tract. They infect a variety of cells 
but preferentially replicate in Ras-transformed cells (Strong et al. 1998, Norman 
et al. 2004, Shmulevitz, Marcato and Lee 2005). In non-Ras activated cells, viral 
replication is inhibited through the autophosphorylation of protein kinase R 
(PKR). PKR binds to viral dsRNA leading to the phosphorylation of eIF2α and the 
inhibition of protein synthesis (Stark et al. 1998, de Haro, Mendez and Santoyo 
1996). In Ras-transformed cells PKR autophosphorylation is inhibited allowing the 
translation of viral proteins. The most extensively studied oncolytic reovirus is 
Reolysin. Multiple clinical trials in prostate cancer (Gollamudi et al. 2010), 
malignant glioma (Kicielinski et al. 2014), multiple myeloma (Sborov et al. 
2014), metastatic melanoma (Galanis et al. 2012) and solid tumours (Gollamudi 
et al. 2010, Kolb et al. 2015, Morris et al. 2013) have demonstrated the safety 
and anti-tumour activity of Reolysin. In 2015 the US FDA granted Reolysin an 
orphan drug status for the treatment of malignant glioma, ovarian cancer, 
fallopian tube cancer and pancreatic cancer (FDA, 2015). 
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1.2.1.2 Paramyxoviridae 
Paramyxoviridae form a family of viruses that uses humans and birds as their 
natural hosts. Two naturally occurring oncolytic viruses that belong to this group 
are the measles virus and the Newcastle disease virus (NDV). PV701 is a naturally 
occurring attenuated strain of NDV. It is a negative strand RNA virus that 
preferentially replicates in tumour cells that have defects in interferon 
signalling. Defects in interferon signalling are believed to give tumours growth 
and survival advantages, disabling interferon’s antiviral function. Phase one 
clinical trials using PV701 have shown that it is safe to use and patients usually 
showed mild flu-like symptoms, which diminished with repeated administration. 
S. A. Laurie et al. observed tumour regression in one patient, and disease 
stabilization in four patients, who had previously progressed following standard 
anti-cancer therapy (Laurie et al. 2006). 
 
Measles virus is an enveloped single-stranded, negative sense RNA virus that 
infects the respiratory system in humans. Oncolytic measles viruses (MV) are 
based on the attenuated live Edmonston vaccine strain, which preferentially 
enters tumour cells that overexpress the CD46 (Dorig et al. 1993, Anderson et al. 
2004) receptor.  MV-NIS is a measles virus that has been engineered to express 
human thyroidal sodium iodide symporter (NIS) gene. A clinical phase I trial 
evaluated the intravenous treatment of MV-NIS in patients with recurrent or 
refractory multiple myeloma (Clinical identifier: NCT00450814) and has led to 
further phase II trials of MV-NIS for the treatment of multiple myeloma 
(NCT02192775) and patients with ovarian, fallopian or peritoneal cancers 
(NCT02364713). 
 
1.2.2 Genetically modified oncolytic viruses 
Besides naturally occurring oncolytic viruses, viruses can also be genetically 
modified to selectively replicate within tumour cells while not being able to 
replicate in healthy tissues. 
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1.2.2.1  Herpes simplex virus 1 
Herpes simplex virus 1 (HSV1) is a large enveloped double-stranded, linear DNA 
virus known to produce cold sores in humans. In 2015, Talimogene laherparepvec 
(T-VEC, Imlygic) was the first oncolytic virus approved by the US FDA for the 
treatment of melanoma (Andtbacka et al. 2015, Greig 2016). Talimogene 
laherparepvec (T-VEC) has deletions in the genes coding for infected cell protein 
34.5 (ICP) and ICP47. ICP34.5 is a neurovirulence factor with a critical role in 
viral replication, in particular suppression of the PKR/eIF2α response following 
infection. Due to its ICP34.5 deletion, T-VEC can only replicate in cells with 
defects in the PKR pathway. ICP47 is involved in inhibiting CD8+ T recognition of 
infected cells. Further, the deletion of ICP47 increases the expression of the 
US11 gene, which counteracts host-mediated shutoff of protein translation 
(Katze 1995, Attrill et al. 2002, Goldsmith et al. 1998). The insertion of 
granulocyte macrophage colony-stimulating factor (GM-CSF) leads to the 
recruitment and activation of antigen-presenting cells leading to a tumour-
specific T-cell response (Toda, Martuza and Rabkin 2000, Dranoff et al. 1993, 
Mach et al. 2000, Liu et al. 2003). 
 
 
1.2.2.2  Vaccinia virus 
Vaccinia virus is an enveloped, linear, double-stranded DNA virus that replicates 
in the cytoplasm of infected cells. JX-594, also known as Pexa-Vec is a 
replication-competent oncolytic and immunotherapeutic vaccinia virus derived 
from the Wyeth vaccine strain. It has a deletion in the thymidine kinase (TK)-
coding gene and has been modified to express GM-CSF. Pexa-Vecs cancer 
selectivity is driven by multiple mechanisms. It selectively replicates in cells 
that have activations in the epidermal growth factor receptor (EGFR)/Ras 
signalling pathway, high levels of TK and are resistant to type-I interferons 
(Parato et al. 2012). At the moment Pexa-Vec’s effectiveness in combination 
with sorafenib is being assessed in a phase III study (PHOCUS trial) 
(NCT02562755) in patients diagnosed with advanced, unresectable 
hepatocellular carcinoma (HCC). In 2013 the US FDA and EU EMA granted Pexa-
Vec orphan drug status for the treatment of HCC. 
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In vivo studies as well as clinical trials have shown that most oncolytic viruses 
are safe to use when careful safety procedures are in place. These studies have 
shown that most common treatment associated toxicity consisted of ‘flu-like’ 
symptoms. Table 2 shows further oncolytic viruses that have been evaluated in 
clinical trials.  
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Table 2: Other oncolytic viruses used in clinical trials. 
Virus group Name 
 
 
Phase of development; targeted 
tumours  
Clinical 
Identifier/ 
Outcome 
HSV1 G207 
 
Orphan drug since 2002; glioma Only Phase I 
studies 
published 
 HSV1716 
 
Ongoing; Phase I/II; malignant 
pleural mesothelioma 
NTC01721018 
 
 TBI-1401 
(HF10) 
Recruting; Phase II; for 
unresectable melanoma 
NTC02272855 
 
 PV-10 
 
Recruiting; Phase III;recurrent 
cutaneous melanoma 
NTC02288897 
Cox-
sackievirus 
CAVATAK/ 
CVA21 
Phase II completed; melanoma NCT01636882 
No results  
Seneca 
Valley virus 
NTX-010 Orphan drug since 2008; 
neuroendocrine tumours 
Only Phase I 
studies 
published 
 SVV-001 
 
Phase I; relapsed neuroblastoma, 
rhabdomysosarcoma 
NTC01048892 
No study 
results 
Maraba 
virus 
MG1MA3 
 
Recruiting; Phase I; MAGE-A3 
protein-expressing cancers 
NTC02285816 
Vaccinia 
virus 
GL-ONC1 
 
Recruting; Phase I; ovarian 
cancer, peritoneal carinomatosis, 
fallopian tube cancer 
NCT02759588 
 
 PROSTVAC+
/- GM-CSF 
Ongoing phase III; treatment of 
prostate cancer 
NTC01322490 
Reo virus Wild type 
 
Ongoing phase II; ovarian 
epithelial, fallopian tube and 
primary peritoneal cancers 
NTC01199263 
Measles 
virus 
MV-NIS 
 
Phase II; treatment of ovarian, 
fallopian and peritoneal cancers 
NCT02364713 
No study 
results 
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Despite their general safety, in 1999 the first death of a patient who 
participated in a clinical trial for gene therapy was reported. Jesse Gelsinger 
had a metabolic disorder, ornithine transcarbamoylase (OTC) deficiency, and 
joined a clinical trial run by the University of Pennsylvania in 1999, where he 
was given an infusion of an attenuated adenovirus virus, which encoded the 
corrective OTC gene (Raper et al. 2003). Four days after injection, he died due 
to a severe inflammatory immune reaction to the adenoviral vector used to 
deliver the gene. The principal investigators in this study broke several rules of 
conduct, which increased the likelihood of his death. Jesse as well as his parents 
had never been informed about the fact that several patients experienced 
serious side effects. Further, three monkeys died during pre-clinical studies due 
to severe liver inflammation and a clotting disorder. Further, he should not have 
been included in the study due to abnormal liver function tests (Sibbald 2001). 
Following this incident, the US FDA introduced two new programmes in 2000 to 
enhance patient protection. 
 
Besides their use as a single agent, oncolytic viruses can also be used in 
combination with chemotherapy and/or radiotherapy, and clinical studies 
investigating the efficacy of these combination therapies have shown a greater 
antitumour effect compared to single therapy (Xia et al. 2004, Nemunaitis et al. 
2000).  
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1.3 Adenoviruses 
1.3.1 History 
Adenoviruses were first discovered in 1953 when Rowe et al. attempted to 
establish tissue culture cell lines from tonsils and adenoidal tissue and observed 
a transmissible agent that induced spontaneous degeneration in tissue culture 
(Rowe et al. 1953). Today there are 57 different adenovirus serotypes, which 
can be classified based on their neutralization with specific antisera (Horwitz 
1996). 
 
Table 3: Adenovirus subgroups, serotypes and their respective cellular attachment 
receptors, if those have been identified. 
 ACAR, BCD46, CSA, DCD80/86, EHeparan sulphate and FDesmoglein 2 
Human Adenovirus 
subgroup 
Serotype 
A 12A, 18, 31A 
B, type 1 3B,D,F, 7F, 16B, 21B, 50B, 55 
B, type 2 11B,F, 14B,14, 34, 35B 
C 1, 2A,E, 5A,E, 6, 57 
D 8C-10, 13, 15A, 17, 19pA, 19aC, 20, 22-30, 32, 33, 36, 37B,C-
39, 42-49,51, 53, 54, 56 
E 4A  
F 40, 41A 
G 52 
 
1.3.2 Adenovirus structure 
Adenoviruses are non-enveloped, icosahedral particles of approximately 70-
100nm diameter. The capsid that surrounds the 36kbp linear dsDNA core consists 
of 240 hexon and 12 penton capsomers at the vertices with a projecting fiber, 
containing a knob domain, at each penton base. The linear dsDNA is associated 
with two major core proteins (polypeptide V and VII) and µ as well as a 55kDa 
terminal protein that is attached at the 5’ end of the linear dsDNA. Figure 1-4 
shows the simplified structure of an adenovirus virion (Doerfler 1996). 
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Figure 1-4: Simplified structure of an adenovirus virion 
 
1.3.3 Adenovirus genome 
The adenovirus genome is about 35-36kb long and shown in figure 1-5. The 
transcription of viral genes, as well as virion assembly, takes place in the 
nucleus. All genes are transcribed by RNA pol II, which is provided by the host 
cell. Genes that are being transcribed by RNA pol II give rise to multiple mRNAs 
through alternative splicing. 
 
 
Figure 1-5: Simplified transcription map of the adenovirus genome 
E: early transcription unit. L: late transcription unit. MLP: major late promoter. ITR: inverted terminal 
repeat. φ: packaging signal. pIX: protein IX. VA I and II: adenovirus VA RNA-derived miRNAs. Iva2: 
transcriptional activator of major late promoter. 
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The first genes transcribed during adenovirus replication are, in order, E1A, E1B, 
E2, E3 and E4, these genes are being referred to as early transcription units. 
Proteins of E1A are involved in activating the transcription of viral genes and 
inducing the host cell to enter S phase, while proteins of E1B are mainly involved 
in the suppression of apoptosis. Proteins of E3 are involved in supressing and 
modulating antiviral host responses. E2A and E2B are involved in the replication 
of viral DNA and whilst E4 proteins regulate transcription of viral DNA and 
mediate the nuclear export of mRNA as well as apoptosis. The inverted terminal 
repeat functions as a DNA replication origin and can be found at each end of the 
viral genome. After the initiation of viral replication the three delayed early 
viral promoters IX, IVa2 and E2 late become active (Ying, Tollefson and Wold 
2010). There are also five families of late mRNA L1 to l5, which are alternative 
splice products of the single major late transcription unit and are involved in the 
production and assembly of the virion capsid. The packaging signal φ is located 
between the left terminal repeat and the region coding for E1A and is involved 
in the packaging of the genome into virion capsids (Shenk 2001). 
 
1.3.3.1 dl922-947 genome 
The oncolytic virus dl922-947 is an adenovirus type 5 deletion mutant. It carries 
a 24 bp deletion in E1A conserved region 2 (CR2) region (Figure 1-6) and a 745bp 
deletion in E3B from Ad5 bp 30005-30750 which was then substituted with 642bp 
of heterologous DNA. This alteration leads to deletion of E3 14.7K and RID α/β 
proteins of adenovirus (Bett, Krougliak and Graham 1995). As described earlier, 
E1A is the first protein to be expressed during adenovirus infection. The CR2 
domain of E1A binds to the retinoblastoma protein (pRb), which leads to the 
release of E2F-1 from the pRb-E2F complex in quiescent cells. Free E2F will then 
stimulate cell entry into S-phase for viral replication and transactivate the 
adenovirus E2 promoter. Therefore dl922-947 can only replicate in cells that 
have abnormalities in the pRb pathway, which is the case for over 90% of human 
cancers (Sherr and McCormick 2002, Flak et al. 2010), leading to its high 
selectivity for cells with high levels of free E2F.  
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Figure 1-6: dl922-947 genome showing the position of its 24bp deletion 
Numbers indicate aminoacid position. CR: conserved region. E: early transcription unit. MLP: major 
late promoter. ITR: inverted terminal repeat. φ: packaging signal. 
 
1.3.4 Adenovirus type 5 adsorption and cell entry 
During attachment, the adenoviral fiber binds to receptors on the cell surface. 
Different adenovirus serotypes will use different cellular receptors for initial 
attachment. Table 3 shows an overview of which serotypes use which kind of 
cellular receptors for attachment. For adenovirus type 5, infection occurs 
through binding of the adenoviral fiber to the coxsackie-adenovirus receptor 
(CAR) (Bergelson et al. 1997) followed by the interaction of the penton base 
with ανβ3, ανβ5 and to a lower extent ανβ1 integrins (Davison et al. 2001, Wickham 
et al. 1993), which leads to the detachment of the viral fibers and stimulates 
integerin-mediated endocytosis of the fibreless virion into clathrin-coated 
vesicles. Inside the endosome the virus undergoes a pH-dependent process called 
uncoating, which involves the partial disassembly of the capsid within the 
endosome to mediate permeabilization of the endosomal membrane and 
facilitates the endosomal escape of partially uncoated virions into the cytosol. 
Microtubules will then transport the virus particles to the nucleus, where it will 
associate with nuclear pore complexes (NPC) leading to the release of viral DNA 
into the nucleus. After hexon and penton capsomers have been produced in the 
cytoplasm, they are imported into the nucleus for virion assembly. Infectious 
virion assembly is completed once the precursor proteins of VI, VII, VIII, µ and 
the terminal proteins are cleaved by a viral protease, which is included in the 
virus particle. Infectious virions are then being released from the cell and virus 
progeny can spread to other cells. 
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1.4 Adenoviruses in oncolytic virotherapy 
Oncolytic adenoviruses have already been used in models of pre-clinical 
research, where they have showed promising activity in metastatic breast cancer 
models (Heise et al. 2000, Bazan-Peregrino et al. 2008, Bazan-Peregrino et al. 
2013), prostate (Satoh et al. 2007), glioma (Kaliberov et al. 2016, Qiao et al. 
2015), bladder (Wang et al. 2006), pancreatic (Cherubini et al. 2011, 
Bhattacharyya et al. 2011) and ovarian cancer (Lockley et al. 2006). The huge 
diversity of DNA and RNA viruses as well as viruses with certain tropisms, offers 
a huge therapeutic window to choose from; and thanks to the development of 
new techniques we are getting more successful at selecting potent anticancer 
viruses.  
 
1.4.1 Adenovirus deletion mutants 
One of the best-described oncolytic adenoviruses is the E1B 55-kDa deleted 
adenovirus ONYX-015 (dl1520), which was originally thought to replicate 
selectively in cells that are p53-deficient. However, it wasn’t until 2004 that the 
mechanism for its selectivity was fully unravelled, when O’Shea et al. showed 
that the late functions of E1B-55K, specifically its involvement in the 
preferential export of late viral RNAs, was the main determent or its selectivity. 
Late viral export is defective in ONYX-015 and therefore restricts its replication 
in primary cells, while tumour cells that allow ONYX-015 replication provide E1B-
55Ks RNA export function (O'Shea et al. 2004). 
 
In 2000 Khuri et al. performed a trial of dl1520 in recurrent head and neck 
cancer (Khuri et al. 2000), where it was used in combination treatment with the 
chemotherapeutic drug cisplatin and 5-fluorouracil. They showed that 
combination treatment was well tolerated by patients and showed disease 
stabilization in some patients. They also observed tumour-selective viral 
replication and the induction of necrosis in injected tumours. In the following 
year Ganly et al. performed a phase I study on dl1520 (Ganly et al. 2001) in 
recurrent head and neck cancer, where they showed that intratumoural 
administration with dl1520 was well tolerated and associated with biological 
activity. This was followed up by a phase II trial performed by Nemunaitis et al. 
in 2001 (Nemunaitis et al. 2001) and a phase III randomized clinical trial by Xia 
et al. in 2004 (Xia et al. 2004). The virus used in Xia et al. study, H101, is a 
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modification of dl1520 and the world’s first approved oncolytic therapy in 
combination with chemotherapy for squamous cell cancer of head and neck or 
esophagus. Further studies and trials with dl1520 were conducted in colorectal 
cancer (Reid et al. 2001) and refractory tumours (Reid et al. 2002), where 
chemotherapy-associated anti-tumoural activity and evidence for chemo 
sensitization were observed. 
 
1.4.2 Adenoviruses with transgenes and other modifications 
Another well-described oncolytic adenovirus is called delta-24-RGD. Delta-24-
RGD is very similar to dl922-947, containing the same E1A-CR2 deletion, but 
which additionally has an RGD-4C peptide motif inserted into the adenoviral 
fiber. This motif allows the virus to anchor directly to integrins by passing 
primary CAR attachment. Various pre-clinical studies and in vivo studies (Jiang 
et al. 2014, Dembinski et al. 2010) have shown that Ad-Δ-24-RGD shows 
antitumour activity in the treatment of glioma (Fueyo et al. 2003, Avci et al. 
2015, Alonso et al. 2008), medulloblastoma (Stolarek et al. 2004), cervical 
cancer(Bauerschmitz et al. 2004) and brain tumour stem cells (Jiang et al. 
2007). ICOVIR-5 (Cascallo et al. 2007), a modified Ad-Δ-24-RGD, has shown 
potent anti-glioma effects in vivo (Alonso et al. 2007) in combination with 
RAD001 or temozolomide (TZM). In 2010 García-Castro et al. performed an 
exploratory study with ICOVIR-5 for the treatment of metastatic neuroblastoma 
(Garcia-Castro et al. 2010, Ramirez, Garcia-Castro and Alemany 2010). They 
used autologous mesenchymal stem cells (MSC) to systemically deliver ICOVIR-5. 
They showed that the treatment was well tolerated and that one patient was in 
complete remission 3 years after therapy.  
 
1.4.3 Directed evolution adenoviruses 
One of the most recent approaches in producing highly selective and potent 
anticancer viruses involved the directed evolution of adenoviruses. A pool of 
different adenovirus serotypes was grown and passaged under conditions that 
invited recombination between the different serotypes. The viral pools were 
then placed under directed selection. The pool with the highest potency (low 
IC50 (Viral particles/cell)) as measured by 3-(4,5-dimethylthiazol-2-yl0-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay and higher 
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relative potency compared to Ad5 was used. To generate highly potent viral 
agents, individual plaques from the pool with the highest potency were purified, 
and the isolated viruses were screened by MTS assay for their lytic potential. 
The result of this method, enadenotucirev (EnAd; also known as ColoAd1), is an 
Ad3/Ad11p chimeric virus with high selectivity for tumour cells and a higher 
potency than other clinical oncolytic adenoviruses, like ONYX-015 in vitro, vivo 
and ex vivo (Kuhn et al. 2008).  
 
This virus has shown to be 2-3 logs more potent and selective than ONYX-015 
(dl1520) (Kuhn et al. 2008, Bauzon et al. 2009) and is undergoing several early 
phase clinical trials including one phase 1/2 clinical trial for the treatment of 
ovarian cancer (OCTAVE). This trial recruits women with platinum-resistant 
disease, ie those whose cancer has recurred within six months of their most 
recent platinum-based chemotherapy. Besides the clinical use of EnAd, new and 
improved oncolytic adenoviruses are needed to increase the therapeutic output 
for patients. One way of improving oncolytic adenoviruses is by better 
understanding the mechanisms of viral infection, replication, spread and killing 
as well as the immune responses they elicit in vitro and vivo. 
 
The oncolytic adenoviruses described here are just very few. Table 4 shows 
further oncolytic adenoviruses that have or are being evaluated in clinical 
research. 
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Table 4: On-going and completed clinical trials using oncolytic adenoviruses 
Virus name Proposed tumour 
targeting 
mechanism 
Phase of development and 
targeted tumours 
References/ 
Clinical 
Identifier 
CG0070 pRB pathway- 
defective cells 
Phase II/III (Burke et al. 
2012) 
EnAd Unknown Phase I/II ongoing; solid 
tumours of epithelial origin, 
metastatic colorectal and/or 
bladder cancer 
NTC02028442 
dl1520/ 
ONYX-015 
Cells that provide 
E1B-55Ks function 
in late RNA export 
Phase II conducted; 
advanced sarcoma, 
metastatic colorectal 
cancer, hepatobiliary 
tumours 
(Galanis et 
al. 2005, 
Hamid et al. 
2003, 
Makower et 
al. 2003) 
dl922-947 pRB pathway 
abnormalities 
Pre-clinical studies (Lockley et 
al. 2006) 
H101 p53-deficient 
cells 
Approved therapy for 
squamous cell cancer of head 
and neck or esophagus 
(Xia et al. 
2004) 
ICOVIR-5 pRB pathway 
abnormalities 
Phase I/II completed; 
metastatic neuroblastoma 
(Garcia-
Castro et al. 
2010) 
ICOVIR-7 pRB pathway 
abnormalities 
Phase I conducted; advanced 
and refractory solid tumours 
(Nokisalmi et 
al. 2010) 
LOAd703  Phase I/IIa ongoing; 
pancreatic cancer 
NCT02705196 
ONCOS-102 pRB pathway 
abnormalities 
Phase II; unresectable 
malignant pleural 
mesothelioma 
NTC02879669 
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1.5 Cell Death Mechanism 
As described earlier one hallmark of cancer is its ability to evade cell death 
mechanism leading to an imbalance in overall cell number due to mutations or 
alterations in proteins that are involved in cell death initiation and/or 
execution. Currently we can distinguish between three regulated cell death 
pathways: apoptosis, autophagy and necroptosis (Fuchs and Steller 2015). 
 
1.5.1 Type I cell death: Apoptosis 
Apoptosis is the best-defined cell death pathway and is well conserved between 
higher multicellular organisms. This pathway has evolved to keep the number of 
cells tightly regulated by controlling the rate of cell division as well as by 
controlling the rate of cell death. 
  
Apoptosis is morphologically characterized by cell shrinkage, chromatin 
condensation and fragmentation of the cell (Kroemer et al. 2009) and is 
regulated by a variety of stimuli coming from within a cell (Intrinsic cell death 
pathway) like the production of reactive oxygen species (ROS) or from its 
environment (Extrinsic cell death pathway) e.g. TNF receptor ligation (Steller 
2008). The intrinsic cell death pathway is mainly dependent on the activation of 
caspases, which are aspartate-specific cysteine proteases that play an important 
role in the induction, transduction and amplification of apoptotic signals(Fan et 
al. 2005). The extrinsic pathway is stimulated through the binding of an 
extracellular ligand with its cell surface receptor. One example is the tumour 
necrosis factor (TNF) superfamily, which interacts with a corresponding 
superfamily of receptors.  Those receptor-ligand interactions are involved in 
different biological events as e.g. proliferation, through the activation of the 
NF-κB pathway, differentiation of immature myeloid cells (Sade-Feldman et al. 
2013), inflammation and apoptosis signalling (Igaki et al. 2002). Defects in TNF 
signalling are associated with autoimmune disorders and cancer. Deregulation of 
TNF can lead to immune-mediated inflammatory diseases like Crohn’s disease 
and rheumatoid arthritis, which can be treated with TNF-blocking antibodies. 
The extrinsic and intrinsic apoptosis death pathways are further described in 
detail in figure 1-7, below. 
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Figure 1-7: Simplified apoptotic signalling in mammals 
Apoptosis can be induced through the extrinsic or intrinsic pathways. Extrinsic apoptosis signalling 
is induced by the interaction of death ligands (FasL, TNF-α, TRAIL etc.) with their corresponding 
transmembrane receptors. This ligation leads to the formation of a Death-inducing signalling 
complex (DISC), which will lead to the activation of the initiator caspase-8 and the activation of the 
executioner Caspases 3, 6 and 7 resulting in apoptosis. Low levels of caspase-8 can also lead to 
the activation of Bak and Bax through cleavage of Bid to the truncated protein tBid. Intrinsic 
apoptosis signalling on the other hand is initiated by a variety of stimuli coming from within the cell, 
like DNA damage or chemotherapy. These stimuli lead to the activation of pro-apoptotic BH3 
proteins. BH3 proteins will promote a conformational shift in Bak and Bax leading to their 
association with the mitochondrial membrane. This leads to the release of Cytochrome c during a 
process called mitochondrial outer membrane permeabilisation (MOMP). This leads to the 
formation of the apoptosome followed by activation of Caspase9 and Caspase 3, 6 and 7, which 
execute apoptosis. Alternatively, the pro-apoptotic mitochondrial proteins Smac/Diablo can be 
released into the cytosol during apoptotic stimuli, where they interact with inhibitors of apoptosis 
proteins (IAPs) leading to the activation of Caspases and therefore apoptosis. 
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1.5.1.1 Inhibition of apoptosis by adenovirus type 5 
As described above, maintaining the balance between cell death and cell 
division is a tightly regulated process that is of great importance in multicellular 
organisms during development and homeostasis. In addition, besides its role in 
these processes, apoptosis plays a functional role as an antiviral defence 
mechanism by limiting the replication of virus-infected cells. Therefore, viruses 
have to overcome host-induced cell death after infection to ensure the 
maturation of virions. 
 
One of the anti-apoptotic proteins expressed by adenoviruses is E1B-19K. E1B-
19K is a BCL-2 homologue that blocks TNF-α-mediated death signalling (Perez 
and White 2000). It can associate with Bax (Sundararajan and White 2001) and 
Bak (Subramanian et al. 2015) to prevent MOMP and the release of cytochrome c 
into the cytoplasm and therefore prevent apoptosis. E1B-55K is another anti-
apoptotic protein encoded by adenovirus. E1B-55K can block apoptosis by 
binding directly to the N-terminal activation domain of p53, by blocking 
interactions between p53 and cellular co-activators of transcription and by 
blocking its interaction with MDM2. Besides this function, E1B-55K can also 
associate with E4orf6 and other cellular proteins to form an ubiquitin ligase 
complex, which can bind p53 leading to p53 polyubiquitination and resulting in 
proteosomal degradation of p53 (Coffin 1996, Schwartz et al. 2008). E4orf6 is 
another viral protein that is able to interact directly with, and inhibit, p53. 
However, besides inhibiting p53, E4orf6 is also able to bind to p73, which is able 
to activate transcription through p53 binding sites. Therefore E4orf6 is able to 
block the function of both p53 and p73 (Coffin 1996). Another viral protein 
involved in inhibiting apoptosis is the receptor internalization and degradation 
(RID) complex, which consists of the E3 proteins 10.4K and 14.5K. They are able 
to form a complex in the plasma membrane and have been shown to down-
regulate surface levels of tumour necrosis factor receptor 1 (TNFR1) (Chin and 
Horwitz 2006, Chin and Horwitz 2005, Fessler, Chin and Horwitz 2004) and to 
inhibit NF-κB activation (Fessler et al. 2004). Besides RID being able to down-
regulate TNFR1, it can also down-regulate FAS (Chin and Horwitz 2005, Zanardi 
et al. 2003, Shisler et al. 1997, Elsing and Burgert 1998, Tollefson et al. 1998) 
surface expression, TNF-related apoptosis-inducing ligand receptor 1 (Tollefson 
et al. 2001, Lichtenstein et al. 2002) and 2 (Benedict et al. 2001, Lichtenstein et 
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al. 2004) (TRAIL1 and 2) and mediates internalization of epidermal growth factor 
(EGFR) (Zanardi et al. 2003, Tollefson et al. 1991, Carlin et al. 1989). Finally, 
the adenovirus E3-14.7K protein is also able to inhibit TNF-induced apoptosis, by 
blocking ligand-induced TNFR1 internalisation by inhibiting the endocytotic 
machinery (Schneider-Brachert et al. 2006). 
 
A summary of proteins expressed by adenoviruses that interfere with the 
apoptotic machinery is shown in table 5.  
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Table 5: Inhibition of apoptosis by adenovirus                                                                       
Table describes viral proteins involved in inhibiting host-induced apoptotic cell death, their host 
target proteins and their mode of action. 
Viral 
Protein 
Target Mode of 
action 
References 
E1B-19K BAX, BAK Anti-apoptotic 
MCL-1 viral 
mimic 
(Subramanian et al. 2015, Tarakanova 
and Wold 2010, Lomonosova, 
Subramanian and Chinnadurai 2005, 
Lomonosova, Subramanian and 
Chinnadurai 2002, Cuconati et al. 
2002, Sundararajan et al. 2001, 
Tollefson et al. 2001, Sundararajan and 
White 2001, Perez and White 1998, 
Han, Sabbatini and White 1996b, 
Debbas and White 1993) 
E1B-55K p53 Binds p53 and 
directs p53 
poly-
ubiquitination 
(Schreiner et al. 2010, BenJilani et al. 
2002, Maheswaran et al. 1998, Debbas 
and White 1993) 
E1B-55K & 
E4orf6 
p53 Proteosomal 
degradation 
(Coffin 1996, Schwartz et al. 2008) 
RIDα/β  
(E3A 
10.4K/14.
5K) 
TNFR1, 
FAS, 
TRAIL-
R1/2, 
EGFR 
Down-
regulation of 
cell surface 
receptors 
(Chin and Horwitz 2006, Chin and 
Horwitz 2005, Fessler et al. 2004, 
Zanardi et al. 2003, Shisler et al. 1997, 
Elsing and Burgert 1998, Tollefson et 
al. 1998, Benedict et al. 2001, 
Tollefson et al. 2001, Lichtenstein et 
al. 2002, Tollefson et al. 1991, Carlin 
et al. 1989, Lichtenstein et al. 2004) 
E3-14.7K TNFR1 Inhibits 
internalization 
of TNFR1 
(Ranheim et al. 1993, Schneider-
Brachert et al. 2006) 
E4orf6 p53, p73 Antagonizes 
p53 and p73 
function 
(Coffin 1996, Luo et al. 2007) 
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1.5.1.2  dl922-947 and apoptosis 
It has been shown in previous work that ovarian cancer cells infected with 
oncolytic adenoviral mutants (E.g. dl922-947 and dlCR2) undergo cell death that 
is not characterized by the features of classical apoptosis (Baird et al. 2008). In 
their investigation, the host lab showed that infecting IGROV1 and OVCAR4 cells 
with dl922-947 showed no detectable activation of caspase-3 after 72 hrs of 
infection in comparison to cells treated with the apoptosis inducer cisplatin. 
Addition of the pan-caspase inhibitor Z.VAD.fmk to dl922-947-infected cells 
showed no effect on virus-induced cytotoxicity. Western blotting of infected 
cells showed minor cleavage of both caspase-3 and poly-ADP ribose polymerase 
(PARP) cleavage during infection. Similarly, there was only trivial 
phospatidylserine (PS) exposure, and only at late time points, while 75% of 
cisplatin treated cells were Annexin V-positive after 72 hrs.  
 
Next they investigated the role of mitochondria in dl922-947 induced cell death, 
since mitochondria play a pivotal role in the intrinsic apoptotic pathway. They 
showed that overexpression of the anti-apoptotic protein BCL-2 had no effect on 
viral cytotoxicity. They also showed that during dl922-947 infection no increase 
in cytochrome c release was observed. Even the addition of cyclosporine A, 
which prevents the mitochondrial permeability transition pore from opening and 
thus releasing cytochrome c into the cytoplasm, showed no effect dl922-947 
induced death. Besides the published data on dl922-947 Abou El Hassan et al. 
showed, using the E1A CR2-deleted viruses, Ad5-Δ24, with E3 region deleted, 
and the infectivity-enhanced Ad5-Δ24RGD in which E3 was intact, that the p53-
Bax apoptotic pathway was not involved in virus cytotoxicity and that inhibiting 
caspases by overexpressing the X-linked inhibitor of apoptosis or by treating cell 
with Z.VAD.fmk did not inhibit adenovirus-induced cell death, leading to their 
conclusion that adenoviruses trigger a non-apoptotic cell death (Abou El Hassan 
et al. 2004). The results presented in both studies show that cells that infected 
with E1A CR2-deleted adenoviruses do not undergo classical apoptosis as 
previously thought. 
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1.5.2 Type II cell death: Autophagy 
Autophagy (Macroautophagy) is a catabolic process of self-degradation of 
cellular components mediated by the lysosomal machinery. It plays an important 
role in response to starvation and stress, as well as in development, cell death, 
aging, immunity and cancer. During starvation autophagy can promote cell 
survival by the production of amino acids and mitochondrial substrates. Besides 
its association with survival, it has been suggested that autophagy may also 
function in cell death since autophagic death is activated in cells lacking Bax and 
Bak or cells that overexpress Bcl-2 or BCL-xL upon cytotoxic treatment (Shimizu 
et al. 2004). We also know that autophagy is a type programmed cell death 
(PCD) that is required during the development of diverse animal groups, like 
amphibians and insects (Baehrecke 2003). Programmed autophagic cell death 
occurs when larval tissues are replaced with adult tissues, for example, salivary 
glands, showing its important role in physiological cell death. Therefore, defects 
in autophagy may play critical roles in cancer, by eliminating defective 
organelles (E.g. mitochodonria) which otherwise can lead to genomic instability, 
the production of ROS and inflammation which ultimately results in an increase 
in tumorigenesis (Degenhardt et al. 2006). The process of autophagy is divided 
into distinct steps: induction, cargo recognition and selection, vesicle formation, 
autophagosome-vacuole fusion and breakdown of the cargo and the release of 
the products into the cytosol. The autophagy pathway in mammals is further 
described in detail in figure 1-8. 
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Figure 1-8: Autophagy in mammals   
When growth factors are available, autophagy is inhibited by mammalian target of rapamycin 
(mTOR), but upon growth factor withdrawal, pathogen infection or amino acid starvation, mTOR is 
inhibited leading to the formation of the ULK complex (consisting of ULK1/2, autophagy-related 
gene (ATG)13, ATG101 and FIP200) and ATG9L (ATG9L1/2) and the recruitment of the 
phosphatidylinositide 3-kinases (PI3K) complex consisting of ATG14L, VPS34, beclin-1 and 
VSP15. The ATG16L1 complex consisting of ATG16L1, ATG5 and ATG12 will then localize to the 
isolation membrane, which will dissociate again upon autophagosome formation. Upon autophagy 
induction, cytosolic LC3-I is cleaved to LC3-II and conjugated to phoshatidylethanolamine (PE) at 
the phagophore. During fusion of the autophagosome with the lysosome the content will be 
digested by lysosomal proteases. 
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1.5.2.1  Autophagy and Adenovirus 
In 2006 Ito et al. suggested that conditionally replicating adenovirus induces 
autophagic cell death in malignant glioma cells (Ito et al. 2006). They used the 
conditionally replicating virus hTERT-Ad (in which the adenoviral E1A promoter 
is replaced with a 255-bp hTERT promoter fragment (Wirth et al. 2003)) and 
showed by using electron microscopy that U87-MG cells infected with hTERT-Ad 
exhibited autophagic and empty vacuoles, which are autophagic features. They 
further observed an increase in acidic vesicular organelles and as well as an 
increase in the ratio of LC3-II compared to LC3-I, indicating that hTERT-Ad 
induces autophagy in malignant cells. Addition of 3-Methyladenine (3-MA), a 
type III Phosphatidylinositol 3-kinases (PI3K) inhibitor that blocks autophagosome 
formation, showed an increase in cell viability in U373-MG cells infected with 
hTERT-Ad and suppressed the formation of acidic vesicles. Experiments using 
HeLa and PC3 cells showed the same results, suggesting that autophagy is a 
common feature of cells infected with hTERT-Ad and that cells infected with 
hTERT-Ad undergo autophagic cell death. 
 
1.5.2.2  dl922-947 and Autophagy 
As mentioned above, recent research by the host lab (SK Baird et al. 2008) 
showed that ovarian cancer cells infected with dl922-947 undergo a novel mode 
of programmed cell death in ovarian cancer. Lysosomes play an important role 
during autophagy. After fusion of the lysosome with the autophagosome its cargo 
will be digested by the proteases inside the lysosome. Sarah Baird examined the 
involvement of autophagy in dl922-947 induced cell death by examining cells 
that were stained with monodansylcadaverine (MDC) under a transmission 
electron microscope (TEM). MDC is an autofluorescent dye that accumulates in 
autophagic vacuoles through ion trapping and lipid interactions. She showed that 
the number of autophagosomes increased during dl922-947 and the formation of 
punctate LC3 staining in IGROV1 cells co-infected with dl922-947 and Ad GFP-
LC3. Addition of 3-MA, during dl922-947 infection, lead to an augmentation in 
cell death. The same results were observed when chloroquine (CQ), a 
lysosomotropic agent that prevents endosomal acidification and therefore 
inhibits lysosomal enzymes, was used. These results confirmed that autophagy 
occurs during viral infection in ovarian cancer.  
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In accordance with our lab findings, in 2012 G Botta et al. published an article 
under the title “Inhibition of autophagy enhances the effects of E1A-defective 
oncolytic adenovirus dl922-947 against glioma cells in vitro and in vivo” (Botta 
et al. 2012). When Botta et al. infected U87MG and U373MG glioma cells with 
dl922-947 and performed AO staining they observed a MOI-dependent increase in 
fluorescence. Further, western blotting showed an increase in LC3-I to LC3-II 
conversion in cells infected with dl922-947. Next they infected U373 GFP-LC3 
cells with dl922-947, which resulted in a localized punctate pattern indicating 
that LC3-II is recruited to the autophagosome. Following this they examined the 
levels of p62/SQSTM1, an autophagy specific substrate, which shows a decrease 
in p62 protein levels upon autophagy. Cells infected with dl922-947 showed 
decreased protein levels of p62 showing that autophagy occurs during dl922-947-
infection. When cells were then infected with dl922-947 and then either treated 
with 3-MA or CQ, an increase in virus-induced cytotoxicity was observed, which 
was further observed in cell clones expressing Atg5 shRNA. Using a mouse 
xenograft model where tumours were infected with dl922-947 and treated with 
CQ or not, they observed a significant reduction in tumour volume of mice 
treated with dl922-947 and CQ. Of note here is that Botta et al. observed that 
inhibition of autophagy with CQ lead to caspase-3 activation, which is an 
indicator of apoptosis-mediated cell death. These results lead to their 
conclusion that CQ treatment enhances the oncolytic effects of dl922-947 in 
glioma cells in vitro and in vivo. 
 
1.5.3 Type III cell death: Programmed necrosis 
Necrosis is a form of caspase-independent cell death that has, until recently, 
been regarded as a purely accidental and uncontrolled form of death, which is 
associated with the death of damaged and diseased tissues.  
 
Necrotic cell morphologically is characterized by an increasingly translucent 
cytoplasm, oncosis (An increase in cell volume, also referred to as swelling), the 
swelling of organelles, a lack of nuclear disintegration including dilatation of the 
nuclear membrane and the loss of membrane integrity leading to cytoplasmic 
leakage (Vanlangenakker, Vanden Berghe and Vandenabeele 2012).   
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1.5.3.1  Programmed necrosis induced by TNF-α/TNFR1 ligation 
In 1988, Scott M. Laster discovered that TNF-α can induce both apoptotic and 
necrotic forms of cell death depending on the cell type, thereby questioning the 
purely unregulated nature of necrosis (Laster, Wood and Gooding 1988). Ever 
since then, accumulating evidence has led to the conclusion that necrosis can 
indeed be regulated (Scaffidi, Misteli and Bianchi 2002, Zong et al. 2004, Zong 
and Thompson 2006). A new form of regulated necrosis was introduced, termed 
programmed necrosis (Necroptosis) (Vandenabeele et al. 2010b).  There are 
several pathways of programmed, regulated necrosis, of which the best known is 
induced by the ligation of TNF-α and Tumour necrosis factor receptor 1 (TNFR1), 
which is described in detail in figure 1-9.  
 
The mechanisms of how MLKL induces membrane rupture (Wang et al. 2014a) in 
the final stages of necrosis have been researched by several groups. Wang et al. 
and Dondelinger et al. have shown evidence that MLKL is able to puncture the 
membrane to form pores. When MLKL becomes phosphorylated it undergoes 
conformational changes (Murphy et al. 2013), leading to the formation of 
oligomers and translocation to the plasma membrane (Hildebrand et al. 2014), 
where its N-terminal domain will directly bind to negatively charged 
phosphatidylinositol phosphates (PIPs) (Dondelinger et al. 2014, Wang et al. 
2014a, Hildebrand et al. 2014, Quarato et al. 2016) and cardiolipin (CL) (Wang et 
al. 2014a) leading to the formation of pores. Another model suggests that MLKL 
may regulate ion channels at the plasma membrane during programmed necrosis 
to mediate osmolysis (Chen et al. 2014, Cai et al. 2014, Xia et al. 2016).  
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Figure 1-9: TNF-induced programmed necrosis  
Tumour necrosis factor receptor 1 (TNFR1) undergoes conformational changes upon (TNF-α) 
binding, which leads to the assembly of the pro-survival TNFR complex I. This complex consists of 
the TNF receptor associated death domain (TRADD), receptor-interacting protein1 (RIPK1), 
cellular inhibitors of apoptosis 1 and 2 (cIAP1/cIAP2), TNF receptor –associated factor 2 (TRAF2) 
and TRAF5. CIAP1/2 catalyses Lys63-linked polyubiquitylation of RIPK1 at Lys377, which in turn 
leads to the recruitment of serveral proteins, which initiate nuclear factor-κΒ (NF-κΒ) activation, 
leading to the transcription of cytoprotective genes and to cell survival (Vandenabeele et al. 
2010b). When cIAPs are inhibited (by smac mimetics) or depleted, another complex called 
complex IIb, which consists of RIPK1/3, FAS-associated protein with a death domain (FADD) and 
caspase8 (Vanlangenakker et al. 2012) forms. This complex can either lead to the activation of 
Caspases resulting in apoptosis or when caspase 8 is deleted or its activity blocked, programmed 
necrosis can be induced.  The necrosome requires the kinase activity of the proteins RIPK1 and 
RIPK3, which will interact at their RHIM domains leading to the formation of microfilament-like 
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structures. Mixed lineage kinase (MLKL) (Sun et al. 2012) then binds to RIPK3 through its C-
terminal kinase-like domain, which is phosphorylated at Thr 231/Ser232 by RIPK3 leading to its 
activation and translocation to the cell membrane, where it is involved in the formation of pores. 
 
1.5.3.2  Programmed necrosis induced by genotoxic stress: The 
ripoptosome 
In 2011, two groups Tenev et al. and Feoktistova et al. published the discovery 
of a novel death-inducing complex, called the ripoptosome (Figure 1-10) that 
forms upon gentoxic stress and/or IAP-depletion (Tenev et al. 2011, Feoktistova 
et al. 2011). They showed that this complex was able to stimulate caspase-8 
mediated apoptosis or caspase-independent necrosis depending on the cellular 
context. Interestingly, this complex is able to form independently of death 
ligands (TNF-α) and the mitochondrial pathway. Further, they showed that RIPK1 
kinase activity is required for the assembly of the ripotosome as well as RIP-
mediated induction of apoptosis and necroptosis.   
 
Figure 1-10: Formation of the ripoptosome  
Under baseline conditions RIPK1 is in a closed (Inactive) conformation but upon genotoxic stress 
or cIAP depletion, RIPK1 changes into an active conformation, which allows its association with 
FADD and Caspase-8 to form the ripoptosome. FLIP and cIAP negatively regulate the formation of 
this complex. Depending on the cellular context, if caspase-8 is available, this complex leads to the 
induction of apoptosis or if caspase-8 is blocked or depleted leading to regulated necrosis, through 
the interaction of rIPK1 and RIPK3 and phosphorylation of MLKL. 
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1.5.3.3  Programmed necrosis induced by Toll-like receptors 
Toll-like receptors are well known for their involvement in mediating 
inflammation and innate immunity by detecting various microbial patterns 
(Medzhitov 2009), but it wasn’t until recently that an intricate connection 
between cell death and inflammation was discovered. To limit infection, the 
host needs to eliminate cells that are carrying infections, while at the same time 
it needs to warn the neighbouring cells and immune system to avoid further 
spread. Therefore it is not surprising that Toll-like receptors (TLRs) can despite 
mediating inflammation also mediate cell death (Silke, Rickard and Gerlic 2015, 
Han, Zhong and Zhang 2011a, Blander 2014) as depicted in figure 1-11. 
 
Caspase-8, which is well known for inducing apoptosis by TNF-α/TNFR1 ligation 
is also central for TLR3 and TLR4 induced apoptosis. Interestingly, 
deletion/deficiency of caspase-8 or mutant caspase-8 expression has shown to 
lead to systemic inflammation (Wallach et al. 2014, Kang et al. 2013, Kovalenko 
et al. 2009) and necroptosis (Gunther et al. 2011), showing that caspase-8 is an 
important suppressor of inflammation in vivo, as well as the intricate 
involvement of caspase-8 in cell death and inflammatory signalling pathways.  
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Figure 1-11: Necroptosis induced by TLR ligation  
Upon recognition of lipopolysaccharide (LPS) by TLR4 and IAP depletion, a complex consisting of 
TRIF, Myd88, RIPK1 and RIPK3 forms (Kaiser et al. 2013a). If caspase-8 is active a complex 
called the ripoptosome forms leading to apoptosis. If caspase-8 is inactive, the necrosome 
consisting of RIPK1 and RIPK3 forms leading to the activation of MLKL and the induction of 
regulated necrosis(Lawlor et al. 2015, Silke et al. 2015, Dondelinger et al. 2016). Binding of TLR3 
with poly(I:C) the TIR domain-containing adaptor protein inducing IFNβ (TRIF), the ripoptosome is 
recruited. The presence of FLICE-like inhibitory protein (FLIP) isoforms in the ripoptosome results 
in different outcomes. The absence of FLIP leads to induction of apoptosis, while high levels of 
FLIPS  in the ripoptosome leads to recruitment of RIPK3 and RIPK3/RIPK1 interaction leading to 
the activation of MLKL and necrosis (Blander 2014, Dondelinger et al. 2016). 
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1.5.3.4  Other necrosis triggers 
Besides the above-discussed necrotic pathways, there are further triggers of 
necrotic cell death. Over the years many different necrotic triggers have been 
identified; those include but are not limited to FASL (Holler et al. 2000b), TNF-
related apoptosis-inducing ligand (TRAIL) (Holler et al. 2000a), TNF-related weak 
inducer of apoptosis (TWEAK) (Wilson and Browning 2002), stimulation of T cell 
receptor (TCR)(Ch'en et al. 2008), pathogen-associated molecular patterns 
(PAMPS) (Kalai et al. 2002), interferons (IFN) (Thapa et al. 2013), retinoic acid 
inducible gene I (RIG-I)-like receptors (Zou et al. 2013) and anticancer drugs like 
shikonin (Han et al. 2007, Huang et al. 2013) . 
 
1.5.3.5  Viruses and necrosis 
Since many viruses, including adenovirus, encode suppressors of cell death (e.g. 
viral caspase 8 inhibitors), being able to execute both apoptotic and necrotic 
cell death is of benefit for the host’s defence. It has been shown now that 
necrosis can be induced by infection with several different viruses like vaccinia 
virus (VV) (Cho et al. 2009), murine cytomegalovirus (MCMV) (Upton, Kaiser and 
Mocarski 2010) and herpes simplex virus type-1 (HSV-1) (Holler et al. 2000b). 
Some of these even encode inhibitors that prevent the cell from undergoing 
regulated necrosis. 
 
1.5.3.5.1  Vaccinia virus  
Lynsey M Whilding, from the host lab, published data in 2013 showing that 
vaccinia virus (VV) induces programmed necrosis in ovarian cancer (Whilding et 
al. 2013). Using TEM she showed that cells infected with VV showed necrotic 
morphology. She also showed that treatment of cells with the RIPK1 inhibitor 
necrostatin-1 (Nec-1) upon VV infection significantly increases cell viability 
(Whilding et al. 2013); furthermore TNF-resistant cells can become sensitized to 
TNF-induced cell death upon infection with VV. Further, they showed that VV 
infection lead to the formation of a pro-necrotic complex consisting of RIPK1, 
RIPK3 and caspase-8 (Cho et al. 2009, Chan et al. 2003, Whilding et al. 2013).  
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1.5.3.5.2  Murine cytomegalovirus  
Cells infected with murine cytomegalovirus (MCMV) show the opposite effects of 
VV infected cells, as they are resistant to TNF-induced necroptosis due to the 
MCMV M45 protein-encoded inhibitor of RIP activation (vIRA) (Upton, Kaiser and 
Mocarski 2012). MCMV vIRA has a RIP homotypic interaction motif (RHIM), which 
targets RIPK3 and disrupts RIPK3-RIPK1 interactions. The same lab has also 
shown that DNA-dependent activator of interferon (DAI) can form a RHIM-
dependent complex with RIPK3 to mediate virus-induced programmed necrosis, 
suggesting the existence of another pathway than classical TNF/TNFR necrosis 
(Upton, Kaiser and Mocarski 2012). 
 
1.5.3.5.3  Herpes simplex virus-1  
Another virus that encodes a protein that interacts with the necrotic machinery 
is Herpes simplex virus-1 (HSV-1). HSV-1 encodes a protein called infected cell 
protein 6 (ICP6). HSV-1 is a virus that has evolved to successfully infect and 
replicate within mouse and human cells and therefore deploys two different 
approaches to block the induction of programmed necrosis. In murine cells ICP6 
binds to RIPK1 and RIPK3 through RHIM interactions, leading to the 
phosphorylation of RIPK3 followed by MLKL phosphorylation and the induction of 
necroptosis. In this scenario the induction of programmed necrosis limits virus 
propagation (Wang et al. 2014b, Huang et al. 2015). In human cells on the other 
hand ICP6 suppresses necroptosis by inhibiting the RHIM-dependent interaction 
of RIPK1 and RIPK3 (Guo et al. 2015).  
 
1.5.3.5.4  dl922-947 and Adenovirus 
As stated above, in 2008 Sarah Baird in the host lab showed that ovarian cancer 
cells infected with oncolytic adenoviral mutants (e.g. dl922-947 and dlCR2) 
undergo cell death that is not characterized by the features of classical 
apoptosis (Baird et al. 2008). Further investigations showed that cell death 
induced by oncolytic adenoviruses does not rely upon mitochondria, autophagy 
as well as on cathepsins and lysosomal membrane permeability, leading to the 
conclusion that a novel mode of programmed cell death must be involved. Using 
phase-contrast and transmission electron microscopy, they further examined cell 
morphology, showing that virus-infected cells showed a rounded morphology, 
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which became more apparent over time with few cells showing membrane 
blebbing, a marker of apoptotic cell death. They further observed chromatin 
condensation and dilation of membranous organelles like mitochondria, Golgi 
apparatus and the endoplasmatic reticulum, which are associated with 
apoptosis. Examination of cellular ATP levels showed an increase following 
infection rather than a decrease, which is associated with necrosis. In another 
study by Abou El Hassan et al, it was shown that oncolytic adenoviruses kill non-
small-cell lung cancer cells via a necrosis-like programmed cell death (Abou El 
Hassan et al. 2004). In this study, the authors showed that the p53-Bax apoptotic 
pathway was not involved and that inhibiting caspases by overexpressing the X-
linked inhibitor of apoptosis or by treating cell with Z.VAD.fmk did not inhibit 
adenovirus-induced cell death, leading to their conclusion that adenoviruses 
trigger a necrosis-like cell death. 
 
1.5.4 Other forms of cell death 
Besides the above well-described three major programmed cell death pathways, 
further cell death mechanisms have been discovered in the recent years. 
 
1.5.4.1  Lysosomal membrane permeabilization 
Lysosomes contain many different hydrolases (E.g. phosphatases, proteases and 
lipases), which take part in the digestion of endocytosed and autophagocytosed 
material. The cathepsins are the most well studied hydrolases and are 
categorised by their active site amino acids: cysteine, aspartate and serine. In 
response to stress lysosomal contents can be released to the cytoplasm by 
lysosomal-membrane permeabilization (LMP) (Kroemer and Jaattela 2005, 
Werneburg et al. 2002). While the massive release of lysosomal hydrolases will 
lead to necrosis, minor LMP can lead to caspase-dependent apoptosis or 
alternative caspase-independent cell death. Changes within this pathway, by 
deregulation or mutations of its components contribute to tumour development 
and invasion (Chi et al. 2010). 
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1.5.4.1.1 dl922-947 and lysosomal membrane permeabilisation 
Sarah Baird showed in 2008 that when IGROV1 or OVCAR4 cells were infected 
with dl922-947 and additionally treated with E64, an irreversible cysteine 
protease inhibitor, minimal effects were observed on virus mediated cell death. 
The same was observed when the aspartic acid protease inhibitor pepstatin A 
was used. The cysteine protease inhibitor E64 is known to inhibit several 
cysteine proteases like cathepsin B and L as well as calpain, while the aspartic 
acid protease inhibitor pepstatin A inhibits cathepsin D. Since inhibiting the main 
lysosomal proteases Cathepsin B and D showed no effect on cell survival, 
lysosomal cell death was excluded in the involvement of dl922-947 mediated cell 
death. Further experiments with acridine orange showed that virus infection 
caused lysosomes to stabilize instead of undergoing lysosomal membrane 
permeabilization (Baird et al. 2008). 
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1.6 Aim of the project 
Oncolytic viruses have shown promise as a cancer therapy in several human 
cancers in pre-clinical as well as clinical research, but little is known about how 
they induce cell death in human cancers. The aim of this project was to 
investigate how oncolytic adenoviruses, specifically dl922-947, induce cell death 
in human ovarian cancer. This goal was further divided into two specific 
research aims: 
 
1.) To investigate programmed necrosis pathways involved in dl922-947-
induced cell death in ovarian cancer.  
 
2.) To investigate whether anti-tumour efficacy can be increased, by 
augmenting programmed necrosis in dl922-947-infected cells and 
tumours. 
 
The overall goal of this research was aimed at identifying the mechanisms of 
adenovirus-induced cell death in ovarian cancer, with a special emphasis on 
programmed necrotic cell death mechanisms.  
 
The long-term aim of this study is to identify targets that can increase oncolytic 
adenovirus efficacy in lysing tumour cells. 
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Chapter 2 
 
 
Materials and Methods 
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2 Materials and Methods 
2.1 Cell lines and culture 
Human cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
(Gibco by Life Technologies, UK) with 10% heat-inactivated foetal bovine serum 
(FBS) (Gibco by Life technologies, UK), 2mM L-Glutamine (Gibco by Life 
Technologies, UK), 100 units/mL penicillin and 100µg/mL streptomycin (Gibco by 
Life Technologies, UK) while human primary cells were cultured in Roswell Park 
Memorial Institute medium (RPMI) supplemented with 25% autologous ascitic 
fluid, 2mM L-Glutamine (Gibco by Life Technologies, UK), 100 units/mL 
penicillin and 100µg/mL streptomycin (Gibco by Life Technologies, UK). All cell 
lines were maintained in a 37ºC humidified incubator with 5% CO2 (Galaxy 170R, 
Eppendorf) and were routinely passaged with 0.05% trypsin-EDTA (Gibco by Life 
Technologies, UK) every time they reached 80% confluency. All cell lines were 
verified by Short Tandem Repeat profiling (STR) at the Cancer Research UK 
Beatson Institute using the Promega GenePrint 10 system (Promega, UK), which 
is a STR multiplex assay that amplifies 9 tetranucleotide repeat loci and the 
Amelogenin gender determining marker. Cell lines were tested for mycoplasma 
every second week. Cell lines were cultured for 10 passages and removed 
afterwards, while new aliquots were resurrected from liquid nitrogen. For long 
time storage, cells were trypsinized and pelleted by centrifugation in a Sigma 3-
16KL centrifuge (Sigma, GER) and the resulting cell pellet was resuspended in 
FBS containing 10% dimethyl sulphoxide (DMSO) (Fisher Scientific, UK). Cells 
were transferred into a Freezing Container (Nalgene, UK) and left for overnight 
storage at -80 degrees before transferring into liquid nitrogen. 
 
The human cervical cancer cell line HeLa were obtained from CRUK Cell Services 
from Clare Hall. JH293 and 293 cells were kindly provided by Dr Yaohe Wang 
(Barts Cancer Institute, London, UK). The human ovarian cancer cell line IGROV1 
and OVCAR4 were obtained from the National Cancer Institute (NCI, Frederick, 
MA, USA), and TOV21G cells were obtained from Fran Balkwill (Barts Cancer 
Institute, London, UK). The embryonic kidney cell lines 293T and Phoenix-AMPHO 
cells as well as the human colorectal cancer cell line HT-29 were kindly provided 
by Dr. Stephen Tait (University of Glasgow, UK). 
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Human primary cells were obtained from patients with ovarian cancer, who were 
drained of ascites for diagnostic cytology and/or symptom relief. 200 mL of 
ascites were transferred into a 250mL Corning centrifuge tube (Corning 
Incorporated, USA) and spun at 2500 revolutions per minute (rpm) for 15 minutes 
at room temperature (RT). The supernatant (autologous fluid) was removed, 
aliquoted into 50mL falcon tubes (Corning Incorporated, USA) and stored -80ºC 
for later use. The cell pellet was incubated for 10 minutes in 5mL red blood cell 
lysis buffer (Sigma-Aldrich, USA) and then transferred to a 50mL tube, topped up 
with 30mL Phosphate-buffered saline (PBS) (Sigma-Aldrich, USA) and spun at 
2000 rpm for 10 minutes. The supernatant was removed and the pellet gently 
resuspended in RPMI medium with 25% autologous fluid in a T75 flask (Corning, 
UK). 
 
2.2 Adenovirus preparation 
2.2.1 Generating seed stock 
293 cells were plated on a 150mm plate (Corning, UK). When cells reached 80-
90% confluency cells were infected with 100-200µL of concentrated virus stock. 
When cytopathic effect (Cpe) was evident, cells were pipetted up and down 
until all were detached. The cells and medium were collected and snap-frozen 
in liquid nitrogen. Afterwards cells were freeze/thawed in liquid nitrogen/37ºC 
waterbath three times. The seed stock was stored at -70ºC immediately. 
 
2.2.2 Bulk preparation 
293 cells were plated onto 20 x 150mm plates. When cells reached 80% 
confluency, the seed stock was defrosted at 37ºC and spun at 2000 rpm for 15 
minutes to pellet cell debris. Medium was carefully removed and 200mL of 
serum-free DMEM were added. 1mL of virus seed stock and 10mL growth medium 
were added to each 150mm plate. After 48-72 hours, when full cpe was evident, 
cells and medium were harvested, transferred to 6 x 250mL Sorvall centrifuge 
bottles (Corning, UK), and spun at 2000rpm for 15 minutes. Medium was 
aspirated, each pellet resuspended in 4.3mL 0.1M Tris pH 8.0 and the total 
transferred to a 50mL Falcon tube (Corning, UK). The tube was snap-frozen in 
liquid nitrogen and freeze/thawed three times and stored at -70ºC. 
 
		
65	
2.2.3 Caesium Chloride (CsCl) purification 
Virus stock was defrosted at 37ºC, spun at 4500rpm for 15 minutes and 
supernatant transferred to a fresh tube. A CsCl gradient was achieved by adding 
11.4mL 1.25g/mL (Buoyant density) CsCl to a 30mL Ultraclear Beckman tube 
(Beckman Coulter, UK) followed by the addition of 7.6ml 1.4g/mL CsCl 
underneath the 1.25g/mL layer without disturbing the interface. The viral 
supernatant was added on top of the CsCl double layer and spun at 25,000rpm 
for 2 hours at 15ºC in an Optima XPN-90 Ultracentrifuge (Beckman Coulter, USA) 
using a SW32 Ti rotor. After centrifugation three distinctive layers were visible 
in the tube. The top layer contains cell debris, the second layer contains empty 
virions and the lowest layer contains the properly packaged virions.  
 
The layer containing the packaged virions was removed by puncturing the tube 
with a 5mL syringe (Beckton, Dickinson and Company, UK) using a 21-gauge 
needle (Beckton, Dickinson and Company, UK). The layer was aspirated off while 
avoiding contamination from the other layers. The virus was divided between 2 x 
5mL Beckman tubes (Beckman Coulter, UK) followed by the addition of 
1.35g/mL CsCl. The virus was spun at 40,000rpm overnight at 15ºC using a SW55 
Ti rotor. After centrifugation a single band of virus should be visible. Using a 
syringe and needle the virus was aspirated and transferred to a new falcon tube. 
 
2.2.4 Dialysis 
2 mL TSG buffer (TSG buffer solution A: 150mM NaCl, 1mM Na2HPO4, 5mM KCl, 
30mM Tris base and 90mL distilled water at pH 7.4. TSG buffer solution B: 
200mM MgCl2, 180mM CaCl2 and 10mL distilled water. 90mL of solution A was 
added to 450µL of solution B and 38.5 mL glycerol making TSG buffer) was added 
to the virus and inserted into a Slide-A-Lyzer dialysis cassette (Thermo 
Scientific, UK) using Slide-A-Lyzer 20mL syringe and 18 gauge needle accessories 
(Thermo Scientific, UK). The virus was dialyzed in the cold room for 24 hours in 
2 litres of dialysis buffer (10mM Tris pH 7.4, 1mM MgCl2, 150mM NaCl and 10% 
glycerol) with gentle stirring. After overnight dialysis, the virus was removed 
from the dialysis cassette, aliquoted and stored at -70ºC. 
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2.2.5 Measuring particle count 
To measure the particle count, 100µL virus stock were added to 100µL 2x 
adenoviral lysis buffer (1% SDS, 0.04M Tris-Cl) and heated for 10 minutes at 
55ºC. 300µL distilled water were added and the optical density (OD) at 260nm 
was read on a BioPhotometer D30 (Eppendorf, UK). 
 
The particle count per mL is calculated the following (Mittereder, March and 
Trapnell 1996): 
 OD!"# x dilution factor9.09 x10!!"  
 
2.2.6 TCID50 
Production of infectious virus progeny was determined by tissue culture 
infectious dose (TCID)50 assay. Tumour cells were plated in triplicate onto a 6 
well plate at a density of 1x105 per well. The following day, they were infected 
with dl922-947 at 10 pfu/cell in 1mL serum-free medium. After 2 hours cells 
were re-fed with normal growth medium. To measure intracellular virus 
production, cells were harvested at desired time points (24-72h post-infection) 
by aspirating the medium, washing cells twice in cold 0.1M Tris pH 8.0 and 
scraping into 0.5mL 0.1M Tris pH 8.0. The Tris, containing the cells, was 
transferred into a sterile Eppendorf tube and placed on ice. Following this 
samples were freeze/thawed (Liquid nitrogen/37ºC) three times. At this point 
samples were centrifuged at 13,000 rpm for 5 minutes and the supernatants 
were either frozen at -80ºC or kept on ice for use straight away. 
 
JH293 cells were plated in a 96 well plate at a density of 1x104 cells/per well in 
180µL of normal growth medium the day before the assay, with at least 4 plates 
per condition. 
 
The virus sample was defrosted on ice and serial dilutions were prepared ranging 
from 10-1-10-6 depending on the cell line and conditions used. The first row of 
each 96 well plate was used as a negative control. Starting from the second row 
20µL of the diluted virus stock was added per well. Using a multichannel pipette 
20µL were removed from the second row and added to the third row while 
		
67	
pipetting up and down to ensure mixing. This was repeated throughout the 
whole plate so that the samples were diluted 1:10 between the rows. Plates 
were incubated at 37ºC for 10 to 11 days at which point the number of wells 
displaying cytopathic effect at each dilution was counted. 
 
The following calculation was used to determine the TCID50 value: 
 
TCID50 = A-D (S-0.5) 
 
A= Log of the highest dilution showing CPE in more than 50% of the wells 
D= Log of the dilution factor 
S= ratio of the number of wells per row with CPE : number without CPE 
 
This yields TCID50 for 20µL virus, and is divided by 0.02 to give TCID50/mL.  
This is then converted to pfu/mL based upon Poisson distribution using the 
following: 
 
P(o)= e(-m) 
 
P(o)= proportion of negative wells in a 96 well plate 
m= mean number of infectious units per volume (PFU/mL) 
 
For any titre expressed as a TCID50: P(o)= 0.5, 
And therefore e(-m)= 0.5 
m= -ln0.5≈ 0.7 
 
Because TCID50 overestimated viral titre by 0.7 log compared to plaque assay, 
TCID50 is converted to pfu/mL using the following formula: 
 
Pfu/mL = 10n-0.7 
Where n = logTCID50/mL 
 
This titration technique is only valid if the lowest dilution gives ≥50% CPE, the 
highest dilution gives ≤50% CPE and the negative control shows no CPE in any 
well. 
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2.3 Cell Survival Assays 
2.3.1 MTT assay 
Cell death was measured using MTT (Sigma, UK) assay (Mosmann 1983). MTT is a 
colorimetric assay, which measures the metabolic activity of cells.  It is a 
tetrazole of yellow colour, which is reduced to non-water-soluble formazan by 
NAD(P)H-dependent cellular oxidoreductase enzymes in viable cells. Since 
formazan is non-water-soluble it must be dissolved in acidified isopropanol or 
other solvents before further analysis. In the experiments described below 
dimethyl sulfoxide (DMSO) (Fisher chemical, UK) was used as solvent. 
 
For MTT assay cells were plated on a 24 well plate at a density of 1x104 
cells/well. Cells were either infected with virus or treated with drugs or/and 
inhibitors. Cell proliferation was measured by adding MTT stock solution 
(5mg/mL) to each well equal to one tenth of the culture volume. Cells were 
incubated for 3 hours with MTT before the medium was removed and DMSO 
added to dissolve the formazan crystals. The plates were read on an Infinite 
M200 Pro (Tecanplate, CH) reader at 560nm.  
 
2.3.2 Sulphorhodamine B assay 
Cells were plated in a 24 well plate at a density of 1x104 cells per well. After 
desired treatment and incubation, cells were washed once in 1mL PBS and 250µL 
of 10% trichloroacetic acid (TCA) were added to each well and incubated for 
30min at 4ºC. Afterwards the TCA was removed, the plate washed 3 times with 
1mL of distilled water and left to dry at room temperature. After plates were 
dried, 250µL of sulphorhodamine B (0.4%) were added to each well and 
incubated for 30 min. The sulphorhodamine B was discarded afterwards and the 
plates washed with 1% acetic acid until running clear. After the plates were 
dried, 500µL of 10mM Tris pH 9 were added to each well, incubated for 5 min at 
room temperature and the absorbance measured at 565nm. 
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2.3.3 Response to TSZ treatment 
Cells were tested for their ability to undergo programmed necrosis by treatment 
with a combination of TNF-α, Smac-mimetic and zVAD-fmk (TSZ). Cells were 
plated at a density of 1x104 cells per well in a 24 plate in 700µL growth medium 
per well. The next day cells were treated with 20ng/mL recombinant human 
TNF-α (PeproTech, UK), 1µM LCL-161 (Smac-mimetic (Chemie Tek, USA)) and 
25µM zVAD-fmk (Tocris Bioscience, USA). Cell survival was assessed 24, 48 and 
72 hours post treatment as described previously. 
 
2.3.4 Dose response to adenovirus strains 
An MTT assay was performed to measure the sensitivity of different cells lines to 
Adenovirus Ad5WT, Ad5 dl922-947, Ad5, dl309, Ad11 and Ad35 infection. 1x104 
cells were plated per well in a 24 well plate as above. After 24 hours cells were 
infected in triplicate with 10-fold serial dilution of virus in 500µL serum-free 
medium. After 2 hours 500µL of growth medium was added to each well. 120 
hours post-infection cell survival was analysed as described in 2.4.1. Using 
GraphPad Prism version 6.0d for Macintosh (GraphPad Software, San Diego, USA) 
a sigmoidal curve was generated and the half maximal effective concentration 
(EC50) calculated. The EC50 value describes the dose that is required to kill 50% 
of cells. 
 
2.3.5 Cytotoxicity of Inhibitors 
The cytotoxicity of all drugs was assessed prior to treatment to select 
appropriate concentrations for combination assays. Cytotoxicity of zVAD-fmk, 
necrostatin-1 (Enzo Life Sciences, CH) and necrosulfonamide (Calbiochem, USA) 
was assessed by MTT assay. 1x104 cells were plated per well in a 24 well plate as 
above. The next day cells were treated in triplicate with 10µM, 15µM, 20µM and 
25µM zVAD-fmk or 10µM, 30µM, 50µM and 100µM for necrostatin-1 or with 1µM, 
3µM, 5µM and 10µM for necrosulfonamide. Cell survival was assessed either 72 or 
120 hours post treatment as described in 2.4.1. 
 
For assessing cytotoxicity of RIPK3 inhibitors from GSK concentrations of 0.5µM, 
1µM, 3µM and 5µM were tested for GSK2791840B, GSK2399872B and 
GSK2393843A. Cell survival was assessed as described before. 
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To assess the cytotoxicity of RIPK1 inhibitors from GSK concentrations of 1nM, 
10nM, 100nM and 1µM were used for GSK2791728A, GSK3002963A, GSK2791729A 
and GSK3002962A. Cell survival was assessed as described before. 
 
2.3.6 Testing the stability of inhibitors 
Since treatment of cells with inhibitors occurs over a time period of 72 to 120 
hours, experiments to ensure inhibitor stability and performance were 
performed. Necrostatin-1, necrosulfonamide and the GSK inhibitors were 
incubated at desired concentration in appropriate growth medium in tissue 
culture medium for 24, 48, 72, 96 and 120 hours in a tissue culture incubator. 
TOV21G cells were plated at a density of 1x104 cells per well in a 24 well plate. 
The next day cells were treated with TSZ and incubated inhibitors as described 
in 2.4.2 for 24 hours. Cell survival was assessed as described before. 
 
2.3.7 Combination assays of virus, siRNA, drugs and inhibitors 
When inhibitors were used in combination with virus, cells were plated and 
infected with appropriate virus as described in 2.4.3. Two hours after infection 
the appropriate amount of inhibitor was added to each well. Cell survival was 
assessed 120 hours post-transfection as described in 2.4.3. 
 
To assess the effect of human TNF-α blocking antibody (R&D Systems, UK) on 
adenovirus cytotoxicity, 20µg/mL human TNF-α antibody were added 2 hours 
post-infection. Cell survival was measured 120 hours post-infection as described 
in 2.4.3. 
 
When siRNA was used in combination with dl922-947, cells were transfected with 
siRNA as described in 2.5.2 and infected with dl922-947 in triplicate 24 hours 
post-transfection. Multiplicity of infection (MOI) was based upon EC50 from 
previous virus dose responses for the relevant cell line. Cell survival was 
assessed 120 hours post-infection as described previously. 
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2.4 Protein expression levels 
2.4.1 Whole protein lysate preparation 
For whole protein lysate preparation, cells were trypsinised and combined with 
their respective media to inactivate the trypsin. Cells were then pelleted by 
centrifugation and washed in PBS before they were centrifuged again. After the 
supernatant was aspirated, cells were lysed on ice for 15 minutes in 
radioimmunoprecipitation assay (RIPA) buffer (50mM Tris-HCL, pH 7.4, 1% NP-40, 
0.5% Sodium-deoxycholate, 0.1% SDS, 150mM NaCl and 2mM EDTA) containing 
one protease inhibitor cocktail tablet (Roche, GER) per 20mL of RIPA buffer. 
Samples were then centrifuged at 15,000 rpm for 20 minutes and the 
supernatant was transferred to clean 1.5mL Eppendorf tubes. The protein 
concentration was determined using Bio-Rad Protein Assay Dye reagent 
concentrate (Bio-Rad, UK). BSA (Sigma, UK) standards were prepared by diluting 
a 1mg/mL BSA stock solution with RIPA buffer. 10µL of BSA standard or sample 
were added per well in a 96 well plate in triplicates before 200µL of the Bio-Rad 
Protein Assay Dye working solution (1:5 dilution of the Bio-Rad Protein Assay Dye 
reagent concentrate in water) were added to each well. The dye was incubated 
for 10 minutes at room temperature before reading at 595nm. A linear standard 
curve was created using Microsoft Excel Mac 2011 (Microsoft, USA) by plotting 
absorbance against concentration for each BSA standard. The resulting formula 
for this standard curve was used to calculate the protein concentration for each 
unknown sample. 
 
Samples were prepared in water and 5x Laemmli buffer (300mM Tris-HCL pH 6.8, 
10% SDS, 50% Glycerol, 20% β-mercaptoethanol and 250mg bromphenol blue) to a 
final protein concentration of 1µg/µL. Samples were denatured at 95ºC for 5 
minutes and used immediately or stored at -20ºC. 
 
2.4.2 SDS Gel electrophoresis 
Samples were run on a 5% stacking gel (3.7125mL distilled water, 850µL 30% 
Acrylamide, 312.5µL 2M Tris-HCl pH 6.8, 50µL 10% SDS, 50µL 10% AMPS and 5µL 
TEMED and 8% resolving gel (5.25mL distilled water, 2.675 mL 30% Acrylamide, 
1.875mL 2M Tris-HCl pH 8.8, 100µL 10% SDS, 100µL 10% AMPS and 6µL TEMED). 
The gels were prepared on a gel cast system (Bio-Rad, UK). The resolving gel mix 
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was added to the gel cast system and allowed to settle before the stacking gel 
mix was added, and a comb was inserted. The whole gel was allowed to set a 
room temperature before it was transferred for storage into a container with 
distilled water at 4ºC or it was used straight away. 
 
The gel was placed in a Mini-PROTEAN tetra system (Bio-Rad, UK) with 1x Tris-
Glycine SDS PAGE running buffer (25mM Tris, 192mM glycine, 0.1% SDS, pH 8.3) 
and 20µg of protein were loaded per well with the addition of one well 
containing 7µL of Novex Sharp pre-stained protein standards (Invitrogen, UK). 
 
The separated proteins were then transferred onto a nitrocellulose blotting 
membrane (GE Healthcare, UK) using the Mini-PROTEAN tetra system by briefly 
soaking the membrane, gel and blotting paper (Bio-Rad, UK) in transfer buffer 
(25mM Tris, 192mM glycine, 20% methanol). The stack was assembled as 
described with one sponge on the bottom followed by one blotting paper, the 
membrane, the gel, another blotting paper and the sponge. The proteins were 
then transferred for 1 hour at 100V. 
 
After transfer membranes were stained with Ponceau S solution (AppliChem, 
GER) to check for successful transfer of proteins onto the membrane. The 
Ponceau S solution was then washed off with Tris-buffered saline buffer (TBS) 
(20mM Tris-HCl pH7.4, 500mM NaCl) until clean.  The membrane was then 
blocked in 5% (w/v) non-fat milk (Marvel, IRE) in TBST (TBS with 0.2% Tween-20) 
for 1 hour at room temperature. Membranes were briefly washed with TBST 
before incubation with primary antibody overnight at 4ºC or for 1 hour at room 
temperature with gentle rocking motion. Antibodies and conditions are listed in 
table 6 and 7. The membranes were washed 3 times for 5 minutes in TBST, 
followed by incubation in Horseradish Peroxidase (HRP) conjugated secondary 
antibody in 2% BSA-TBST at room temperature for 1 hour. Afterwards the 
membranes were washed in TBST a further 3 times for 5 minutes each. 
 
Proteins were detected using either enhanced chemiluminescence (ECL) Western 
Blotting analysis system or its Prime version (GE Healthcare, UK) and visualized 
using the Bio-Rad ChemieDoc MP Imaging System (Bio-Rad, UK). 
 
		
73	
For the detection of other proteins on the same membrane, membranes were 
stripped for 45 minutes at 50ºC in 50-degree warm harsh stripping buffer (20mL 
10% SDS, 12.5mL 0.5M Tris-HCl pH 6.8, 67.5mL Distilled water, 0.8 mL β-
mercaptoethanol). The membrane was then washed extensively in running tap 
water and was re-blocked in 5% milk in TBST for 1 hour before incubation with 
the next primary antibody. 
 
Table 6: Antibodies used for protein detection by western blotting. 
Primary 
Antibodies 
Catalogue 
number 
Condition Supplier 
Adenovirus-2/5 
E1A 
sc-430 1:1000 in 5% BSA TBST Santa Cruz 
Biotechnology, 
USA 
Anti-Adenovirus ab36851 1:500 in 3% BSA TBST Abcam, UK 
Caspase 8 554002 1:1000 in 5% BSA TBST BD Pharmingen, 
UK 
Caspase 8 4790 1:300 in 5% BSA TBST Cell Signaling, 
USA 
FADD 610399 1:1000 in 5% BSA TBST BD Pharmingen, 
UK 
GAPDH ab9485 1:1000 in 3% BSA TBST Abcam, UK 
MLKL MABC604 1:1000 in 3% BSA TBST Millipore, UK 
MLKL ab184718 1:1000 in 3% BSA TBST Abcam, UK 
Phospho-MLKL 91689 
 
1:1000 in 5% BSA TBST Cell Signaling, 
USA 
RIPK1 3493 1:1000 in 5% BSA TBST Cell Signaling, 
USA 
RIPK3 NBP2-
24588 
1:1000 in 3% BSA TBST Novous 
Biologicals, UK 
Β-Actin ab6276 1:1000 in 3% BSA TBST Abcam, UK 
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Table 7:  Secondary Antibodies used for Western Blotting. 
Secondary 
Antibodies 
Catalogue 
number 
Condition Supplier 
Goat Anti-Mouse 
heavy chain 
ab97240 1:1000 in 2% BSA TBST Abcam, UK 
Rabbit Anti-
Mouse 
P026002-2 1:1000 in 2% BSA TBST Dako, USA 
Goat Anti-Rabbit P044801-2 1:2000 in 2% BSA TBST Dako, USA 
Rabbit Anti-Goat P044901-2 1:1000 in 2% BSA TBST Dako, USA 
Rabbit Anti-Rat P0450 1:1000 in 2% BSA TBST Dako, USA 
Rat Anti-Mouse 
kappa light chain 
ab99632 1:2000 in 3% BSA TBST Abcam, UK 
 
2.4.3 Co-Immunoprecipitation (Co-IP) 
Co-immunoprecipitation was performed to detect the formation of either the 
RIPK1/RIPK3/FADD/Caspase 8-containing ripoptosome or the RIPK1/RIPK3/MLKL-
containing necrosome. 5x106 TOV21G cells were plated in a T150 flask (Corning, 
UK). The next day cells were infected with dl922-947 at 10 plaque-forming units 
per cell (pfu/cell) in serum-free medium. After 2 hours the medium was 
replaced with normal growth medium. As a positive control cells were either 
treated with 100µM etoposide (Fresenius Kabi, UK), 25µM Z.VAD.fmk and 
20ng/mL TNF-α for 24 hours or with TSZ (1µM SM, 25µM Z.VAD.fmk and 20ng/mL 
TNF-α) for 6 hours. Untreated cells were used as a negative control. Cells were 
trypsinised and pelleted by centrifugation at 1200 rpm for 3 minutes in their 
respective medium. The supernatant was then removed and cells were washed 
once in ice cold PBS followed by centrifugation at 1200 rpm for 3 minutes. The 
supernatant was removed and the pellet was resuspended on ice in 1mL of NP40 
buffer (10mM Tris pH 8.0, 150 mM NaCl, 1% Nonidet P-40) with protease and 
phosphatase inhibitor cocktail 2 (Sigma-Aldrich, UK). The lysate was incubated 
for 15 minutes on a rolling wheel at 4ºC and then centrifuged for 20 minutes at 
14,000 rpm at 4ºC. The supernatant was transferred to a fresh Eppendorf tube 
and its protein concentration was determined by Bradford assay. Samples at a 
concentration of 1µg/µL in Laemmli buffer were prepared and denatured at 95ºC 
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for 5 minutes for use as protein input controls while the rest of the sample was 
used for co-IP. 
 
For co-IP 1mg of each protein sample was prepared in a total volume of 500µL. 
The antibodies shown in table 8 were used for the co-immunoprecipitation of 
death-inducing complexes. 
 
Table 8: Antibodies used for co-immunoprecipitation. 
Antibody Concentration Supplier Catalogue 
number 
Caspase-8 1:50 Enzo ADI-AAM-118-E 
RIPK3 1:50 SantaCruz Sc-374639 
 
 
For detection of the ripoptosome, an anti-Caspase 8 antibody (Enzo, UK) was 
added to the lysates while for detection of the necrosome an anti-RIPK3 
antibody (SantaCruz, USA) was added to the lysates. The lysate/antibody mix 
was then incubated overnight at 4ºC on a rolling wheel. The next day 15µL of 
Dynabeads Pan Mouse IgG magnet beads (Invitrogen, UK) per sample were 
washed once in lysis buffer before they were added to the lysate/antibody mix. 
The lysate/antibody/bead mix was then incubated for 2 hours at 4ºC on a rolling 
wheel. After the incubation step the lysates were washed 3 times in ice-cold 
NP40 buffer. To pull down the desired complex 16µL of water and 4µL of 5x 
Laemmli buffer were added to the beads, vortexed and denatured at 95ºC for 5 
minutes. The magnetic beads were removed and the samples run on a SDS-PAGE 
gel.  
 
The SDS gel electrophoresis was performed as described previously. To detect 
human FADD an HRP-conjugated goat anti-mouse IgG1 heavy chain (Abcam, UK) 
specific antibody was used. 
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2.5 Transfection 
2.5.1 Transfection of plasmids into cells 
Two wells were plated for each plasmid/guide at a density of 40000 cells/well in 
a six well plate (Costar, USA). The next day 10µL of Lipofectamine 2000 
(Invitrogen, UK) were carefully added to 240µL Opti-MEM (Gibco by Life 
Technologies, UK) in an Eppendorf tube and mixed by inverting the tube three 
times. In a new tube 4µg of the desired plasmid were carefully added to 250µL 
Opti-MEM and mixed by inverting the tube three times. The tubes were spun 
briefly and incubated at RT for 5 minutes. After 5 minutes the contents of both 
tubes were combined and gently mixed by inverting the tube three times. The 
mix was briefly spun down and incubated for 20 minutes at RT. After 20 minutes 
the whole content (500µL) was added to the intended well by pipetting drops 
over the well. To assure even mixing the plate was gently swirled in the figure of 
an eight. The next day the medium was removed from each well and replaced 
with fresh medium. The following day the media was removed from each well 
and replaced with new media containing 2.5µg/mL puromycin (Sigma-Aldrich, 
UK). After all control wells have died replace media with new media without 
puromycin and let cells grow until they reach 80% confluency. 
 
2.5.2 Transfection of small interfering ribonucleic acid (siRNA)  
Cells were seeded into a six well plate at a density of 5x105 cells per well in 
antibiotic free medium. The following day 2µL Dharmafect 1 (Thermo Scientific, 
UK) and 198µL serum-free Opti-MEM per sample were added, mixed and 
incubated for 5 minutes. Different concentrations of target small interfering 
ribonucleic acid (siRNA) (100nM, 60nM, 30nM and 10nM) were prepared by 
diluting the siRNA in a total volume of 200µL serum-free Opti-MEM. The siRNA 
was mixed and incubated for 5 minutes at room temperature. The same 
conditions were used for the non-targeting control siRNA. Afterwards the 
Dharmafect mix was added to the siRNA mix and mixed by gently pipetting up 
and down and left to incubate for 30 minutes at room temperature. The mix was 
added in droplets to each well. To ensure even mixing the plate was gently 
swirled in the figure of an eight.  
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Cells were incubated with siRNA for 24 hours before the medium was replaced 
with normal growth medium. Depending on the experimental conditions cells 
were harvested 24 - 120 hours post-transfection and prepared for whole protein 
lysis to confirm knockdown of target proteins by western blotting. 
 
2.5.3 Retroviral Transduction 
The pBabe-Bcl-2 plasmid was obtained from KM Ryan, Institute of Cancer 
Sciences University of Glasgow and Cancer Research UK Beatson Institute, 
Glasgow, UK. 
 
The Lzrs-RIPK3 plasmid was obtained from S Tait, Institute of Cancer Sciences 
University of Glasgow and Cancer Research UK Beatson Institute, Glasgow, UK 
and described in (Rodriguez et al. 2016) 
 
Phoenix Ampho cells were plated at a density of 2x106 cells per 10cm plate 
(Corning, UK). The next day a transfection mix was prepared by adding 400µL 
Opti-MEM to 5µg retroviral plasmid and 400µL of Opti-MEM to 10µL 
Lipofectamine 2000. Each mix was incubated for 5 minutes at room temperature 
before they were combined, briefly centrifuged and incubated for another 20 
minutes at room temperature. 6.2mL antibiotic-free DMEM were added to the 
810µL transfection mix and added to the cells. After 6 hours of incubation, cells 
were gently washed twice with PBS and normal medium was added to the cells. 
After 48 hours the viral supernatant was collected, filtered, polybrene added at 
a 1:1000 dilution and added to the desired target cells. New medium was added 
to Phoenix Ampho cells to maintain virus production. The next day viral 
supernatant was collected as described before and target cells were infected for 
a second time. The next day the transduced cells were washed twice with PBS 
and fresh growth medium was added. Cells were left to recover before selection 
medium containing antibiotics was added. 
 
2.6 Flow Cytometry 
2.6.1 Measuring viral cell entry 
Flow cytometry was used to measure infectability of cells. Cells were plated in 
triplicate on 6 well plates at a density of 5x105 cells per plate. After 24 hours 
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cells were infected with Ad-GFP, an E1-deleted Ad5 vector that expresses the 
green fluorescent protein driven by a CMV-promoter, at MOI 5 and 50 for each 
condition. Cell were trypsinised 24 hours after infection, washed three times in 
PBS and resuspended in a total volume of 500µL PBS. Samples were analysed in a 
BD FACS Calibur cytometer (BD Biosciences, USA) using FlowJo software 8.8.4. 
Infectivity was determined by comparing the percentages of GFP-positive events 
after a total of 10,000 events were recorded. 
 
2.7 Microscopy 
2.7.1 Transmission Electron Microscopy (TEM) 
TOV21G and OVCAR4 cells were plated separately on Thermanox coverslips (Agar 
Scientific Ltd., UK) at a density of 5x105 cells/well in a 6 well plate in 2mL of 
growth medium. The next day cells were infected in triplicate with dl922-947 in 
serum-free medium (MOI 1 pfu/cell for TOV21G, MOI 3 for OVCAR4). After 2 
hours the medium was replaced with normal growth medium. As a positive 
control cells were treated with 1mM SM, 25µM Z.VAD.fmk and 20ng/mL TNF-α 
for 6 hours (TOV21G) or 24 hours (OVCAR4). In both cases untreated cells were 
used as a negative control. Cells were then washed in PBS and fixed in 1.5% 
glutaraldehyde/0.1M sodium cacodylate buffer for 1 hour at 4ºC. Afterwards the 
cells were washed three times for 5 minutes each in 2% sucrose/0.1M sodium 
cacodylate buffer rinse. 
 
Further processing was carried out by Margaret Mullin, Electron Microscopy 
Facility, University of Glasgow. Samples were post-fixed in 1% osmium 
tetraoxide/0.1M sodium cacodylate buffer for three times 10 minutes and 
washed for 30 minutes in distilled water. Samples were then block stained with 
0.5% aqueous uranyl acetate for 1 hour in the dark and washed again twice for 1 
minute each with distilled water. The samples were then dehydrated through a 
graded ethanol series of 30%, 50%, 70% and 90% ethanol for 10 minutes for each 
concentration followed by absolute ethanol for four times for 5 minutes each. 
Afterwards the samples were transferred into dried absolute ethanol four times 
five minutes each and moved into propylene oxide for three times 5 minutes 
each. The samples were then put into 1:1 propylene oxide: araldite/epoxy 812 
resin overnight. The next day samples were changed to fresh resin, embedded in 
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flat bed moulds and polymerized for 48 hours at 60ºC. The coverslip was 
removed by inverting into liquid nitrogen and the coverslip was “popped-off” 
leaving the cells embedded in the resin. 
 
60-70nm ultrathin sections were produced using a LEICA Ultracut UCT (Leica 
Microsystems, UK) and Diatome diamond knife (Diatome, USA) at an angle of 6 
degrees. Sample sections were picked up on 100mesh formvar coated copper 
grids and then contrast stained with 2% methanolic uranyl acetate for 5 minutes 
followed by Reynolds Lead Citrate for 5 minutes. 
 
Samples were viewed on a FEI Tecnai T20 (Zeiss, UK) at an accelerating voltage 
of 200kV and images were captured using the GATAM Digital Imaging system. 
 
2.8 Gene Editing Techniques 
2.8.1 Clustered regularly-interspaced short palindromic repeats (CRISPR) 
CRISPR/Cas9 technology was used to induce gene deletions in human Mixed-
lineage kinase like (MLKL) in TOV21G cells. 
 
2.8.1.1 Designing guides 
The desired gene target sequences were analysed for potential guides using 
https://chopchop.rc.fas.harvard.edu and http://crispr.mit.edu/. Guides were 
chosen depending on a high score, which represented the inverse likelihood of 
off-target binding. Another selection criterion for guide selection was that 
guides should target important functional structures within the protein needed 
for the induction or execution of programmed necrosis.  
 
For MLKL the following guide for MLKL was used: 
Guide 5: AACACAGACTTCCATGAGTTTGG located at MLKL’s catalytic sites and  
 
Oligos were ordered from Invitrogen (Invitrogen, UK). 
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2.8.1.2 Annealing of oligos and restriction digest 
Oligos were resupended at 100µM in nuclease-free water (Ambion, USA) and 1µL 
of each oligo was added to 1µL of 10x annealing buffer (100mM Tris, pH 7.5, 
500mM NaCl, 10mM EDTA) and 7µL nuclease-free water. The annealing mix was 
placed in a mini dry bath (Flowgen Bioscience, UK) for 3 minutes at 95ºC and 
then left for another 20 minutes with the mini dry bath being switched off and 
was then left to cool to room temperature (RT). A sample of the annealed oligos 
was diluted 1 in 250 with nuclease-free water. 
 
The plasmid pX335 was digested with Bbsl (New England Biolabs, UK). 20 units of 
Bbsl were added to 1µg of DNA, 5µL of 10x NEB buffer (50mM NaCl, 10mM Tris-
HCL, 10mM MgCl2, 100µg/mL Bovine serum albumin (BSA), pH 7.9 at 25ºC and 
topped up with nuclease free water to a total reaction volume of 50µL. The 
reaction mix was then incubated at 37ºC for 1 hour on a Grant JBN/5 water bath 
(Grant Instruments, UK). 
 
The digest was run on a 0.7% agarose (Melford biolaboratories Ltd, UK) gel with 
0.002% ethidium bromide solution (Sigma, UK). 0.7% w/v agarose was dissolved 
in Tris-acetate-EDTA (TAE) buffer (40mM Tris pH 7.6, 20mM acetic acid, 1mM 
EDTA) and casted in a Bio-Rad Sub-Cell GT chamber (Bio-Rad, UK) with combs 
and allowed to set at room temperature. Once the agarose gel was set, the 
chamber was filled with TAE buffer. 10µL of 6x Orange DNA loading dye (Thermo 
Scientific, UK) was added to the whole digest and added to one well of the gel 
alongside with 5µL O’GeneRuler 1kb DNA ladder (Thermo Scientific, UK). The gel 
was run at 20V overnight at room temperature. 
 
2.8.1.3 DNA Extraction  
To extract linearised plasmid DNA a QIAquick Gel Extraction Kit (Qiagen, UK) was 
used. The gel was excised on a high performance transilluminator (Ultra Violet 
Products, USA) and the desired DNA fragment was removed using a disposable 
scalpel (Swann-Morton, UK). The removed slice of gel was transferred to a clean 
Eppendorf tube and weighed on a Secura 224-1CEU scale (Satorius, UK). 3 
volumes of buffer QG were added to 1 volume gel. The buffer and gel were 
incubated at 50ºC for 10 minutes with vortexing on a Grant-bio PV-1 Vortex 
Mixer (Grant, UK) or until the gel slice was completely dissolved resulting in a 
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yellow colour of the mix. One volume of isopropanol (Sigma-Aldrich, UK) was 
added to the sample and mixed well. Afterwards the sample was placed in a 
QIAquick spin column with the provided collection tube and centrifuged on an 
Eppendorf Centrifuge 5424 (Eppendorf, UK) at full speed for 1 minute. The flow-
through was discarded and 500µL of buffer QG were added to the column and 
centrifuged at full speed for 1 minute. The flow-through was discarded again 
and 750µL of buffer PE were added and left to incubate for 5 minutes. Then the 
mix was spun at full speed for 1 minute twice to remove residual wash buffer 
while the flow-through was discarded each time. To elute the DNA 50µL of 
buffer EB were added to the centre of the membrane, incubated for 3 minutes 
and centrifuged for 1 minute at full speed. The DNA concentration was measured 
on a Nanodrop 2000 Spectrophotometer (Thermo Scientific, UK).  
 
2.8.1.4  Ligation and transformation into competent E.coli 
To ligate the oligos with the vector a ligation mix was prepared using the Roche 
rapid Ligation Kit. 50ng of pX335 vector were added to 1µL of diluted annealed 
oligos and toped up with nuclease-free water to a total volume of 9µL. Then 
10µL of the 2x reaction buffer and 1µL of T4 DNA Ligase were added and left for 
incubation at room temperature for 5 minutes. 
 
25µL of One Shot TOP10 chemically competent E. coli cells (Invitrogen, UK) were 
transformed with 2µL of the ligation mix. The cells were first left on ice for 5 
minutes, were then heat shocked at 42ºC in a water bath for 30 seconds and 
were then immediately transferred back on ice for another 2 minutes. 1mL of 
warm super optimal broth with catabolite repression medium (S.O.C.) (2% w/v 
Tryptone, 0.5% w/v yeast extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM 
MgSO4, 20mM glucose) (Invitrogen, UK) was added and incubated for 1 hour at 
37ºC. The cell suspension was then spun down, resuspended in 100µL water and 
plated out on 100 µg/mL ampicillin (Calbiochem, USA) containing Lennox L broth 
(LB) (1% w/v SELECT peptone 140, 0.5% w/v SELECT yeast extract, 0.5% w/v 
NaCl, 1.5% w/v Agar (Sigma, UK)) (Invitrogen, UK) plates. The plates were 
incubated overnight at 37ºC in a Genlab mini/75 incubator (Genlab Limited, 
USA). 
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2.8.1.5  Plasmid Miniprep and sequencing 
After overnight incubation, three different single colonies were picked from 
each plate, transferred to 7mL LB containing 100µg/mL ampicillin in culture 
tubes (VWR, USA) and incubated overnight at 37ºC in an Innova 44 
incubatorshaker series (New Brunswick Scientific, UK). The next day 2mL of cell 
culture were put aside for later expansion and the left 5mL were spun down at 
2000 rpm for 15 minutes on an Allegra x-12R centrifuge (Beckman Coulter, USA). 
The supernatant was removed and the resulting pellet was used for sequencing. 
 
All plasmids were sequenced by the molecular technology and reagent service at 
the Cancer Research UK Beatson Institute on an Applied Biosystems 3130xl 
sequencer (Applied Biosystems, UK) using the BigDye v3.1 Cycle Sequencing Kit 
(Applied Biosystems, UK). 
 
2.8.1.6  Plasmid isolation 
After sequencing results were obtained one colony was chosen and expanded by 
adding the 2mL of the remaining cell culture to 250mL of LB containing 
100µg/mL ampicillin. The starter culture was incubated overnight at 37ºC. The 
next day cells were pelleted at 2000 rpm for 15 minutes on a Beckman Coulter 
J6-MI centrifuge (Beckman Coulter, USA) and the resulting cell pellet was used 
for plasmid isolation. 
 
Plasmids were isolated and purified by the molecular technology and reagent 
service at the Cancer Research UK Beatson Institute using a Qiagen 8000 
Biorobot (Qiagen, UK).  
 
2.8.1.7  Transfection with CRISPR/Cas9 guides 
Guides were transfected as described in 2.5.1. 
2.8.1.8  Dilution Cloning and screening for deletion clones 
Once cells reached 80% confluency, they were trypsinized and resuspended in 
medium and counted on a Cellometer Auto 1000 (Nexcelon Bioscience, UK). To 
make dilution clones 200,000 cells were resuspended in 5mL of medium followed 
by two 10x dilutions of 500µL cell suspension in 4.5mL medium. After the last 
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dilution 1mL of this dilution was added to 39mL of media to give an average of 
10 cells per mL. 200µL of the cell suspension were pipetted into each well of a 
96 well plate (Costar, USA) to give an average of 2 cells per well. Five days after 
plating the wells were inspected for visible colonies and single cell colonies were 
recorded. After another 4 days plates were checked again as colonies become 
more obvious over time. 
 
After single cell colonies reached 80% confluency, cells were trypsinized and 
resuspended in 150µL medium. Single cell clones were plated on a 96 well plate 
by adding 50µL of the cell suspension to 150µL new medium, resulting in three 
96 well plates with one replicate of each single cell clone. Once cells reached 
60% confluency, one plate was frozen down for later use, one plate was used for 
picking control clones and one plate was used for the screen. Deletion clones 
were screened by treating the cells with 20ng/mL recombinant human Tumour 
Necrosis Factor-α (TNF-α) (PeproTech, USA), 1µM LCL-161/smac-mimetic (SM) 
(Chemie Tek, USA) and 25µM carbobenzoxy-valyl-alanyl-[O-methyl]-
fluoromethylketone (Z.VAD.fmk) (ApexBio, USA). The next day surviving clones 
were recorded as potential knock out or deletion clones while dead clones were 
recorded as potential control clones. Clones were checked again 72 hours later 
to see if there was a time difference in response to the treatment.  
 
2.8.1.9  DNA Extraction and PCR 
DNA was extracted from cultured cells using the QIAamp DNA FFPE Tissue Kit 
(Qiagen, UK). 5x106 cells were trypsinized, washed in PBS, centrifuged and 
resuspended in 200µL PBS and 10µL proteinase K was added. 200µL buffer AL was 
added, mixed and 96% ethanol were added and mixed thoroughly by vortexing. 
The mixture was transferred to a DNeasy spin column with 2mL collection tube 
and centrifuged at 6000xg for 1 minute. The flow-through was discarded and the 
column placed in a new collection tube. 500µL buffer AW1 were added, 
centrifuged at 6000xg for 1 minute and the flow-through was discarded with the 
collection tube. The spin column was placed in a new 2mL collection tube, 
500µL buffer AW2 were added, centrifuged at 20,000xg for 3 minutes and the 
flow-through was discarded with the collection tube. The spin column was then 
transferred to a new 1.5mL eppendorf tube. DNA was eluted by adding 200µL 
nuclease-free water onto the membrane of the spin column, incubating it at 
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room temperature for 1 minute followed by centrifugation for 1 minute at 
6000xg. 
 
PCR mastermix was prepared by adding 1µL 10mM dNTP with 1.5µL 50mM MgCl2, 
2.5µL 10µM forward primer, 2.5µL 10µL reverse primer, 5µL 10x PCR buffer, 
0.3µL Taq polymerase per reaction. 20ng template DNA was added to nuclease-
free water to a total volume of 37.2µL per sample. The PCR mastermix was 
added to the sample (50µL total volume), gently mixed, centrifuged and 
incubated in a thermal cycler using the following conditions shown in table 9. 
 
The following primer pair was used for clones targeted with guide 5: 
Forward: TAGCAACAATCCCTGCCCTTTAC 
Reverse: TCAAACTCCTCCAAGGACCACC 
 
Primers were ordered from Invitrogen (Invitrogen, UK). 
 
Table 9: PCR program settings 
 Polymerase 
Activation/ DNA 
Denaturation 
PCR Reaction 
Cycle 1 35 cycle 
Temperature 
(ºC) 
94 94 55 72 
Time 3 mins 45 sec 30 sec 90 sec 
 
An agarose gel was prepared and samples run as described previously. 
 
2.8.1.10 Transformation of PCR product into competent E.coli 
The TOPO TA Cloning Kit (Invitrogen, UK) was used for transformation of PCR 
amplified products into E.coli. 2µL of fresh PCR product was added to 1µL salt 
solution, 2µL water and 1µL TOPO vector. The reaction mix was incubated for 30 
minutes at room temperature and transformed into competent E.coli as 
described previously, miniprepped and sequenced using M13 forward and reverse 
primers. 
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2.9  PCR based assays 
2.9.1 qRT-PCR 
2.9.1.1 RNA Extraction from Cells 
The Qiagen RNeasy kit (Qiagen, UK) was used for RNA extractions from human 
cells. Cells were plated at a density of 5x106 cells per 10cm dish (Corning, UK). 
The next day cells were harvested as a pellet, 350µL RLT buffer were added, 
vortexed followed by the addition of 350µL 70% ethanol. Following thorough 
mixing, the sample was transferred to an RNeasy Mini spin column with 2mL 
collection tube and centrifuged for 15 seconds at 8,000xg. The flow-through was 
discarded. 
 
For the on-column DNase digestion 350µL buffer RW1 were added and 
centrifuged for 15 seconds at 8,000xg. The flow-through was discarded and a 
DNase incubation mix prepared. For every sample 10µL DNase 1 stock were 
added to 70µL buffer RDD. The mix was gently mixed by inverting and briefly 
centrifuged. 80µL DNase mix were added onto the membrane of each column 
and incubated for 15 minutes at RT. Afterwards 350µL of buffer RW1 were added 
to the column, centrifuged for 15 seconds at 8,000xg and the flow-through 
discarded. Then 700µL of buffer RW1 were added to the column, centrifuged for 
15 seconds at 8,000xg and the flow-through was discarded. Samples were then 
washed twice with 500µL of RPE buffer by centrifugation for 15 seconds at 
8,000xg and 2 minutes at 8,000xg. The flow-through was discarded after each 
wash in RPE. The column was placed in a new 1.5mL collection tube and 30-50µL 
RNase-free water were added and centrifuged for 1 minute at 8,000xg to elute 
the RNA. The eluted RNA was then aliquoted and stored at -80ºC for later use or 
used straight away. Samples were analysed on a Nanodrop 2000 
spectrophotometer. 
 
2.9.1.2 Reverse Transcription (RT) 
The ABI High Capacity cDNA Transcription Kit (ABI, UK) was used for reverse 
transcribing total RNA. 0.5 -1µg RNA were transcribed per sample. The desired 
amount of RNA was prepared in a total volume of 10µL in nuclease-free water. A 
2x RT mastermix was prepared by adding 2µL 10x RT buffer, 0.8µL 25x dNTP 
mix, 2µL 10x Random Primers, 1µL Reverse Transcriptase and 4.2µL nuclease-
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free water per sample. 10µL of 2x RT mastermix were added to 10µL RNA sample 
in a fresh PCR tube and mixed gently before briefly centrifuging. Tubes were 
place on ice until they were ready to load onto the thermal cycler. Samples 
were run on a Veriti 96 well thermal cycler (Thermo Fisher, UK) using the 
conditions shown in table 10. 
 
Table 10: Thermal cycler conditions for RT. 
 Step 1 Step 2 Step 3 Step 4 
Temperature (ºC) 25 37 85 4 
Time (min) 10 120 4 ∞ 
 
cDNA samples were removed from the thermal cycler and kept on ice while the 
universal probe mix (Bio-Rad, UK) was thawed at room temperature. 
 
2.9.1.3 qRT-PCR for simplex experiment 
Mastermix was prepared by adding 10µL 2x iTaq Universal Probe supermix to 1µL 
20x Primer/Probe assay and 7µL nuclease-free water per sample. The mastermix 
was gently mixed, briefly centrifuged and kept on ice until ready to use. 2µL of 
DNA template were added to the bottom of a PCR plate well followed by the 
addition of 18µL of appropriate mastermix. The plate was sealed and run on a 
CFX96 Real time System (Bio-Rad, UK) using the conditions shown in table 11. 
 
Table 11: Cycling conditions for BioRad iTaq Universal Probes conditions. 
 Polymerase Activation/ 
DNA Denaturation 
PCR Reaction 
Cycle 1 40 cycle 
Temperature (ºC) 95 95 60 
Time 2-5 mins 2-5 sec 30 sec 
 
Files were analysed in BioRad CFX Manager. 
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2.10  In vivo experiments 
All animal experiments were performed in the Cancer Research UK Beatson 
Institute Biological Services Unit (registered facility 60/2607) under appropriate 
Home Office personal (40/04001) and project licence (60/4181) authority. All 
experiments adhered to NCRI Guidelines on the use of animals in medical 
research (Workman et al. 2010). Animals were allocated treatment randomly by 
cage.  All injections and tumour measurements, as well as all decisions about 
animal welfare were taken by BSU staff to prevent bias. Tumour volume was 
calculated using equation: 
 𝑥2×𝑦×𝑦 
 
Where χ= longest diameter and y= perpendicular width 
 
2.10.1 Intratumoural spread of dl922-947 
Female CD1 nu/nu mice were injected subcutaneously with 5x106 HeLa Lzrs, 
HeLa RIPK3 D2 or HeLa RIPK3 E4 cells in 100µL PBS. After tumours reached 100-
200mm3 in volume, mice were randomly separated into two groups of 4 per cell 
line. One group received a single intratumoural dose of 1x1010 particles of dl922-
947 while the other group received a single intratumoural dose of PBS. 48 hours 
after injection mice were killed and tumours excised. Tumours were cut into 
two parts; one part was snap frozen on dry ice, whilst the other was fixed in 10% 
NBF over night before they were handed over to the histology service at the 
Cancer Research UK Beatson Institute, where they were processed and stained 
for adenoviral proteins by immunohistochemistry. 
 
2.10.2 Intratumoural efficacy of dl922-947 
Female CD1 nu/nu mice were injected subcutaneously with 5x106 HeLa Lzrs, 
HeLa RIPK3 D2 or HeLa RIPK3 E4 cells in 100µL of PBS. Mice were randomly 
separated into two groups of 4 per cell line. Each group received a total of two-
intratumoural doses of 1x1010 particles of dl922-947 or a dose of PBS. The first 
dose was administered after tumours 100-200mm3 in volume followed by a 
second dose 9 days after the first injection. Mice were monitored for signs of ill 
health and tumour volumes were measured three times a week. Mice were killed 
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when tumours reached the maximum allowed size of 1.4cm3 or when there were 
signs of ulceration in accordance with the UK Home Office regulations. 
 
2.11  Immunohistochemistry 
2.11.1 Tissue Preservation and Processing 
Harvested tissues were fixed overnight in 10% Neutral Buffered Formaldehyde 
(NBF) (CellPath, UK). The overnight processing of the samples was performed by 
the histology service at the Cancer Research UK Beatson Institute. The following 
steps were performed at 40ºC in a Thermo Excelsior Tissue Processor (Thermo 
Scientific, UK) unless stated otherwise. The cassetted tissues were transferred 
to 70% ethanol for 35 minutes, followed by 40 minutes in 90% ethanol, 45 
minutes in 95% ethanol, 50 minutes in 100% ethanol, another 50 minutes in 100% 
ethanol and a further 55 minutes in 100% ethanol. Tissues were then transferred 
through xylene for 45, 50 and 60 minutes and then immersed into wax at 61ºC 
for 70, 80 and 100 minutes. The tissues were then sectioned at 4µm and stained 
with Haematoxlin and Eosin (H&E) to display morphological structure. 
 
2.11.2 Immunostaining on paraffin sections: Anti-Adenovirus-2/5 E1A 
Anti-Adenovirus-2/5 E1A (Santa-Cruz Biotechnology, USA) or IgG control staining 
was performed on HeLa Lzrs, HeLa RIPK3 D2 and HeLa RIPK3 E4 tumours, which 
had been injected either with PBS or with or 1x1010 particles of dl922-947 for 48 
hours. Staining was performed on 4µm sections by the histology service at the 
Cancer Research UK Beatson Institute.  
 
Sections were de-waxed for 5 minutes in xylene, followed by rehydration 
through 2x 1 minute immersions in 100% ethanol, 1 minute in 70% ethanol 
followed by a 5 minute wash in water. Sections were placed for 25 minutes in PT 
Module (Dako, UK) containing pH6 sodium citrate retrieval buffer (Thermo 
Scientific, UK) at 98ºC and washed in Tris-buffered Tween (TBT).  
 
All staining was performed on a Dako Autostainer Link48. Peroxidase block 
(Dako, UK) was initially dispensed on the sections were for 5 minutes to quench 
endogenous peroxidases before washing sections with TBT. Sections were 
incubated with anti-adenovirus-2/5 E1A at a 1:200 dilution for 35 minutes and 
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washed twice in TBT, followed by a 30-minute incubation with Rabbit EnVision 
(Dako, USA) and another 2 washes in TBT. Next sections were incubated for 10 
minutes in 3,3’-Diaminobenzidine tetrahydrochloride to visualize antibody-
antigen complex before washing for 1 minute in deionized water to terminate 
chromogenic reaction. The sections were then stained with Haematoxylin Z 
(Cellpath, UK) for 7 minutes and washed for 1 minute in deionized water. 
Sections were next dipped twice into 1% acid alcohol, washed for 30 seconds in 
water and transferred for 1 minute into Scotts Tap Water Substitute to blue the 
nuclei. Samples were then dehydrated through graded alcohol, cleared with 
xylene and mounted with DPX mountant for microscopy (CellPath, UK).  
 
2.11.3 Immunostaining on paraffin sections: Anti-Adenovirus 
The immunohistochemical protocol used for the anti-Adenovirus (Abcam, UK) or 
IgG control staining was the same as described in section 2.8.1.2 with the 
following exceptions: after the endogenous peroxidase was blocked, sections 
were washed twice in TBT. 2.5% Normal horse serum (Vector, UK) was applied to 
the section for 20 minutes before two washes with TBT. The anti-Adenovirus 
antibody was applied at a 1:1000 dilution for 35 minutes and two washes in TBT. 
Afterwards sections were incubated for 30 minutes in ImmPRESS anti-goat 
reagent (Vector, UK) followed by the steps described in section 2.8.1.2.  
 
2.11.4 Immunostaining on paraffin sections: F4/80 
The immunohistochemical protocol used for the Anti-F4/80 (Abcam, UK) or IgG 
control staining was the same as described in section 2.8.1.2 with the following 
exceptions: After sections were placed in 70% ethanol, they were washed under 
running tap water for 5 minutes, washed for 5 minutes in TBT and treated with 
Proteinase K solution (Dako, UK) for 10 minutes. Sections were then washed 
once in TBT, blocked for endogenous peroxidase for 5 minutes, washed twice in 
TBT and blocked for 30 minutes in ImmPRESS normal goat blocking serum. 
Afterwards section were washed twice in TBT, incubated for 35 minutes in F4/80 
(Abcam, UK) at a 1:400 dilution, washed twice in TBT and incubated for 30 
minutes in ImmPRESS anti-Rat reagent (Vector, UK) followed by the steps 
described in section 2.8.1.2. 
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2.11.5  Immunostaining on paraffin sections: NIMP 
The immunohistochemical protocol used for the Anti-F4/80 (Abcam, UK) or IgG 
control staining was the same as described in section 2.8.1.2 with the following 
exceptions: After sections were placed in 70% ethanol, they were washed under 
running tap water for 5 minutes, washed for 5 minutes in TBT and treated with 
Proteinase K solution (Dako, UK) for 10 minutes. Sections were then washed 
once in TBT, blocked for endogenous peroxidase for 5 minutes, washed twice in 
TBT and blocked for 30 minutes in ImmPRESS normal goat blocking serum. 
Afterwards section were washed twice in TBT, incubated for 35 minutes in NIMP-
R14  (Abcam, UK) at a 1:50 dilution, washed twice in TBT and incubated for 30 
minutes in ImmPRESS anti-Rat reagent (Vector, UK). Next sections were 
incubated for 10 minutes in 3,3’-Diaminobenzidine tetrahydrochloride to 
visualize antibody-antigen complex before washing for 1 minute in deionized 
water to terminate chromogenic reaction and followed by the steps described in 
section 2.8.1.2. 
 
2.11.6  Cytospin 
Cytospin analysis was performed by Elaine Leung and Darren P. Ennis, Institute 
of Cancer Sciences, University of Glasgow. Slides with filter cards and sample 
chambers were put into slide holders and attached to the cytocentrifuge rotor. 
Next a stock solution containing 2x105 cells/mL PBS was prepared. 0.1mL (2x104 
cells/slide) was added to the cell suspension chamber and centrifuged at 
1000rpm for five minutes. Slides were then removed and incubated in UMFIX for 
3 minutes, followed by two washes, each five minutes in PBS.  
 
2.11.7  Immunostaining on cytospin slides: CK7 
Slides were stained by Jane MacMillan at the Histology service unit at the Queen 
Elizabeth University Hospital, Glasgow, UK, according to standard protocol for 
CK7 (NCL-L-CK7, Leica, UK).  
 
2.11.8  Immunostaining on cytospin slides: ERA 
Slides were stained by Jane MacMillan at the Histology service unit at the Queen 
Elizabeth University Hospital, Glasgow, UK, according to standard protocol for 
ERA (ERA M3525, DAKO, UK).  
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2.11.9  Histoscoring 
Histoscoring was performed by Clare Orange, Institute of Cancer Sciences, 
University of Glasgow. Slides were digitised using the Hamamatsu NanoZoomer 
slide scanner, at 20x objective lens with 0.75 numerical aperture (NA).  Images 
were then stored on our dedicated servers and loaded to Leica Microsystems 
Slidepath Digital Image Hub v4.0 (DIH). 
 
Images were analysed using the Image Analysis module of the DIH.  Algorithms 
are available for nuclear, cytoplasmic and membranous staining using the 
Measure Stained Cells algorithm embedded in the software. The algorithms are 
applied on a threshold and segmentation basis and parameters can be adjusted 
within these algorithms to suit the size, shape and proximity of cells of interest. 
 
Cells are classed as positive or negative and then further graded as strong, 
moderate or weak depending on the intensity thresholds set. Results are 
returned as a weighted Histoscore along with number and percentage of 
negatively and positively stained cells. 
 
Areas of necrosis within tumours (defined as regions lacking nuclei) was 
measured using the area measuring tool on Slidepath Digital Image HUB and 
presented as percentage total tumour area per section. 
 
2.12  Statistics 
Microsoft Excel 2011 for Macintosh (Microsoft Corporation, USA) was used to 
normalise cell survival in treated cells as, presented as percentage of untreated 
cell (100%) and to calculate mean and standard deviation. 
 
GraphPad Prism version 6.0d for Macintosh (GraphPad Software, San Diego, USA) 
was used to generate sigmoid dose response curves and to calculate the EC50, 
which describes the dose that is required to kill 50% of cells.  
 
All statistical analyses were performed using GraphPad Prism (version 6.0d). Cell 
survival and IC50 values were compared using unpaired t-test or One Way ANOVA 
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with multiple comparisons and p<0.05 (*) was considered statistically significant 
throughout. The level of statistical significance is shown using asterisk (*p<0.05, 
**p<0.01, ***p<0.001 and ****p<0.0001). 
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3 Adenoviruses and their potential in ovarian cancer 
treatment 
3.1 Introduction 	
As discussed in the chapters above, adenoviruses contain features that make 
them suitable for oncolytic virotherapy, especially viruses of the serotype 5 that 
have been tested in many models of pre-clinical research (Davison et al. 2001, 
Heise et al. 2000, Satoh et al. 2007, Cherubini et al. 2011, Bhattacharyya et al. 
2011), where they have showed promising activity. In this chapter, I aim to 
assess the potential of dl922-947 for the treatment of ovarian cancer and to 
compare the cytotoxicity induced by Ad5WT, Ad11, Ad35 and dl922-947. I 
further aim to assess the potential of dl922-947 for the treatment of ovarian 
cancer, cytotoxicity, infectivity and the expression of viral proteins during 
infection in vitro was assessed in IGROV1, OVCAR4 and TOV21G and its efficacy 
in lysing human primary ascites cells. 
 
3.2 Cytotoxicity of adenovirus in vitro 
To test the oncolytic efficacy of several adenovirus serotypes, human ovarian 
cancer cell lines were infected with wild-type Ad5 (Ad5WT), Ad11, Ad35 as well 
as the E1A CR2-deleted Ad5 vector dl922-947 to examine their sensitivity to 
oncolytic adenovirus and to evaluate their potential as a therapeutic agent. 
 
A panel of human ovarian cancer cells was infected with increasing MOI of 
indicated adenovirus serotypes and cell survival was measured 120 hours post-
infection by MTT assay (Figure 3-1). Adenovirus serotype 35 (Ad35) showed the 
same sensitivity in IGROV1 (EC50: 1.6 pfu/cell), OVCAR4 (EC50: 3.3 pfu/cell), and 
TOV21G (EC50: 1.8 pfu/cell), with no significant difference between EC50. 
Adenovirus serotype 11 (Ad11) also showed no difference in sensitivity between 
cell lines: IGROV1 (EC50: 41.8), OVCAR4 (EC50: 38.9) and TOV21G (EC50: 40.1). 
TOV21G (EC50: 1.2) was most sensitive to Adenovirus 5 wild type (Ad5WT) while 
IGROV1 (EC50: 40.8), was the least. Sensitivity of OVCAR4 (EC50: 14.6) was in the 
middle of IGROV1 and TOV21G, when infected with Ad5WT. The amount of cell 
death induced by dl922-947 was either comparable or significantly higher than 
Ad5WT for each cell line. TOV21G (EC50: 0.1) was most sensitive to dl922-947, 
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followed by OVCAR4 (EC50: 4.4) and with IGROV1 (EC50: 5.6) being least 
sensitive. These results are consistent with previous publications from the host 
lab (Lockley et al. 2006). 
 
 
Figure 3-1: Cytotoxicity of Ad5WT, dl922-947, Ad11 and Ad35 in the human ovarian cancer 
cell lines IGROV1, OVCAR4 and TOV21G                                                                                         
Cells were infected in triplicate with a serial dilution of indicated viruses and cell survival was 
assessed 120 hours post-infection by MTT assay. Cell survival was normalized to uninfected cells 
and the EC50 values calculated from sigmoidal dose response curves using GraphPad Prism. 
Shown are EC50 values. Points represent mean EC50 +/- STDEV from at least three experiments 
with each experiment performed in triplicate.                                                                                                         
P values are calculated using One way ANOVA with multiple comparisons ** shows p<0.01. 
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3.3 Infectability with adenovirus type 5 vectors 
As shown in table 3 adenoviruses of the serotype 5 use CAR as their primary 
cellular attachment receptor, but the expression of CAR itself varies between 
cell lines and as shown previously, can even be up-regulated in paclitaxel 
resistant cells (Ingemarsdotter et al. 2015). Therefore, I wanted to investigate if 
differences in infectivity in cell lines can be a cause for the differences in 
cytotoxicity described above.  
 
A way to measure infectivity is by infecting different cell lines with Ad-GFP, 
which is an E1-deleted non-replicating type 5-adenovirus. Ad-GFP contains a 
CMV early promoter, which drives the expression of the green fluorescent 
protein (GFP). 24 hours after cells have been infected at a known MOI, 
infectivity can be determined as the percentage of GFP-positive cells and be 
compared between different cell lines using flow cytometry. IGROV1, OVCAR4 
and TOV21G were infected with Ad-GFP at MOI 5. 24 hours post-infection, cells 
were analysed and infectivity was determined after 10,000 total events were 
recorded. 
 
Figure 3-2 shows infectability of IGROV1, OVCAR4 and TOV21G with Ad-GFP. 
After 24 hours post-infection at MOI 5 76.7% of IGROV1 cells were GFP-positive, 
57.7% of OVCAR4 cells were positive and 92.3% of TOV21G cells were positive. 
According to this data TOV21G is the most infectable cell line followed by 
IGROV1 and with OVCAR4 being the least infectable cell line. For easier reading 
table 12 shows GFP percentage for each cell line and condition. 
 
 
Table 12: Percentage of GFP positive cells for each condition. 
Cell line GFP positivity (%) 
 dl922-947 MOI 5 Ad-GFP MOI 5 
IGROV1 0.011 76.7 
OVCAR4 0.057 57.7 
TOV21G 0.022 92.3 
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Figure 3-2: Infectability of IGROV1, OVCAR4 and TOV21G with Ad-GFP in vitro                       
A) IGROV1,                                                                                                                                         
B) OVCAR4 and                                                                                                                                 
C) TOV21G were either infected with dl922-947 or Ad-GFP at MOI 5 for 24 hours in duplicate. After 
24 hours, cells were prepared for flow cytometry analysis. Cells were analysed for GFP expression 
after 10,000 events were recorded. Shown are representative graphs from one experiment 
performed in duplicate. 
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3.4 Expression of viral proteins during dl922-947 infection 
Besides infectivity, the expression of viral proteins can differ from cell line to 
cell line, meaning that some cell lines might have the machinery to allow faster 
transcription and/or translation of viral proteins. This can lead to the production 
of more infectious virus particles resulting in more cytotoxicity. 	
To analyse the expression of viral proteins in different cell lines; IGROV1, 
OVCAR4 and TOV21G cells were infected with either dl922-947 or Ad5WT at MOI 
10. Samples were taken 0, 24 and 48 hours post-infection for western blot 
analysis. 	
Figure 3-3 shows the expression of early and late viral proteins during dl922-947 
and Ad5WT infection. The first viral protein to be expressed during adenovirus 
infection is E1A. As shown below E1A protein expression can be seen in all shown 
cell lines infected with dl922-947 at 24 hours post-infection as well as the 
expression of viral core and capsid proteins. TOV21G cells infected with dl922-
947 show more expression of E1A at 24 hours in comparison to IGROV1 and 
OVCAR4, while E1A expression starts to decrease in TOV21G at 48 hours, an 
increase in E1A expression from 24 to 48 hours post-infection is observed in 
IGROV1 and OVCAR4. The expression of viral core and capsid proteins can be 
observed in all cell lines at 24 hours post-infection with an increase in protein 
level at 48 hours. Interestingly, E1A expression is higher at 24 hours post-
infection in dl922-947 infected cells compared to Ad5WT with OVCAR4 showing 
very low amounts of E1A at 24 hours post Ad5WT infection. Also the expression 
of viral core and capsid proteins is delayed in Ad5WT infected cells compared to 
dl922-947 infected cells. While cells infected with dl922-947 start showing 
expression of core and capsid proteins at 24 hours post-infection, cells infected 
with Ad5WT only show the expression of these proteins at 48 hours. 
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Figure 3-3: Western blot of viral proteins in IGROV1, OVCAR4 and TOV21G                     
IGROV1, OVCAR4 and TOV21G were infected with Ad5WT at MOI 10 or mock-infected. Samples 
were taken at indicated time points and prepared for Western blot analysis. Samples were blotted 
for β-actin (42 kDa), Ad2/5 E1A (48-54 kDa) and Anti-Adenovirus (Hexon at 108kDa and penton 
base at 63 kDa). One representative western blot out of 2 experiments is shown.                       
Asteriks indicate non-specific bands. Arrows indicate Ad2/5 E1A bands. 
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3.5 Replication of dl922-947 
To further assess differences in dl922-947 sensitivity in different cell lines, I 
aimed to study its replication kinetics for those. Replication was assessed using 
TCID50 in the human ovarian cancer cell lines IGROV1, OVCAR4 and TOV21G over 
a time period of 48 hours, infected at MOI 10. 
 
Figure 3-4A shows the replication of dl922-947 in a panel of ovarian cancer cell 
lines. Viral titres increase in IGROV1 and OVCAR4 from 24 to 48 hour post-
infection, while they decrease in TOV21G due to virus-induced cell death (Figure 
3-4B). Further, OVCAR4 and TOV21G show similar titres at 24 hour post-
infection, while IGROV1 shows decreased replication at the same time point, but 
reaches similar titres as OVCAR4 at 48 hour post-infection. 
 
Figure 3-4: Replication of dl922-947 in ovarian cancer cell lines                                                  
A) Cells were infected with dl922-947 at MOI 10 over a time course of 48 hours. Viral titres were 
determined by TCID50 assay. Points represent mean +/- STDEV from one experiment performed in 
triplicate.                                                                                                                                             
B) Cells were infected with dl922-947 at MOI 10 and cell survival was assessed at 0, 24 and 48 
hours post-infection by MTT assay and normalized to uninfected cells. Shown is survival as 
percentage. Points represent mean +/- STDEV from one experiment performed in quadruplicate 
wells. 
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3.6 Isolation of human primary ascites cells 
After dl922-947 ability to infect and lyse established tissue culture cell lines was 
analysed, I sought to further determine its efficiency in human primary ascites 
cells. Human primary ascites cells were isolated, cultured and then prepared for 
cytospin. Cells were stained for the epithelial cell markers, cytokeratin 7 (CK7) 
and epithelial related antigen (ERA).  
 
Figure 3-5 shows that human primary ascites cells are positive for CK7 and ERA, 
showing their epithelial origin. Interestingly, upon closer examination it was 
observed that a mix of different cell types had been isolated. 
 
Figure 3-5: CK7 and ERA immunohistochemistry of human primary ascites cells                 
Human ascites cells were collected and processed for cytospin as described in chapter 2. Samples 
were stained for cytokeratin 7 (CK7) and epithelial related antigen (ERA).                                         
A) CK7 staining of ascites cells with A’) being a magnified picture of A).                                               
B) ERA staining and B’) magnified picture of B). 
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3.7 Cytotoxicity of dl922-947 in human primary ascites  
Next, I wanted to further investigate dl922-947’s efficacy in lysing human 
primary ascites cells.  
 
As shown in figure 3-6, dl922-947 showed great variance in lysing human primary 
ascites between different patient samples. dl922-947 was most successful in 
lysing patient sample AB followed by the patient samples AS and ED. dl922-947 
was the least efficient in lysing patient samples DW, JMcD, MH and MMcL. 
 
 
Figure 3-6: dl922-947s ability to lyse cells varies between different primary human ascites 
samples.                                                                                                                                      
Primary human ascites cells were infected with dl922-947 at indicated MOI. Cell survival was 
assessed 120 hours post-infection by MTT assay and normalized to uninfected cells. Points 
represent mean +/- STDEV from one experiment performed in triplicate wells. 
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3.8 Discussion 
Oncolytic adenoviruses have already been used in models of pre-clinical 
research, where they have shown promising activities in several cancer models, 
but only few made it into clinical trials. As described earlier a few oncolytic 
adenoviruses (ONYX-015, H101 and EnAd) have been evaluated in clinical trials, 
with one of them being approved in combination with chemotherapy for the 
treatment of squamous cell cancers of head and neck or oesophagus in China. 
New and improved oncolytic adenoviruses are needed to increase the 
therapeutic outcome for patients. There are many different aspects that can be 
researched in further detail, to help understand the mechanisms behind 
successful virotherapy. These include, but are not limited to, better 
understanding the mechanistics of viral infection and replication. The spread of 
viral particles and how viruses induce cell cytotoxicity as well as what immune 
responses virus elicit in vitro and vivo and how these can be modified to 
increase immunogenicity. 
 
The use of Ad5 –based oncolytic adenoviruses in research has come across 
several difficulties in the recent years, with one of its major limitations being 
the down-regulation of its primary cell entry receptor in several human tumours 
due to Raf-MAPK pathway activity (Anders et al. 2003), while CD46 (Ad11 and 
Ad35 entry receptor) is commonly up-regulated in human cancers (Thorsteinsson 
et al. 1998, Hulin-Curtis et al. 2016). Comparison of the adenovirus subgroup B, 
type 2 adenoviruses Ad11 and Ad35 as well as of the subgroup C adenovirus Ad5 
in the ovarian cancer cell lines IGROV1, OVCAR4 and TOV21G showed that 
sensitivity greatly varied between cell lines and adenoviruses. While Ad11 and 
Ad35 showed similar EC50 values between cell lines, Ad5WT and the E1A-CR2 
deleted Ad5 mutant dl922-947 showed greater variation between the cell lines. 
Adenoviral efficacy partly depends on the expression of the primary cell entry 
receptors on the host cell, as in the case for Ad11 and Ad35, CD46 is their 
respective primary entry receptor, but even though they are using the same 
entry receptor, cytotoxicity was significantly different between those two 
adenoviruses in the same cell line, with Ad35 being significantly more cytotoxic 
in each cell line than Ad11. Research performed by (Wong et al. 2012) showed 
that the expression of CD46 did not correlate with Ad11-mediated cytotoxicity, 
showing that other mechanisms determine Ad-induced cytotoxicity, and explains 
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why a significant difference between Ad11 and Ad35-induced cytotoxicity was 
observed in the same cell line, which was also observed by (Shashkova, May and 
Barry 2009). They further showed that Ad11’s potency was also not related to its 
infectivity but rather that the expression of early gene transcription mediates 
Ad11 cytotoxicity (Wong et al. 2012). Since Ad11 and Ad35 were used for the 
same cell lines, differences in intracellular events or mutation status can be 
excluded, leading to the conclusion that differences in the biology of Ad11 and 
Ad35 determined their efficacy to induce cytotoxicity. (Stone et al. 2003) 
published the complete DNA sequence and transcription map of Ad11; and 
analysis and genome sequence comparison showed that Ad35 and Ad11 show the 
highest genome homology (>98%) with major base pair mismatches found in the 
hexon and fiber genes region. Their overall conclusion was that: “… Ad11 was 
evolutionarily derived from a cross-serotype fiber substitution into the Ad35 
genome, or that Ad35 was derived in the same manner from an Ad11 genome.” 
This further shows that, though Ad11 and Ad35 show high genome homology, 
they differ in their biology. Evidence further suggests that Ad11 might utilize 
another unidentified receptor (Tuve et al. 2006), offering another explanation 
for differences in sensitivity between Ad35 and Ad11. Further, the consistently 
low amounts of cytotoxicity induced by Ad11 observed here, could hinder its use 
as an oncolytic adenovirus. Though Ad35 showed promising sensitivity in ovarian 
cancer cells, its ability to down-regulate CD46 and the slow complete restoration 
time of CD46 expression are known problems (Sakurai et al. 2007).  
 
Though Ad5WT showed greater cytotoxicity in some ovarian cancer cells 
(OVCAR4 and TOV21G) than Ad11, Ad5WT showed a great variability between 
cell lines with an average EC50 of 41 pfu/cell for IGROV1, 14 pfu/cell for 
OVCAR4 and an average of 1 pfu/cell for TOV21G at 120 hours post-infection. 
Also the E1A-CR2 deleted Ad5 mutant dl922-947 showed greater variation 
between the cell lines with an average EC50 of 5 pfu/cell for IGROV1, 4 pfu/cell 
for OVCAR4 and 0.1 pfu/cell for TOV21G though it showed to induce significantly 
higher cytotoxicity than Ad5WT. This observation is in line with findings by the 
host lab that, in vitro, dl922-947 induced lysis with greater efficacy than Ad5WT 
(Lockley et al. 2006). This was further confirmed by western blot analysis, 
showing that adenoviral proteins are being expressed at earlier time points in 
dl922-947 infected cells than in Ad5WT infected cells. This observation is again 
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in line with Lockley, et al. 2006, where they showed that dl922-947’s increase in 
efficacy was marked by earlier expression of viral proteins, as well as the earlier 
induction of S-phase.  
 
Besides dl922-947s superior efficiency in vitro in comparison to Ad5WT,  
intratumoral and intravenous efficacy of dl922-947 was assessed in vivo by the 
lab of David Kirn (Heise et al. 2000), showing that tumour-bearing animals 
treated with dl922-947 showed superior survival and tumour regression in 
comparison to vehicle controls or dl1520 treated mice, making it a promising 
treatment of cancer from the pre-clinical point of view. 
 
It was of great interest that, though cells were sensitive to dl922-947, 
experiments demonstrated that sensitivity could vary at least 50-folds between 
cell lines. To further analyse the differences in sensitivity, infectivity between 
the cell lines using Ad-GFP, an E1 deleted non-replicating type 5-adenovirus that 
contains a CMV early promoter that drives GFP expression, was compared. 24 
hours post-infection with Ad-GFP at MOI 5, 92% TOV21G cells were GFP positive, 
while 76% of IGROV1 were positive and only 57% of OVCAR4 cells were GFP 
positive offering another explanation for the observed differences in 
cytotoxicity. The most likely explanation is that IGROV1, OVCAR4 and TOV21G 
express different amounts of CAR and integrins on the cell surface, which are 
used by dl922-947 to enter the host cell, resulting in differences in infectivity 
with Ad-GFP and also resulting in differences in viral load. In accordance with 
this explanation, Okegawa et al. reported significant differences in CAR 
expression in several human bladder cancer cell lines and that those correlated 
with their sensitivity to adenovirus infection (Okegawa et al. 2000) making 
different levels of CAR expression a possible answer. 
 
In line with this, analysis of viral protein production showed that viral proteins 
are being produced at earlier time points in TOV21G, which was also the easiest 
to infect cell line. Strong E1A expression was observed at 24 hours post-infection 
followed by a decrease in E1A at 48 hours, which is associated with an increase 
in adenoviral core and capsid proteins. This shows that there is a higher 
availability of viral proteins which can lead to an earlier assembly of new 
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infectious viral particles, which will once the particles are assembled lead also 
to an earlier induction of cell death to help viral spread.  
 
Further analysis of differences in replication kinetics of dl9222-947 showed that 
TOV21G and OVCAR4 produced a higher titre than IGROV1 24 hours post-
infection. Interestingly TOV21G cells showed a reduction in viral titre at 48 
hours post-infection, which was associated with a decrease in cell survival. The 
resulting cell death in TOV21G at 48 hours leads to the release of infectious 
particles allowing another round of viral infection and lysis. This observation 
gives a further explanation for why TOV21G is so sensitive to dl922-947-induced 
cytotoxicity and why differences in sensitivity between the cell lines are 
observed. 
 
Overall, a higher infectivity rate, which results in a higher load of adenovirus 
particles, leads to the early and high expression of adenoviral proteins. This 
allows earlier viral assembly and induction of virus-induced death and explains 
partly why TOV21G showed greater sensitivity to Ad5WT and dl922-947-induced 
cytotoxicity than IGROV1 and OVCAR4. Besides these observations a study by 
Connell CM et al. has shown that virus-induced host cell DNA damage signalling 
and repair mechanisms are a further key determinant of oncolytic adenoviral 
efficacy (Connell et al. 2011) in human ovarian cancer and in addition, Tookman 
et al. showed in a recent paper that intact homologous recombination (HR) 
function promotes viral DNA replication and augments overall oncolytic 
adenoviral efficacy (Tookman et al. 2016). Therefore, showing the highly 
complex biology of how adenovirus efficacy is influenced by cellular intrinsic 
mechanisms. 
 
Human primary ascites cells (MH) were analysed for their expression of the 
epithelial markers CK7 and ERA. Though cells were shown to be positive for the 
markers, confirming their epithelial origin, upon further inspection it was 
observed that the ascites that were cultured did not consist of a homogenous 
population but rather consisted of several cell types. Considering the origin of 
the ascites cells and that the cells are nucleated, it is likely that those cells 
could be lymphocytes, monocytes/macrophages or even neutrophils that are in 
circulation and have been isolated as well. To confirm the origin of these cells 
		
107	
further IHC on NIMP (Neutrophil marker), F4/80 (Macrophage marker) and PAX-5 
(B-cell marker) etc. need to be performed until then their origin can only be 
speculated. Further, for successful in vitro use, these cells need to be further 
isolated to avoid background induced by different cell populations within the 
culture. 
 
Besides CK7 and ERA IHC, Tagged-amplicon sequencing (TAm-sequencing) of MH 
using a high-grade serous ovarian cancer panel, performed by Anna Piskorz at 
the CRUK Cambridge Centre, showed that cells were TP53 mutant (data not 
shown), which is in line with data showing that TP53 mutations are near 
universal in HGSOC (Ahmed et al. 2010, TCGA 2011) and indicates that those 
cells are likely to be ovarian high grade serous carcinoma cells.  
 
When isolated human primary ascites cells were infected with dl922-947 they 
showed great variability in cytotoxicity. One of the reasons why primary ascites 
showed differences in sensitivity is that they might express different levels of 
dl922-947s primary cell attachment receptor as described earlier. This might be 
the most likely case for cells that were completely resistant to dl922-947 like 
MH, DW, MMcL and JMcD. Primary ascites cells ED and AS showed to be 
somewhat sensitive to dl922-947 induced infection at higher MOI. This shows 
that the virus was able to infect the cell, but intrinsic mechanisms lead to a 
lower viral efficacy, while ascites cells AB showed the highest sensitivity. 
Mechanistically speaking those cells must have allowed for easy viral infection 
and replication, which is highly desirable for oncolytic virotherapy. 
Unfortunately, limited availability and difficulty in maintaining primary cells in 
culture beyond 3-4 passages did not allow us to follow up on further experiments 
to address as to why these patient samples showed different sensitivities. These 
data are also in line with my in vitro data and published research showing that 
dl922-947 efficacy varies greatly between different cell lines and tumours and 
that it greatly depends on CAR expression (Okegawa et al. 2000), but besides 
dl922-947’s dependency on CAR and its down-regulation in many cancers (Anders 
et al. 2003) the host lab showed in 2015 that CAR expression is up-regulated in 
paclitaxel-resistant ovarian cancer cells and patient samples (Ingemarsdotter et 
al. 2015), making administration of Ad5 derived oncolytic adenoviruses a 
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possible future therapy for women with ovarian cancers resistant to 
conventional paclitaxel treatment.  
To conclude this chapter, the host lab and I have been able to show that dl922-
947 shows superior efficiency to Ad5WT and to the well-described oncolytic 
adenovirus ONYX-015 (dl1520) in lysing tumour cells in vitro (Lockley et al. 
2006). We showed, that changes in efficacy between different cell lines resulted 
from differences in infectivity, replication, the production of viral proteins and 
dl922-947’s ability to induce S-phase in the host cells. Besides its efficacy in 
vitro, the host lab also showed that dl922-947 infection resulted in a dramatic in 
vivo survival advantage. Further, I have been able to show that dl922-947 was 
able to induce cell death in three out of seven patient derived human primary 
ascites cells. These results show that dl922-947 may have clinical potential for 
the treatment of ovarian cancer.  	
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4 Mechanisms of dl922-947-induced cell death 
4.1 Introduction 
Programmed cell death is important for homeostasis, the development of 
organisms, during injury and as a response mechanism to infections. To limit 
infection, multicellular organisms have developed several defence mechanisms; 
these include innate and adoptive immune responses as well as the induction of 
interferons, which can lead to the activation of programmed cell death, 
therefore limiting the production and release of viral progeny.  
 
As described previously, adenoviruses encode several inhibitors of apoptosis but 
how they induce cell death has not been studied in detail. It has been shown 
that several adenovirus proteins are implicated in the induction of apoptosis e.g. 
E1A (Debbas and White 1993, Lowe and Ruley 1993), E4 (Marcellus et al. 1996) 
and E3 (Tollefson et al. 1996) to facilitate cell lysis and the release of viral 
progeny, but both Abou Hassan et al. 2004 and Sarah Baird et al. 2008 showed 
that oncolytic adenoviral mutants may induce a novel mode of cell death. 
 
In this chapter I aim to further characterize cell death induced by dl922-947 in 
ovarian cancer cell lines, with an emphasis on programmed necrosis 
 
4.2 Apoptosis 
4.2.1 Z.VAD.fmk does not inhibit dl922-947 induced cell death 
To further examine the involvement of apoptosis in dl922-947-induced cell 
death, I made use of Z.VAD.fmk, which is a non-cytotoxic, cell permeable pan-
caspase inhibitor that irreversibly binds to caspase proteases through their 
catalytic sites. It has been previously shown that Z.VAD.fmk is able to inhibit 
Caspase-1, 2, 3, 4, 5, 6, 7, 8 and 9 (Ekert, Silke and Vaux 1999, Garcia-Calvo et 
al. 1998) making it a broad spectrum inhibitor for the intrinsic as well as 
extrinsic apoptotic pathway. 
 
To test whether Z.VAD.fmk was able to rescue dl922-947-induced cell death, 
IGROV1, OVCAR4 and TOV21G cells were infected with dl922-947 at varying MOI 
and treated with 25µM Z.VAD.fmk or DMSO. 
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As seen in figure 4-1A, no significant reduction in cytotoxicity was observed in 
IGROV1 and OVCAR4 when cells were infected with dl922-947 in the presence of 
25µM Z.VAD.fmk. Comparisons of average EC50 values for vehicle (DMSO) versus 
Z.VAD.fmk treatment showed no significant difference, while for TOV21G there 
was a significant increase in dl922-947-induced cell death in the presence of 
Z.VAD.fmk. This observation is in accordance with the necrosis literature, 
showing that inhibition of caspases can lead to a more extensive non-apoptotic 
form of cell death (Figure 4-1A and D)(Vercammen et al. 1998). 
 
 
Figure 4-1: dl922-947 induced cell death is not rescued by the addition of the pan-caspase 
inhibitor Z.VAD.fmk                                                                                                                          
A) IGROV1, OVCAR4 and TOV21G were infected with dl922-947 and were either treated with 
25uM Z.VAD.fmk or vehicle. Cell survival was assessed 120 hours post treatment by MTT assay. 
Points represent mean EC50 +/- STDEV from at least three experiments with each experiment 
performed in triplicate wells. Differences in EC50 values between treated and untreated cells are 
not significant unless indicated in the figure.                                                                                       
B-C) show representative dose response curves for each cell line.                                                   
P values are calculated using unpaired t-test, ** shows p<0.01. 
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4.2.2 BCL-2 overexpression does not inhibit dl922-947-induced cell death 
B-cell lymphoma 2 (BCL-2) belongs to the BCL-2 family of proteins that regulate 
pro- and anti-apoptotic signalling. BCL-2, with the anti-apoptotic proteins BCL-xL 
and BCL-w, is known for its regulatory function and inhibition of apoptosis, and 
is a well-known oncogene.  
 
Next, I wanted to investigate if dl922-947-induced cell death was triggered 
through the activation of the apoptotic mitochondrial pathway (intrinsic 
pathway) as a result of cellular stress during virus infection. Therefore, I created 
a cell line that overexpressed the anti-apoptotic protein BCL-2, which blocks 
apoptosis by inhibiting the pro-apoptotic proteins Bax and Bak. 
 
As seen in figure 4-2A, OVCAR4 cells do not express BCL-2, while cells 
transduced with a retrovirus encoding BCL-2 show expression of BCL-2 on the 
protein level. In figure 4-2B, staurosporine, a well-known inducer of apoptosis 
(Falcieri et al. 1993, Bertrand et al. 1994, Koh et al. 1995), was used to assess if 
BCL-2 overexpression would rescue cell death as described in the literature 
(Reynolds et al. 1996, Takeda et al. 1997). As seen in figure 4-2B, staurosporine 
induces apoptosis in OVCAR4 cells, which can be significantly rescued by BCL-2 
overexpression, but has no effect on dl922-947-induced cell death, figure 4-2C. 
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Figure 4-2: BCL-2 overexpression does not rescue dl922-947-induced cell death in OVCAR4 
OVCAR4 cells were transduced with retroviruses containing an empty pBabe vector or pBabe 
containing the BCL-2-alpha protein sequence.                                                                                    
A) Immunoblot of OVCAR4 cells with and without BCL-2 overexpression. Samples were blotted for 
GAPDH (37 kDa) and BCL-2 (26 kDa). One representative western blot from two experiments is 
shown.                                                                                                                                                   
B) OVCAR4-pBabe and OVCAR4-BCL-2 were treated with 1µM staurosporine for 10 hours. Media 
was then removed and new medium was added and sulforhodamine B assay was performed 72 
hours post treatment. Points represent mean +/- STDEV of one experiment performed in 
quadruplicate wells.                                                                                                                             
C) OVCAR4-pBabe and OVCAR4-BCL-2 were infected with dl922-947 at indicated MOI. Cell 
survival was assessed 120 hours post-infection by MTT assay and normalized to uninfected cells. 
Points represent mean +/- STDEV from one experiments performed in triplicate.                                
P values are calculated using unpaired t test, ** shows p<0.01. 
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4.3 Programmed necrosis 
Historically necrosis was considered for a long time as an unregulated form of 
accidental cell death that is caused by sudden tissue damage. This view of 
necrosis has been rewritten in the past two decades with data showing that 
necrosis can be regulated (Laster, Wood and Gooding 1988). It has been shown 
that receptor interacting kinases are critical regulators of what has now been 
termed “Programmed Necrosis”. 
 
4.3.1 Inducing programmed necrosis in ovarian cancer cell lines 
It has previously been shown that Smac-mimetic (SM) can induce apoptosis in 
certain cancer cell lines and that the addition of a pan-caspase inhibitor, such as 
Z.VAD.fmk or Q-VD-OPH, can inhibit cell death (Bertrand and Vandenabeele 
2011). For some cell lines, this treatment in combination with TNF-α can lead to 
exacerbated cell death. These cells show morphological features of necrosis, 
such as discontinuous cytoplasmic membranes and swollen mitochondria. In 
addition, death can be blocked with the receptor interacting protein kinase 1 
(RIPK1) inhibitor necrostatin-1 (Nec-1) (Degterev et al. 2008) or the mixed-
lineage kinase-like protein (MLKL) inhibitor necrosulfonamide (NSA) (Sun et al. 
2012).  
 
A panel of ovarian cancer cell lines was tested to assess their ability to undergo 
programmed necrosis by treating cells with different combinations of TNF-α (T), 
Smac-mimetic (S), Z.VAD.fmk (Z), Nec-1 and NSA for 24 hours. 
 
As seen in Figure 4-3, no cell death was observed when IGROV1 cells were 
treated with TS, therefore no rescue could be observed when they were 
additionally treated with TSZ, TSZ+Nec-1 or NSA. Treatment of OVCAR4 with TS 
resulted in cell death, which could be rescued by Z.VAD.fmk. No further 
increase in cell survival was observed when cells were additionally treated with 
Nec-1 or NSA. Treatment of TOV21G with TS led to a great reduction in cell 
survival, which was further increased by the addition of Z.VAD.fmk. The addition 
of Nec-1 or NSA to TSZ treated TOV21G cells was able to significantly increase 
cell survival. 
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Figure 4-3: TOV21G undergoes programmed necrosis during TSZ treatment                    
IGROV1, OVCAR4 or TOV21G cells were treated with TS, TSZ, TSZ+Nec-1 or TSZ+NSA at the 
following concentrations: TNF-α: 20ng/mL, Smac mimetic: 1µM, Z.VAD.fmk: 25µM, necrostatin-1: 
10µM and necrosulfnamide: 1µM. Cell survival was assessed 24 hours post-treatment by MTT 
assay. Data show % cell survival +/- STDEV of a single experiment, performed in triplicate wells.   
P values are calculated using One Way ANOVA with multiple comparisons, *** shows p<0.001. 
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4.3.2 RIPK3 expression determines cellular ability to undergo programmed 
necrosis 
It has been shown that the execution of programmed necrosis induced by TSZ 
relies on the expression of the protein receptor interacting protein kinase 3 
(RIPK3) and that RIPK3 expression in different cell lines correlates with the 
responsiveness to necrosis induction, making it the critical determinant of 
cellular necrosis in response to TNF-α (He et al. 2009). Other components 
involved in the necrotic machinery include the protein RIPK1, which directly 
interacts with RIPK3 through its RIP homotypic interaction motif (RHIM) domain 
forming the necrosome (Sun et al. 2002), and the downstream mediator MLKL 
(Sun et al. 2012, Zhao et al. 2012). Therefore, protein expression levels of 
RIPK1, RIPK3 and MLKL in IGROV1, OVCAR4 and TOV21G were analysed by 
Western blotting. 
 
In keeping with results from figure 4-3, IGROV1 expressed no RIPK3 protein at 
57kDa, which correlates with data shown for programmed necrosis induction 
using TSZ. In addition, IGROV1 expressed low amounts of RIPK1 protein at 78 kDa 
in comparison to OVCAR4 and TOV21G. OVCAR4 expresses low amounts of RIPK3, 
resulting in a very faint band at 57kDa, while TOV21G shows expression of both 
proteins, RIPK1 and RIPK3. As seen in figure 4-4 all three cell lines express MLKL 
to comparable levels. 
 
Figure 4-4: Protein expression of RIPK1, RIPK3 and MLKL in IGROV1, OVCAR4 and TOV21G 
Cell lysates were prepared, run on SDS-PAGE, transferred to a nitrocellulose membrane and 
blotted for indicated proteins. Samples were blotted for RIPK1 (78 kDa), RIPK3 (57 kDa), MLKL 
(54 kDa) and GAPDH (37 kDa). One representative western blot from two experiments is shown.  	
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4.3.3 Expression of necrotic core proteins in human primary ascites cells 
Next, I wanted to assess if human primary ascites cells express the core proteins 
of the necrosome by western blot. 
 
Figure 4-5, shows that most human primary ascites cells express RIPK1, RIPK3 
and MLKL, though protein levels vary considerably between patient samples. 
Sample AC is the only one found that does neither express RIPK1 or RIPK3 on the 
protein level. 	
	
Figure 4-5: Human primary ascites cells express components of the necrosome                                        
Human primary ascites cells were collected and prepared for western blot analysis. Samples were 
probed for RIPK1 (78 kDa), RIPK3 (57 kDa), MLKL (54 kDa) and β-actin (42 kDa). 																				
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4.3.4 Levels of RIPK1, RIPK3, Caspase 8 and MLKL during dl922-947 
infection 
It has been shown that during adenovirus infection, host protein translation is 
down-regulated to allow the translation of viral proteins, which are needed for 
the assembly of new infectious virions (Cuesta, Xi and Schneider 2004, Walsh 
2010). In addition, many host proteins themselves are targeted for proteasomal 
degradation to promote viral gene expression, translation, assembly and spread.  
To determine if adenovirus infection alters the expression of core necrotic 
proteins, the ovarian cancer cell line IGROV1, OVCAR4 and TOV21G were 
infected with dl922-947 at MOI 10 for 0, 24 and 48 hours and changes in protein 
expression were analysed.  
 
Figure 4-6 shows that there are no changes in the expression of the core necrotic 
proteins RIPK1, Caspase 8 and MLKL during dl922-947 infection. Interestingly, 
RIPK3 protein expression is down-regulated in TOV21G during infection. 
 
 
Figure 4-6: Expression of RIPK1, RIPK3, Caspase 8 and MLKL during dl922-947 infection                   
IGROV1, OVCAR and TOV21G were infected with dl922-947 at MOI 10 for 0, 24 and 48 hours and 
analysed according to western blotting protocol. Samples were blotted for RIPK1 (78 kDa), RIPK3 
(57 kDa), MLKL (54 kDa), Caspase 8 (55/50 kDa) and GAPDH (37 kDa). One representative 
western blot from 2 experiments is shown. Asterisk indicates an unspecific band. 
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4.3.5 Ovarian cancer cells display necrotic features during dl922-947 
infection 
During programmed necrosis, cells undergo distinct morphological changes that 
are different from other modes of cell death such as apoptosis or autophagy. 
Morphological changes of necrotic cell death include the dilatation of the 
nuclear membrane and the condensation of the chromatin, swelling of the cell, 
mitochondria and other organelles as well as the loss of plasma membrane 
integrity resulting in the leakage of the cellular content. 
 
Transmission Electron Microscopy (TEM) was performed on TOV21G and OVCAR4 
cells to examine morphological changes during adenovirus infection. Cells were 
either mock infected, treated with TSZ for 6 hours (TOV21G) or infected with 
dl922-947 at MOI 1 (TOV21G) or MOI 3 for 72 hours (OVCAR4). Cells were 
prepared in accordance with the TEM preparation protocol and then imaged at 
the Electron Microscopy Facility at the University of Glasgow and further 
analysed. 
 
Figure 4-7A shows the morphology of OVCAR4 cells during mock-infection. The 
cells are elongated and show normal nuclear and organelle morphology. Figure 
4-7B shows an OVCAR4 cell during dl922-947 infection. Morphological changes in 
dl922-947-infected cells included a ‘swelling’ phenotype of the cell, where cells 
seem to lose their epithelial cell morphology and start to round up. Further, 
cells showed clear evidence of infection in the nucleus. A mix of mature and 
immature virions could be detected in the nucleus (Figure 4-7C). 
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Figure 4-7: Transmission electron microscopy of dl922-947 virions in OVCAR4                         
A) OVCAR4 cells were either mock-infected and then further processed for transmission electron 
microscopy.  Mock-infected cells show normal epithelial morphology.                                                                   
B-C) OVCAR4 cells were infected with dl922-947 at MOI 3 for 48 hours. B) shows a cell during the 
early stages of dl922-947 infection with the lattice and virions located within the nucleus.                                                                                                                              
C) shows virions within the nucleus of an infected cell. Arrowheads indicate mature virions. 	
TOV21G cells that were treated with TSZ showed a necrotic morphology (Figure 
4-8C-F) in comparison to mock treated cells (Figure 4-8A-B). Mock treated 
TOV21G cells showed epithelial morphology with healthy looking nuclei and 
mitochondria (Figure 4-8A-B), while TSZ treated cells showed enlarged and 
swollen nuclei (Figure 4-8C), signs of plasma membrane rupture, condensation of 
the chromatin into patches (Figure 4-8C, D and F), as well as an increasingly 
translucent cytoplasm, rupture of the nuclear membrane (Figure 4-8E) and dense 
mitochondria (Figure 4-8F). 
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Figure 4-8: TOV21G cells treated with TSZ show necrotic morphology                                      
A-B) TOV21G cells were mock-treated with DMSO and then further processed for transmission 
electron microscopy. A) shows normal epithelial morphology of a mock-treated cell and B) shows 
the morphology of normal mitochondria as indicated by arrows.                                                                                                                           
C-F) show TOV21G cells treated with with 20ng/mL TNF-α, 1µM smac-mimetic and 25µM 
Z.VAD.fmk (TSZ) for 6 hours. C-D) treatment with TSZ leads to the rounding up of the cell and the 
rupture of the plasma membrane. Asterisks indicate areas where the plasma membrane has 
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ruptured. Frames indicate magnified areas. E) is a magnified image of F) as indicated by frame and 
shows the rupture of the nuclear membrane. F) shows dense mitochondria (white closed 
arrowheads) in TSZ treated cells. 
 
With similarity to TSZ treated cells, TOV21G infected with dl922-947 also show 
necrotic features during infection.  Figure 4-9A shows TOV21G infected with 
dl922-947. Cells do not show signs of fragmentation. The cell has lost its 
epithelial morphology and parts of the cell are translucent due to loss of 
cytoplasmic integrity. Figure 4-9C shows the plasma membrane with ill-defined 
edges. According with infection vacuolisation can be observed (Figure 4-9B). 
Further, dense mitochondria were found in dl922-947-infected cells. 
 
Figure 4-9: TOV21G infected with dl922-947 show necrotic morphology   
A) TOV21G cells were infected with dl922-947 at MOI 1 for 48 hours and then further processed 
for transmission electron microscopy. Frames indicate magnified areas.                                                            
B) shows dense mitochondria (white arrow heads) and vacuolization (arrows).  
C) is a magnified image of A, asterisks indicate areas where the plasma membrane starts to 
become translucent, before membrane rupture. 
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4.3.6 Investigating the role of TNF-α in dl922-947-induced cytotoxicity 
There are several pathways of programmed, regulated necrosis, of which the 
best described pathway is induced by the ligation of TNF-α to the Tumour 
necrosis factor receptor 1 (TNFR1) (Han et al. 2011a). Besides the induction of 
programmed necrosis, the ligation of TNF-α with TNFR1 receptor can also lead to 
the activation of the NF-κB pathway or the induction of apoptosis depending on 
the cellular context. It is known that adenovirus infection induces acute 
inflammatory cytokine production including the upregulation of TNF-α (Salako et 
al. 2011). Therefore, adenovirus-induced programmed necrosis could be induced 
by autocrine TNF-α production and consequent TNF-α /TNFR1 interaction during 
infection. 
 
To test if adenovirus-induced cell death depends on autocrine TNF- α production 
IGROV1, OVCAR4 and TOV21G cells were infected with dl922-947 at varying MOI 
and two hours post-infection, a human TNF-α blocking antibody was added at a 
concentration of 1µg/ml. 
 
HeLa cells overexpressing the pro-necrotic protein RIPK3 (see chapter 5) are 
sensitized to cell death induction when treated with the cytokine TNF-α 
compared to their wild type counterpart. As shown in figure 4-10A, treating 
HeLa RIPK3 cells with 20ng/mL TNF-α resulted in a significant induction of cell 
death within two hours of treatment. This cell death could be completely and 
significantly rescued when cells were additionally treated with a human TNF-α 
blocking antibody. When cells were infected with dl922-947 and additionally 
treated with a TNF-α blocking antibody, no change in adenovirus-induced 
cytotoxicity was observed compared to vehicle treated cells infected at the 
same MOI (Figures 4-10B-D).  
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Figure 4-10: Blocking TNF-α using an anti-TNF-α antibody has no effect on dl922-947 
induced cytotoxicity.  
A) HeLa RIPK3 cells were treated with 20ng/mL TNF-α or with 20ng/mL TNF-α with the addition of 
1µg/mL TNF-α blocking antibody. Cell survival was assessed 24 hours post treatment by MTT 
assay.  Points represent mean +/- STDEV from one experiment performed in triplicate wells.  
B-D) Show one representative dose response curve for each cell line from two experiments 
performed in triplicate wells.  
P values are calculated using One Way ANOVA with multiple comparisons, * shows p≤0.05. 
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In experimental situations, programmed necrosis is induced by a combination of 
recombinant TNF-α, Smac-mimetic and Z.VAD.fmk. Interestingly the amount of 
TNF-α added to cells to induce programmed necrosis is higher than the amount 
of TNF-α that is generated by dl922-947 infected cells (Salako et al. 2011).  
Therefore, I wanted to investigate next if the further addition of TNF-α to dl922-
947 infected cells would increase viral cytotoxicity by creating a more prominent 
necrotic phenotype. 
 
As seen in figure 4-11A, the addition of 20ng/mL of TNF-α to dl922-947 infected 
IGROV1 cells had no effect on virus-induced cytotoxicity, but did lead to a 
significant increase in virus-induced cytotoxicity in OVCAR4 and TOV21G cells.  
 
 
Figure 4-11: Addition of TNF-α to dl922-947 infected cells increases cytotoxicity in OVCAR4 
and TOV21G 
A) IGROV1, OVCAR4 and TOV21G were infected with dl922-947 with vehicle control or with 
dl922-947 with the addition of 20ng/mL TNF-α. Cytotoxicity was assessed 120 hours post 
treatment by MTT assay. Points represent mean EC50 +/- STDEV from at least two experiments 
with each performed in triplicate wells.  
B-D) show representative dose response curves for each cell line.  
P values are calculated using unpaired t test, *shows p<0.05 and **p<0.01. 
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Next, I investigated if the addition of TNF-α to dl922-947 infected OVCAR4 cells 
did indeed made cell death more necrotic. If cell death under these conditions 
was of an apoptotic nature, the addition of Z.VAD.fmk should be able to rescue 
cell death additionally induced by TNF-α.  However, if it was of necrotic nature, 
Z.VAD.fmk should augment cell death or show no effect at all. 
 
 
As shown in figure 4-12, Z.VAD.fmk was partly able to rescue cell death induced 
by TNF-α in dl922-947, but was not able to completely rescue cell death to 
vehicle-treated conditions. 
 
Figure 4-12: Z.VAD.fmk does not completely rescue cell death induced by the addition of 
TNF-α during dl922-947 infection   
A) OVCAR4 cells were infected with dl922-947, dl922-947with 20ng/mL TNF-α, dl922-947 with 
25µM Z.VAD.fmk or dl922-947 with 20ng/mL TNF-α and 25µM Z.VAD.fmk. Cytotoxicity was 
assessed 120 hours post treatment by MTT assay. Points represent mean +/- STDEV from 1 
experiment performed in triplicate wells.  
B) Figure shows one representative graph from two experiments performed in replicate wells. 
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4.3.7 Investigating the role of RIPK1 in dl922-947-induced cell death 
4.3.7.1  Blocking RIPK1 with necrostatin-1 
It has been shown that necrosis induced by VV (Whilding et al. 2013) depends on 
the formation of a pro-necrotic RIPK1-RIPK3 complex, due to sensitization of 
cells to TNF-induced cell death. Further, it has also been shown that treatment 
with necrostatin-1 (Nec-1) upon HSV-1 (Holler et al. 2000b) infection resulted in 
increased cell viability, showing that RIPK1 is important for the induction of cell 
death during VV and HSV-1 infection.  
 
To determine the appropriate concentration of the RIPK1 inhibitor (Nec-1) for 
treatment, IGROV1, OVCAR4 and TOV21G were treated with increasing amounts 
of Nec-1 (10µM, 30µM, 50µM and 100µM) and incubated for 120 hours before cell 
survival was assessed using MTT assay.  
 
As shown in figure 4-13A, Nec-1 does not induce any cytotoxicity in IGROV1 or 
OVCAR4 at concentrations as high as 100µM over a period of 5 days, while it 
induces dose-dependent non-specific cytotoxicity in TOV21G. As a compromise 
between induced cytotoxicity and concentrations used previously in the host lab 
(Whilding et al. 2013), 30µM Nec-1 was used in all the following experiments. 
 
After the optimal concentration was determined, the stability of Nec-1 was 
assessed. Nec-1 was dissolved in tissue culture medium at desired concentration 
and incubated for 1, 2, 3, 4 and 5 days in a tissue culture incubator. After the 
indicated incubation period, TSZ was added to Nec-1 to investigate Nec-1’s 
ability to block programmed necrosis.  
 
As shown in figure 4-13B, Nec-1 is stable over the indicated period of time, when 
added to tissue culture medium. Even when incubated in tissue culture medium 
at 37ºC for 5 days prior to necrosis induction, Nec-1 is still able to rescue TSZ-
induced death. 
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Figure 4-13: Necrostatin-1 induces unspecific cytotoxicity at high concentrations  
A) IGROV1, OVCAR4 and TOV21G cells were treated with 10, 30, 50 or 100µM Nec-1. 
Cytotoxicity was assessed 120 hours post treatment by MTT assay. Points represent mean +/- 
STDEV from one experiment performed in triplicate well.  
B) 30µM Nec-1 was incubated for 1, 2, 3, 4 and 5 days in DMEM at 37ºC in a tissue culture 
incubator before TSZ was added to induce programmed necrosis in TOV21G. Nec-1 stability was 
assessed 24 hours post treatment by MTT assay. Points represent mean +/- STDEV from one 
experiments performed in triplicate wells. 
 
To investigate the importance of RIPK1 in oncolytic adenovirus-induced cell 
death IGROV1, OVCAR4 and TOV21G cells were infected with dl922-947 and 
treated with 30µM Nec-1 two hours after infection. 72 hours after infection, 
medium was aspirated and replaced with fresh medium containing 30µM Nec-1.  
 
Figure 4-14C shows that there is no significant difference in EC50 values between 
cell lines infected with dl922-947 when treated with vehicle or 30µM of Nec-1. 
Figures 4-14D-F show typical dose response curves for cells either treated with 
vehicle or 30µM Nec-1 during dl922-947 infection.  
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Figure 4-14: Necrostatin-1 treatment does not rescue dl922-947-induced cell death  
A) IGROV1, OVCAR4 and TOV21G were infected with dl922-947 and treated with vehicle or 30µM 
Nec-1. Medium was replaced 72 hours post-infection and fresh medium containing 30µM Nec-1 
was added. Cytotoxicity was assessed 120 hours post treatment by MTT assay. Points represent 
mean EC50 +/- STDEV from at least four experiments with each experiment performed in triplicate 
wells. Differences in EC50 values between treated and untreated cells are not significant unless 
indicated in the figure.  
B-C) show representative dose response curves for each cell line. 
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4.3.7.2  Blocking RIPK1 with novel GSK inhibitors 
It has been shown in recent studies that the RIPK1 inhibitor Nec-1 is chemically 
identical to an inhibitor of the immunomodulatory enzyme indoleamine 2,3-
dioxygenase (IDO) called methyl-thiohydantoin-tryptophan (MTH-Trp), therefore 
making it an inhibitor both RIPK1 and IDO (Takahashi et al. 2012, Vandenabeele 
et al. 2013). Therefore, new analogues of Nec-1 are required to study the 
contribution of RIPK1 in cell death and survival. Besides the analogues Nec-1i 
(inactive) and Nec-1s (more stable variant) (Degterev, Maki and Yuan 2013) 
GlaxoSmithKline (GSK) has developed new RIPK1 inhibitors GSK2791728A 
(GSK’728A) and GSK3002963A (GSK’963A)) as well as their inactive controls 
(GSK2791729A (GSK’729A) and GSK3002962A (GSK’962A)) for future cell death 
studies. In 2015, GSK identified and described a new RIPK1 kinase inhibitor 
(GSK’963), which showed a 100-fold increase over Nec-1 in cell-based assays and 
increased selectivity for RIPK1 over other kinases. GSK’962A is the inactive 
enantiomer of GSK’963A and used to confirm off-target effects (Berger, Bertin 
and Gough 2015a, Berger et al. 2015b). 
 
Next I wanted to test if using the more selective GSK’963A inhibitor and its 
respective inactive form GSK’962A had an effect on dl922-947-induced cell 
death. 
 
As seen in figure 4-15A, GSK’728A and GSK’963A are able to significantly rescue 
TSZ-induced programmed necrosis induced in TOV21G. GSK’728A and GSK’963A 
are able to rescue cell death to comparable levels as the well described necrosis 
inhibitors Nec-1 and NSA. The inactive enantiomers GSK’729A and GSK’962A are 
not able to rescue TSZ-induced cell death and show comparable amounts of cell 
death to TSZ treatment alone. Figure 4-15B-D shows representative graphs of 
IGROV1, OVCAR4 and TOV21G infected with dl922-947 and treated with vehicle, 
20nM GSK’962A or 20nM GSK’963A. As shown below, no difference in dl922-947-
induced cytotoxicity was observed. 
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Figure 4-15: GSK RIPK1 inhibitors do not rescue dl922-947-induced cell death 
A) TOV21G cells were treated with TSZ and either vehicle, 10µM Nec-1, 3µM NSA, 10nM 
GSK'729A, 100nM GSK'728A, 10nM GSK'962A or 10nM GSK'963A were added. Cell survival was 
assessed 24 hours post-treatment by MTT assay. Data shows mean +/- STDEV of a single 
experiment, performed in triplicate wells.  
B-D) IGROV1, OVCAR4 and TOV21G cells were infected with dl922-947 with the addition of 
vehicle, 20nM GSK’962A or 20nM GSK’963A. Cell survival was assessed 120 hours post-infection 
by MTT assay and normalized to uninfected cells. Shown is one representative graph, where 
points represent mean +/- STDEV from one experiment performed in triplicate wells.  
P values are calculated using One Way ANOVA with multiple comparisons, ** shows p<0.01 and 
****p<0.0001. 
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4.3.7.3  Knock down of RIPK1 using siRNA 
To exclude the possibility that RIPK1’s presence alone might lead to the 
autophosphorylation of its interaction partner RIPK3 and other non-specific 
effects induced by using chemical inhibitors, RIPK1 was knocked down using 
siRNA to see if loss of RIPK1 would have any effect on adenovirus-induced death.  
 
First I determined the lowest concentration of siRNA that would give a complete 
protein knock-down after 24 hours.  
 
As shown in figure 4-16 there is no difference in RIPK1 expression between non-
transfected and 100pmol scrambled siRNA transfected cells, while all used 
concentrations of RIPK1 siRNA gave a complete protein knock-down after 24 
hours of transfection. To avoid any siRNA-mediated off-target effects, the 
lowest amount of RIPK1 siRNA (10pmol) was used for all following experiments 
using RIPK1 siRNA. 
 
 
Figure 4-16: RIPK1 knock-down in TOV21G using siRNA  
TOV21G cells were transfected with 100pmol scrambled or 10, 30, 60 or 100pmol of RIPK1 siRNA 
for 24 hours. After 24 hours samples were taken and prepared for western blot analysis. Samples 
were blotted for RIPK1 (78 kDa) and β-actin (42 kDa). One representative western blot from two 
experiments is shown.  					
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Next, IGROV1 and TOV21G cells were transfected with 10pmol scrambled or 
10pmol of RIPK1 siRNA. After 24 hours cells were then infected with dl922-947. 
The effect of siRNA-mediated knock down of RIPK1 in virus-infected cells was 
analysed 120 hours post infection. 
 
Figure 4-17 shows the effect of siRNA-mediated knockdown on adenovirus-
infected cells. As shown in figure 4-17E) siRNA-mediated knock down of RIPK1 
significantly rescues TSZ-induced cell death in TOV21G while in figure 4-17A) 
siRNA-mediated knock down of RIPK1 does not rescue cell death in A) IGROV1 
and C) TOV21G cells during dl922-947 infection. Western blot analysis was 
performed at time of MTT assay, showing that RIPK1 protein levels are down-
regulated in IGROV1 B) and TOV21G D). 
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Figure 4-17: siRNA-mediated knock down of RIPK1 does not rescue dl922-947-induced cell 
death  
A) IGROV1 and C) TOV21G cells were transfected with 10pmol scrambled or 10pmol RIPK1 
siRNA. 24 hours post-transfection cells were infected with dl922-947 at indicated MOI. Cell survival 
was assessed 120 hours post-infection by MTT assay and normalized to uninfected cells treated 
with the same amount of siRNA. Points represent mean +/- STDEV from one experiment 
performed in triplicate wells.  
B) IGROV1 and D) TOV21G samples were taken 120 hours post infection and blotted for RIPK1 
(78 kDa) and GAPDH (37 kDa). One representative western blot from three experiments is shown. 
E) TOV21G cells were transfected with 10pmol scrambled or 10pmol RIPK1 siRNA. 24 hours post-
transfection cells were treated with 20ng/mL TNF-α, 1µM smac-mimetic and 25µM Z.VAD.fmk. Cell 
survival was assessed 48 hours post-treatment by MTT assay. Points represent mean +/- STDEV 
from one experiment performed in triplicate wells. P values are calculated using unpaired t-test, *** 
shows p<0.001. 
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4.3.8 Investigation of the role of RIPK3 in dl922-947-induced cell death 
4.3.8.1 Inhibiting RIPK3 with novel GSK inhibitors 
It has been shown that the execution of programmed necrosis relies on the 
expression of the protein RIPK3 and that its expression in different cell lines 
correlates with the responsiveness of these to necrosis induction, making it the 
determinant for cellular necrosis in response to TNF-α (He et al. 2009). So far 
the only known RIPK3 inhibitors have been described by Kaiser et al. (Kaiser, 
Upton and Mocarski 2013b) and were identified by screening small-molecule 
libraries in a collaboration with GSK. This screen revealed three compounds 
(GSK’840B, GSK’872B and GSK’843A) that bound RIPK3’s kinase domain and 
therefore inhibited its kinase activity, while showing minimal cross-reactivity. 
 
Using the new RIPK3 inhibitors provided by GSK, I wanted to investigate if they 
were able to rescue dl922-947-induced cell death by inhibiting the protein 
RIPK3. 
 
As seen in figure 4-18A the RIPK3 inhibitor GSK’840B was able to rescue 
programmed necrosis induced by TSZ treatment to comparable levels as Nec-1 
and NSA in TOV21G. The RIPK3 inhibitor GSK’872B was also able to rescue 
programmed necrosis, but to a lesser extent as GSK’840B. GSK’843A was not 
able to rescue programmed necrosis induced by TSZ in TOV21G. Figure 4-18B and 
C shows that treatment of OVCAR4 and TOV21G with 10µM GSK’840B or 
GSK’872B has no effect on dl922-947-induced cell death. 
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Figure 4-18: Inhibition of RIPK3 using inhibitors does not rescue dl922-947-induced cell 
death                                                                                                                                                 
A) TOV21G were treated with TSZ to induce programmed necrosis and 10µM GSK’840B, 10µM 
GSK’872B or 10µM GSK’843A. Points represent mean +/- STDEV from one experiment performed 
in triplicate wells.                                                                                                                                  
B-C) OVCAR and TOV21G were infected with dl922-947 with the addition of vehicle, 10µM 
GSK’840B or 10µM GSK’872B. Cell survival was assessed 120 hours post-infection by MTT assay 
and normalized to uninfected cells treated with the same amount of vehicle or inhibitor. Shown is 
one representative graph from two experiments. Points represent mean +/- STDEV from one 
experiment performed in triplicate wells.                                                                                              
P values are calculated using One Way ANOVA with multiple comparisons, * shows p<0.05 and 
***p<0.001. 
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4.3.8.2 Knock down of RIPK3 using siRNA 
Next I wanted to test if siRNA-mediated knock down of RIPK3 was able to rescue 
dl922-947-induced cell death since pharmacological inhibitors can show off-
target effects. First the lowest amount of RIPK3 siRNA was determined as 
described earlier. 
 
As shown in figure 4-19 10pmol of RIPK3 siRNA are enough to achieve knock 
down of RIPK3 on the protein level. Further, figure 4-19 shows some very faint 
bands at 57kDa in all used concentrations. 
 
 
Figure 4-19: siRNA-mediated knock down of RIPK3 in TOV21G.  
TOV21 cells were transfected with 100pmol scrambled or 10, 30, 60 or 100pmol of RIPK3 siRNA 
for 24 hours. After 24 hours samples were taken and prepared for western blot analysis. Samples 
were blotted for RIPK3 (57 kDa) and β-actin (42 kDa). One representative western blot from two 
experiments is shown.  		
TOV21G cells were then transfected with 10pmol scrambled or 10pmol of RIPK3 
siRNA. After 24 hours, cells were infected with dl922-947 and the effect of 
siRNA-mediated RIPK3 knock down on virus-infected cells was analysed 120 hours 
post infection. 
 
Figure 4-20B shows the effect of RIPK3 siRNA-mediated knock down on dl922-947 
infected cells. Figure 4-20C shows that siRNA-mediated knock down of RIPK3 
significantly rescues the induction of programmed necrosis in TSZ treated 
TOV21G cells, while as shown at figure 4-20A knock down of RIPK3 was partially 
able to rescue cell death induced by dl922-947. As shown in the figure there is a 
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considerable difference in the amount of rescue between cells that are infected 
at a MOI of 1 in comparison to cells infected at a MOI of 0.1. Western blot 
analysis at the time of MTT confirmed that RIPK3 was down regulated on the 
protein level. 
 
 
Figure 4-20: siRNA-mediated knock down of RIPK3 partially rescues dl922-947-induced cell 
death in TOV21G 
A) TOV21G cells were transfected with 10pmol scrambled or 10pmol RIPK3 siRNA. 24 hours post-
transfection cells were infected with dl922-947 at indicated MOI. Cell survival was assessed 120 
hours post-infection by MTT assay and normalized to uninfected cells treated with the same 
amount of siRNA. Points represent mean +/- STDEV from one experiment performed in triplicate 
wells.  
B) TOV21G samples were taken 120 hours post infection and blotted for RIPK3 (57 kDa) and β-
actin (37 kDa). One representative western blot from three experiments is shown.  
P values are calculated using unpaired t-test, * shows p<0.05. 
C) TOV21G cells were transfected with 10pmol scrambled or 10pmol RIPK3 siRNA. 24 hours post-
transfection cells were treated with 20ng/mL TNF-α, 1µM smac-mimetic and 25µM Z.VAD.fmk. Cell 
survival was assessed 48 hours post-treatment by MTT assay. Points represent mean +/- STDEV 
from one experiment performed in triplicate wells. P values are calculated using unpaired t-test, 
**** shows p<0.0001. 		
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4.3.8.3  Investigating the role of MLKL in dl922-947-induced cell death 
4.3.8.3.1  Inhibition of MLKL using necrosulfonamide 
The protein Mixed lineage kinase domain-like protein (MLKL) has been identified 
as a RIPK3 substrate in a chemical compound screen (Sun et al. 2012). Sun et al. 
showed that MLKL binds to RIPK3 through its C-terminal kinase-like domain, 
which is phosphorylated at Thr231/Ser232 by RIPK3 and that NSA is able to block 
necrosis downstream of RIPK3 by covalently modifying MLKL.  
 
First, I wanted to investigate further if MLKL is also a downstream component of 
adenovirus-induced cell death. I determined NSA-induced non-specific 
cytotoxicity by treating the cells with increasing concentration of NSA over a 
timeframe of 120 hours before cell survival was assessed. As shown in figure 4-
21A NSA does induce non-specific cytotoxicity in OVCAR4 and TOV21G in a dose-
dependent manner over an incubation period of 120 hours; therefore, 3µM of 
NSA was used in further experiments.  
 
After the optimal concentration of NSA was determined, its stability was 
assessed as described earlier. As shown in figure 4-21B NSA is stable over a 
period of 120 hours and is able rescue TSZ-induced cell death. 
 
Figure 4-21: Necrosulfonamide induces non-specific cytotoxicity at high concentrations.  
A) IGROV1, OVCAR4 and TOV21G cells were treated with 1, 3, 5 or 10µM NSA. Cytotoxicity was 
assessed 120 hours post treatment by MTT assay. Points represent mean +/- STDEV from one 
experiment performed in triplicate wells. Shown is one representative graph from two experiments.  
B) DMEM containing a final concentration of 3µM NSA was incubated over a period of five days at 
37ºC in a tissue culture incubator before TSZ was added to induce programmed necrosis in 
TOV21G. NSA stability was assessed 24 hours post TSZ treatment by MTT assay. Points 
represent mean +/- STDEV from one experiment performed in triplicate wells.  One representative 
graph from two experiments is shown. 
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Next, cells were infected with dl922-947 and treated with either 3µM NSA or 
vehicle. After 72 hours the medium was changed and new medium containing 
3µM NSA or vehicle was added. 
 
Figure 4-22 shows that NSA was able to significantly reduce dl922-947-induced 
cytotoxicity in all three cell lines tested.  
 
 
Figure 4-22: Necrosulfonamide reduces dl922-947-induced cytotoxicity  
A) IGROV1, OVCAR4 and TOV21G were infected with dl922-947 and treated with vehicle or 3µM 
NSA. Medium was replaced 72 hours post-infection and medium containing 3µM NSA was added. 
Cytotoxicity was assessed 120 hours post treatment by MTT assay. Points represent mean EC50 
+/- STDEV from at least four experiments with each experiment performed in triplicate wells.  
B-D) shows one representative graph for each cell line.  
P values are calculated using unpaired t-test, * shows p<0.05 and **p<0.01. 
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To show that the increase of cell viability during dl922-947 infection was due to 
blockage of MLKL by NSA and not by NSA affecting other cellular events during 
viral infection, I performed western blotting of the early viral protein E1A during 
dl922-947 infection and NSA treatment. 
 
Figure 4-23 shows that there is no difference in E1A expression between cells 
that have been treated with 3µM NSA or vehicle during dl922-947 infection. 
 
Figure 4-23: Necrosulfonamide treatment does not alter the expression of viral proteins    
TOV21G cells were infected with dl922-947 and either treated with vehicle or 3µM NSA. Protein 
samples were taken at indicated time points and analysed for differences in viral E1A protein 
expression (48-54 kDa) and differences in β-actin (42 kDa). Figure shows one representative 
western blot from two experiments. 	
Next I wanted to assess if NSA might affect viral replication, leading to a lower 
viral titre that could lead to a decrease in viral cytotoxicity. Therefor a TCID50 
assay was performed on OVCAR4 and TOV21G. Cells were infected with dl922-
947 at MOI 10 and either treated with vehicle or 3µM NSA. 48 hours post-
infection samples were taken and prepared for TCID50 assay as described before. 	
Figure 4-24 shows TCID50 assay performed on OVCAR4 and TOV21G treated with 
vehicle or 3µM NSA and infected with dl922-947 at MOI 10 for 48 hours. As shown 
in the figure, there are no differences in the production of infectious viral 
particles between cells treated with NSA or vehicle at 48 hours post-infection. 
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Figure 4-24: Necrosulfonamide treatment does not alter the production of infectious viral 
particles.                                                                                                                                       
TCID50 assay was performed on OVCAR4 and TOV21G infected with dl922-947 at MOI 10 for 48 
hours, treated with vehicle or 3µM NSA. Viral titres were determined by TCID50 assay. Points 
represent mean +/- STDEV from one experiment performed in quadruplicate. 																											
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4.3.8.3.2  Knock down of MLKL using siRNA 
It has been shown in previous experiments that NSA induces non-specific 
cytotoxicity, which is cell- as well as dose-dependent. Therefore, siRNA 
mediated MLKL knock down was used to validate data obtained with NSA. 
 
First, a siRNA dose response on TOV21G was done, to determine the lowest 
concentration of MLKL siRNA needed to achieve a complete protein knock down.  
As shown in figure 4-25, transfection of MLKL siRNA resulted in a considerable 
decrease in MLKL on the protein level but complete knock-down was not 
achieved. Since there was no considerable difference between the knock-down 
achieved by 10pmol or 100pmol of MLKL siRNA, a concentration of 10pmol was 
used for all following experiments. 
 
Figure 4-25: SiRNA is not able to completely knock-down MLKL  
A) TOV21G was transfected with 100pmol scrambled or 10, 30, 60 and 100pmol RIPK3 siRNA. 
After 24 hours, cells were lysed and prepared for western blotting of MLKL (54 kDa) and GAPDH 
(37 kDa). Figure shows representative western blots from two experiments. 
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In the next experiment I wanted to evaluate if siRNA mediated knock down of 
MLKL was able to rescue dl922-947-induced cell death. Figure 4-26C shows that 
siRNA-mediated knock down of MLKL is able to significantly rescue cell death 
induced by TSZ treatment in TOV21G, while as shown in figure 4-26B MLKL is 
knocked down at protein level, but there is no consistent difference in dl922-
947-induced cytotoxicity figure 4-26A. 
 
 
Figure 4-26: siRNA mediated knock down of MLKL does not rescue dl922-947-induced cell 
death 
A) TOV21G cells was transfected with 10pmol scrambled or 10pmol RIPK3 siRNA for 48 hours. 
After 48 hours, cells were infected with dl922-947 at indicated MOI. Cell survival was assessed 120 
hours post-infection by MTT assay and normalized to uninfected cells treated with the same 
amount of siRNA. Points represent mean +/- STDEV from one experiment performed in triplicate 
wells.  
B) TOV21G samples were taken 120 hours post infection for western blotting to assess if MLKL 
was down regulated at time of MTT assay. Shown is one representative figure from two 
experiments. 
C) TOV21G cells were transfected with 10pmol scrambled or 10pmol MLKL siRNA. 24 hours post-
transfection cells were treated with 20ng/mL TNF-α, 1µM smac-mimetic and 25µM Z.VAD.fmk. Cell 
survival was assessed 48 hours post-treatment by MTT assay. Points represent mean +/- STDEV 
from one experiment performed in triplicate wells. P values are calculated using unpaired t-test, *** 
shows p<0.001. 				
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4.3.8.4  Knockout of MLKL using CRISPR/Cas9 
To further assess the potential importance of MLKL in virus-induced cell death, I 
aimed to create cells with stable knockout of MLKL, since siRNA mediated knock-
down of MLKL is time limited and therefore would make further in vivo 
experiments more complicated. 
 
Using the CRISPR/Cas9 system, I started by designing guides targeting specific 
regions of the gene encoding MLKL using the online designing tools provided 
http://crispr.mit.edu and http://chopchop.rc.fas.harvard.edu. Guides were 
chosen based on the amount of potential off-target effects and depending on if 
they were identified by both online programmes. The guides were then ligated 
into the pX335 vector and sequenced. TOV21G cells were then transfected with 
the resulting plasmid and selected with puromycin. Following dilution cloning, 
single cell clones were pre-selected by TSZ treatment.  
 
Several clones from guide 5.1 were selected, their DNA extracted, PCR amplified 
using the primers listed in chapter 2 and run on an agarose gel. 
 
Figure 4-27 shows PCR results for the region targeted by guide 5.1 with the 
parental PCR product running at approximately 836bp. Clones D3 and F5 are 
running at about the basepair length as parental, while clones D6, F9 and E8 
show a double, indicating that something has happened to the original sequence. 
 
Figure 4-27: Identification of clones with edited MLKL   
DNA was extracted from parental cells, clone D3, F5, D6, F9 and E8, PCR amplified with primers 
indicated in chapter 2 and run on an agarose gel. 
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Clones that showed a visibly shorter PCR product or double bands on the agarose 
gel and that were resistant to TSZ treatment were considered to have a 
modification in the sequence of MLKL, until sequencing was completed. 
 
Following this, western blotting was performed to assess if clones showed 
differences in MLKL protein expression. 
 
Figure 4-28 shows MLKL expression in parental and CRISPR/Cas9 transfected cells 
containing MLKL guide 5.1. Clone F5 shows similar MLKL protein expression as 
parental cells and clone D3 showing only slight down regulation of MLKL. The 
clones F9, E8 and D6 show the greatest down regulation of MLKL protein.  
	
Figure 4-28: MLKL is downregulated in CRISPR/Cas9 transfected TOV21G containing MLKL 
guide 5.1  
Parental cells and single cell clones of CRISPR/Cas9 transfected cells containing guides for MLKL 
were prepared for western blotting and samples were analysed for MLKL (54 kDa) and β-actin (42 
kDa) expression. 	
Next I wanted to further assess how these clones react to TSZ treatment and if 
additional Nec-1 treatment would be needed to achieve complete rescue to TSZ-
induced cell death. 
 
As shown in figure 4-29, clones reacted in accordance with data shown in figure 
4-28, meaning that clones showing MLKL expression on the western blot (Clone 
D3 and F5) were able to undergo TSZ-induced programmed necrosis. When 
clones D3 and F5 were treated with TS, the cells started to die and a further 
increase in cell death was observed when Z.VAD.fmk was added. Cell death 
induced by TSZ in these clones was rescued by the addition of Nec-1. Clones D6 
and F9, which showed down regulation of MLKL, died in response to TS 
treatment, but cell death was in part rescued when cells were additionally 
treated with Z.VAD.fmk. This increase in cell viability could even be further 
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increased through the addition of Nec-1. Interestingly, the amount of cell death 
induced by TS treatment in clone D6 was considerably greater than in F9. 	
 
Figure 4-29: TSZ treatment in CRISPR/Cas9 transfected cells containing MLKL guide 5.1 
Parental and single cell and single cell clones were treated with different combinations of 20ng/mL 
TNF-α (T), 1µM Smac-mimetic (S), 25µM Z.VAD.fmk (Z) or 10µM Nec-1. Cell survival was 
assessed 24 hours post-treatment by MTT assay and normalized to vehicle treated cells. Points 
represent mean +/- STDEV from one experiment performed in triplicate wells. Shown is one 
representative figure from two experiments.  
P values are calculated using One ANOVA with multiple comparisons, ** shows p<0.01. 
 
To further investigate the importance of MLKL in dl922-947-induced cell death, a 
panel of guide 5.1 clones was selected for dl922-947 infection. Figure 4-30 shows 
that down-regulation of MLKL has no effect on dl922-947 induced cytotoxicity. 
Clones D3 and F5, which behave like they have WT MLKL show similar amounts of 
cell death compared to parental TOV21G. Interestingly, clone F5 (mean cell 
survival: 61.5%), which is supposed to have WT MLKL shows lower amounts of 
cell death compared to parental cells (mean cell survival: 29.3%) and the other 
proposed clone containing WT MLKL, clone D3 mean cell survival: 34,8%) and the 
potentially MLKL edited clones D6 (mean cell survival: 37.6%), and F9 (mean cell 
survival: 24.8%). Another interesting observation is the changes in response to 
Z.VAD.fmk during dl922-947 infection. In keeping with results shown in Fig 4.1, 
dl922-947-induced cell death is augmented in Z.VAD.fmk treated parental 
TOV21G cells as well as in the potentially WT MLKL clones D3 and F5. However, 
in cells that are potentially edited for MLKL (clone D6 and F9), cell death is not 
augmented during additional Z.VAD.fmk treatment. 
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Figure 4-30: Down-regulation of MLKL rescues augmented cell death phenotype induced by 
Z.VAD.fmk during dl922-947 infection  
A) Parental TOV21G and MLKL edited clones D3, F5, D6 and F9 were infected with dl922-947 at 
MOI 0.1 and either treated with vehicle or 25µM Z.VAD.fmk. Cytotoxicity was assessed 120 hours 
post treatment by MTT assay. Points represent mean +/- STDEV from at least three experiments 
with each experiment performed in triplicate wells.                                                                           
B-F) Cells were infected with dl922-947 at indicated MOI and either treated with vehicle or 25µM 
Z.VAD.fmk. Cell survival was assessed 120 hours post-infection by MTT assay and normalized to 
uninfected cells. Shown is one representative graph, where points represent mean +/- STDEV from 
one experiment performed in triplicate wells.  
P values are calculated using unpaired t-test, ** shows p<0.01 and ****p<0.0001. 
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4.3.8.4.1  MLKL phosphorylation during dl922-947 infection 
Cai et al. showed in 2014 that plasma membrane translocation of MLKL is 
required for TNF-induced programmed necrosis. They also showed that MLKL 
forms trimers and is phosphorylated by RIPK3. They further showed that 
phosphorylation of MLKL is needed for its translocation to the plasma membrane 
(Cai et al. 2014). Later on in 2014 Chen et al. showed that MLKL can also form 
oligomers, which then translocate to lipid rafts of the plasma membrane (Chen 
et al. 2014). It was just a few months later in same year that Wang et al. 
showed that MLKL was phosphorylated at T357 and S358 by RIPK3 and binds to 
phosphatidylinositol lipids and cardiolipin. Besides discovering MLKL’s 
phosphorylation sites, they also developed an antibody that specifically only 
recognised MLKL in its phosphorylated state (Wang et al. 2014a). 
 
To further assess the involvement of MLKL in adenovirus-induced cell death, I 
wanted to investigate if MLKL is phosphorylated during dl922-947 infection. 
Therefore, TOV21G cells were either vehicle treated, treated with TSZ or with 
dl922-947 and changes in MLKL phosphorylation were analysed by western blot. 
 
Figure 4-31 shows that MLKL is expressed during mock- and TSZ treatment as 
well as during dl922-947 infection, but phosphorylated MLKL is only observed 
during TSZ treatment. 
 
Figure 4-31: pMLKL levels during dl922-947 infection 
TOV21G cells were mock-treated, treated with 20ng/mL TNF-α, 1µM Smac-mimetic and 25µM 
Z.VAD.fmk (TSZ) for 6 hours or infected with dl922-947 at MOI 10 for 48 hours. Samples were then 
prepared for western blot and analysed for pMLKL (54 kDa), MLKL (54 kDa) and GAPDH (37 kDa). 
Shown is one representative western blot from two experiments. pMLKL= phospho-MLKL. 
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4.4 Discussion 
Adenoviruses were discovered first in 1953 (Rowe et al. 1953)and ever since then 
extensive research has been performed to better understand their nature. This 
research also includes insights into mechanisms adenoviruses employ to avoid 
immune cell detection and the induction of host-controlled cell death 
mechanisms to contain infection and further spread. For a long time, it was 
thought that adenoviruses induce apoptosis in host cells, but research from as 
early as 1992 (White et al. 1992)described that adenoviral genes encode proteins 
that can interfere with the intrinsic as well as extrinsic apoptotic machinery 
(Han et al. 1996a, Debbas and White 1993, Tollefson et al. 1991), which stands 
in conflict with the assumption that they induces apoptosis. Further, recent 
research performed by the host lab and others has shown that adenoviruses 
induce a novel mode of cell death that resembles necrosis (Baird et al. 2008). 
 
Characterization of the ovarian cancer cells IGROV1, OVCAR4 and TOV21G 
showed that IGROV1 was resistant to apoptosis induced by TS, while OVCAR4 did 
undergo apoptosis during TS treatment, which could be rescue by Z.VAD.fmk and 
TOV21G was able to undergo apoptosis induced by TS as well programmed 
necrosis induced by TSZ. Further characterization of those cell lines showed that 
only few of them expressed the protein RIPK3, which determines if a cell can 
undergo programmed necrosis (Cho et al. 2009). Interestingly though, recent 
research has shown that RIPK3 is repressed through methylation near its 
transcriptional start site (Koo et al. 2015). The authors showed that normal cells 
express RIPK3 and suggest that upon tumour development RIPK3 deficiency is 
positively selected since it contributes to chemosensitivity through the induction 
of programmed necrosis. This would also explain why RIPK3 expression has been 
rarely observed in ovarian cancer cell lines. OVCAR4 cells expressed low amounts 
of RIPK3, but were not able to undergo programmed necrosis. This might be due 
to the fact that RIPK3 expression was too low to activate the threshold needed 
to induce programmed necrosis with TSZ. Further, morphological 
characterization during TSZ treatment confirmed that TOV21G cells were able to 
undergo programmed necrosis in response to TSZ. 
 
I then decided to perform two small experiments with dl922-947, which should 
give an indication on if dl922-947 induces apoptosis.  Apoptosis is a tightly 
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regulated form of cell death, which depends on the activation of aspartate-
specific cysteine proteases (Caspases). Caspases play important roles in the 
induction, transduction and amplification of apoptotic signals and can therefore 
be categorised into initiator caspases (Caspase 2, 8 and 9) and effector caspases 
(Caspase 3, 6 and 7) (Tait and Green 2010). Research has discovered several 
proteins encoded by the adenoviral genome that can interfere with the 
apoptotic machinery, like E3A 10.4K/14.5K (Also known as RIDα/β) that are able 
to down-regulate the cell death surface receptors like TNFR1, FAS, TRAILR1/2, 
which can stimulate caspase 8 activation and though there are known viral 
proteins that inhibit caspases directly as competitive, irreversible (e.g. 
baculovirus protein p35 (Clem, Fechheimer and Miller 1991) and Cowpox virus 
protein CrmA (Gagliardini et al. 1994)) none has been described for adenoviruses 
yet.   
 
When dl922-947 infected cells were treated with Z.VAD.fmk either no rescue in 
cell death or, in the case of TOV21G, attenuation was observed. This observation 
was very interesting, since the host lab had published results showing that 
adenovirus infection can lead to the minor activation of procaspase 3 (Baird et 
al. 2008). This leads to the conclusion that firstly, though adenoviruses can block 
and interfere with intrinsic and extrinsic apoptosis signalling, the activation of 
procaspase 3 is still possible through not yet identified mechanisms, and 
secondly although there is minor procaspase 3 activation, it does either not 
contribute towards virus-induced cell death since blocking caspases with 
Z.VAD.fmk showed no effect on death or that there is not enough procaspase 3 
activation to pass the threshold to lead to the induction of apoptosis. In the 
context of TOV21G and adenovirus infection this gets even more interesting. 
TOV21G can undergo programmed necrosis as shown before, whilst during 
adenovirus infection and Z.VAD.fmk treatment, caspases are being inhibited, 
which leads to attenuated cell death, which has been described extensively as a 
phenomenon that has been observed in and is associated with programmed 
necrosis (Vercammen et al. 1998). This is another indicator that adenoviruses 
cannot directly block caspases or at least, that they are not efficient in blocking 
them. Another method of studying the involvement of apoptosis is by using 
overexpression models of anti-apoptotic proteins like BCL-2. Alterations in anti-
apoptotic proteins like BCL-2 can contribute to the pathogenesis and progression 
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of human cancers since BCL-2 overexpression can block the intrinsic apoptosis 
signalling by blocking the activation of BAX and BAK, but again overexpression of 
anti-apoptotic BCL-2 was not able to rescue dl922-947 –induced cell death, 
indicating that apoptosis is not induced. Further, it has been shown that 
adenoviruses encode proteins that can interfere with the induction of MOMP; for 
example E1B-19K functions as an anti-apoptotic MCL-1 viral mimetic that targets 
BAX and BAK, therefore inhibiting MOMP. 
 
Overall, these findings, in accordance with findings previously published (Baird 
et al. 2008, Abou El Hassan et al. 2004) and in accordance with findings showing 
that adenovirus contain a multitude of proteins that specifically inhibit apoptosis 
(Tollefson et al. 2001, Han et al. 1996a, Schreiner et al. 2010, Tollefson et al. 
1998, Schneider-Brachert et al. 2006, Luo et al. 2007), lead to my conclusion 
that apoptosis is not involved in dl922-947-induced cell death. 
 
Further morphological characterization of TOV21G during dl922-947 infection 
showed that cells morphologically showed a necrotic phenotype. This was very 
interesting since pharmacological and or antibody inhibition of TNF-α, RIPK1 and 
RIPK3 was not able to rescue dl922-947-induced death. Furthermore knock-down 
of MLKL was also not able to rescue cell death, making those major programmed 
necrosis components redundant. Interestingly, though pharmacological inhibition 
of RIPK3 was not able to attenuate cell death, siRNA-mediated knock-down was. 
Since siRNA-mediated knock-down showed that RIPK3 protein levels were down-
regulated over the complete time course of infection, I decided to give more 
weight to these results. Further, experiments performed with shRNA for 
confirmation, failed due to unstable knock-down (Data not shown). These data 
show that dl922-947 does not induce classical programmed necrosis through 
TNF/TNFR ligation, but rather might use one of the many other programmed 
necrosis pathways that have been described (Han et al. 2011b, Kalai et al. 2002, 
Thapa et al. 2013). One of those has been described by the lab of Pascal Meier 
(Tenev et al. 2011), who showed the formation of a RIPK1-dependent death-
inducing complex called the ripoptosome, which forms upon genotoxic stress. 
This complex was able to induce caspase-dependent apoptosis as well as 
regulated necrosis independently of death ligands. Therefore, dl922-947 could 
potentially induce necrosis through the induction of the ripoptosome. It has 
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been shown that dl922-947 induces genomic DNA damage through the induction 
of DNA double strand breaks leading to the accumulation of γH2AX and RAD51 
foci (Connell et al. 2011), a hallmark of cellular genotoxic stress (Lisby et al. 
2004, Shah and O'Shea 2015) while at the same time inhibiting the repair 
mechanisms employed by cells to maintain genomic integrity (Boyer, Rohleder 
and Ketner 1999, Brestovitsky et al. 2016). This accumulation of DNA damage 
leads to the induction of genotoxic stress, which can then result in RIPK1-
dependent cell death either through apoptosis or necrosis. Since experiments 
with dl922-947 suggested that RIPK1 expression is redundant, I further concluded 
therefore that the ripoptosome is also not the mediator of cell death-induced by 
dl922-947 infection. 
 
Interestingly, so far the only indication that TOV21G undergoes necrosis during 
dl922-947 infection has been observed by siRNA-mediated knock-down of RIPK3 
and by observing morphological changes. Besides trying to inhibit cell death 
induced by dl922-947, I made observations that indicated that dl922-947-
induced cell death could be increased. This would be is of high relevance since 
one of the long-term aims is to identify targets that can increase oncolytic 
adenovirus efficacy. As mentioned earlier, Z.VAD.fmk was able to attenuate cell 
death induced by dl922-947 in necrosis competent cells and interestingly, this 
attenuated form of cell death was rescued in cells that had CRISPR/Cas9-
mediated down-regulation of MLKL. Therefore I conclude that in necrosis-
competent cells during dl922-947 infection, necrosis is not efficiently induced; 
firstly because siRNA-mediated RIPK3 knock-down was not able to completely 
rescue cell death and secondly because dl922-947 does not encode a direct 
inhibitor of Caspase 8, but upon inhibition of caspase 8 (as shown by Z.VAD.fmk 
experiments), the cell was able to induce programmed necrosis, which resulted 
in increased death, which in turn could be rescued by knock-down of MLKL.  
 
Besides trying to block apoptosis in necrosis-competent cells to increase dl922-
947 efficacy, the addition of recombinant hTNF-α can also attenuate cell death 
in certain cell lines. When OVCAR4 cells were infected with dl922-947 and 
recombinant hTNF-α was added, cell death was attenuated. Interestingly, this 
increase in cell death could only be partly rescued by the addition of Z.VAD.fmk, 
which showed that it was not completely of an apoptotic nature. This suggests 
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that the addition of hTNF-α can result in the induction of different cell death 
modalities in OVCAR4, since the treatment of dl922-947-infected cells with 
Z.VAD.fmk did neither completely rescue nor increase cell death. As I have 
shown before, OVCAR4 cells do not undergo programmed necrosis in response to 
TSZ, though they express small amounts of RIPK3, but the addition of hTNF-α in 
the context of dl922-947 infection might be able to pass the threshold to induce 
necrosis, and apoptosis to certain levels. Interestingly research performed by 
(Hirvinen et al. 2015) showed that a chimeric oncolytic adenovirus expressing 
hTNF-α (Ad5/3-D24-hTNFα) showed an increase in cytotoxicity in vitro and in 
vivo in a syngeneic melanoma model in immunocompetent C57Bl/6 mice, 
compared to a chimeric oncolytic adenovirus that does not express hTNF-α 
(Ad5/3-D24). Further, they were able to show that Ad5/3-D24-hTNFα increased 
immunogenicity and anti-tumour responses and that tumours treated with 
Ad5/3-D24-hTNFα and radiotherapy underwent apoptotic and necrotic cell 
death. Also, research performed by Nogusa, et al. has shown that host cells can 
activate parallel pathways of necroptosis and apoptosis to protect against 
influenza A virus infection (Nogusa et al. 2016). 
 
 
To conclude this chapter, I have been able to show that the adenovirus deletion 
mutant dl922-947 does not induce apoptosis in the ovarian cancer cell lines 
IGROV1, OVCAR4 and TOV21G and that upon dl922-947 infection cells undergo 
morphological changes that strongly resemble necrosis. Further analysis of 
proteins involved in the programmed necrosis pathway showed that cell death 
induced by dl922-947 was independent of TNF-α, RIPK1 and MLKL, therefore 
excluding the involvement of classical programmed necrosis induced by 
TNF/TNFR ligation and by the ripoptosome. Further analysis showed that the 
inhibition of caspases in necrosis competent cells might be of therapeutic value 
as well as arming oncolytic adenoviruses with TNF-α. 
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5 Devising a RIPK3 overexpression model for in vivo 
studies 
5.1 Introduction 
In the previous chapter, my results suggested that inhibition of RIPK3 using small 
molecule inhibitors had little effect upon the efficacy of dl922-947, but siRNA-
mediated knockdown partially reversed dl922-947 cytotoxicity in TOV21G. 
Therefore, I wanted to further investigate whether over-expression RIPK3 
influenced adenovirus induced cell death in vitro and in vivo.  
 
5.2 RIPK3 overexpression increases dl922-947 induced cytotoxicity 
HeLa WT cells do not express RIPK3 and therefore do not undergo programmed 
necrosis in response to TSZ. However, the laboratory of Dr. Stephen Tait has 
cloned the sequence of human RIPK3 into a retroviral vector allowing the 
expression of human RIPK3. HeLa wild type cells were transduced with the 
retroviral vector Lzrs encoding human RIPK3 and tested for their expression of 
RIPK3 and their ability to undergo programmed necrosis when treated with a 
necrotic stimulus (TSZ) and following dl922-947 infection. 
 
As seen in figure 5-1A HeLa Lzrs cells containing the empty vector express no 
detectable RIPK3 by immunoblot. Following selection, HeLa cells transduced 
with the Lzrs-RIPK3 lenivirus were dilution cloned and four separate single cell 
clones were expanded and analysed by western blotting. The selected clones 
express slightly different amounts of RIPK3. Figure 5-1B shows that all RIPK3 
expressing clones undergo cell death when treated with TS, which induces 
apoptosis. HeLa Lzrs cells also undergo minor apoptosis following TS treatment, 
which can be rescued by the addition of the pan-caspase inhibitor Z.VAD.fmk. A 
small amount of rescue (approx. 10%) can be observed in the clones B2, E4 and 
E10. The addition of the MLKL inhibitor NSA was able to almost completely 
rescue TSZ-induced cell death, except for the clones D2 and E10. Only 50% total 
cell survival was achieved in clone D2 and 85% in cloneE4 and E10 when cells 
were treated with TSZ and additional NSA. Figure 5-1C and D show that RIPK3 
expression significantly increases adenovirus-induced cytotoxicity and that the 
increase in cytotoxicity was RIPK3–dependent, since addition of the RIPK3 
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inhibitor GSK’840B restored cell survival to similar levels of the empty vector 
control (Figure 5-1E).  
 
Figure 5-1: RIPK3 overexpression attenuates dl922-947-induced cell death  
A) HeLa WT cells were either transduced with an empty Lzrs vector or one containing human 
RIPK3. Cells were selected, dilution cloning performed and protein samples taken to evaluate 
RIPK3 expression by western blot.  
B) Cell were treated with different combinations of 20ng/mL TNF-α, 1µM Smac-mimetic, 25µM 
Z.VAD.fmk and 3µM NSA to induce cell death, programmed necrosis or to rescue programmed 
necrosis. Cell death was measured 24 hours after treatment using MTT assay. Points represent 
mean +/- STDEV from one experiment performed in triplicate wells. P values were calculated using 
One Way ANOVA with multiple comparisons, ***shows p<0.001                                                         
C) HeLa cells Lzrs or RIPK3 dilution clones were infected with dl922-947 in triplicate at indicated 
MOI. Cell survival was assessed 120 hours post-infection by MTT assay. Points represent mean 
+/- STDEV of one experiment performed in triplicate wells.  
D) HeLa Lzrs and Hela RIPK3 expressing cells were infected with dl922-947 and their respective 
EC50 values for differences analysed. P values are calculated using unpaired t test, **shows 
p<0.01. 
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E) HeLa cells Lzrs or HeLa RIPK3 clone D2 were either treated with 10µM GSK’840B or vehicle 
and infected with dl922-947 in triplicate at indicated MOI. Cell survival was assessed 120 hours 
post-infection by MTT assay. Points represent mean +/- STDEV of one experiment performed in 
triplicate wells.                                                                                                                                       
 
Next I wanted to investigate if the overexpression of RIPK3 would affect virus 
and viral protein production, since this can affect overall viral cytotoxicity. 
Therefore, I infected Hela Lzrs and the Hela RIPK3 clones D2 and E4 with dl922-
947. Protein lysates were harvested at 0, 24 and 48 hours post-infection and 
analysed by western blot. 
 
Picture 5-2 shows the expression of viral proteins in dl922-947 infected HeLa 
Lzrs and HeLa RIPK3 D2 and E4 cells. As expected no viral proteins were 
detected at 0 hours post infection. Expression of viral E1A can be observed at 24 
hours post-infection. E1A expression is stronger in clone D2 and E4 at 24 hours 
post-infection in comparison to Lzrs but decreases more rapidly in both RIPK3-
expresing clones by 48. The expression of viral core and capsid proteins is similar 
in Lzrs, HeLa RIPK3 D2 and E4. 
 
Figure 5-2: RIPK3 expression leads to changes in the expression of viral proteins   
HeLa Lzrs (Lzrs), HeLa RIPK3 D2 (D2) and HeLa RIPK3 E4 (E4) were infected with dl922-947 at 
MOI 10 for 0, 24 and 48 hours. Sample were taken and further analysed for β-actin (42 kDa), E1A 
(25-35 kDa) and Anti-Adenovirus (40-100 kDa) by western blot. Shown is one representative 
western blot from two experiments. Lanes E4 48 hours and 24 hours have been labelled 
deliberately this way. 
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Next, I wanted to assess if RIPK3 expression could influence the production of 
infectious viral particles, since an increase in viral particle production could 
explain the increase in cytotoxicity. Figure 5-3 shows a TCID50 time plot of 
intracellular virus production between HeLa Lzrs and HeLa RIPK3 D2 and E4 cells 
over a period of 72 hours. The graph shows that virus production is slightly 
higher in clone E4 in comparison to Lzrs and clone D2 at 24 hours post-infection. 
Overall clone D2 produces a lower titre, while clone E4 and Lzrs produce similar 
amounts of virus at 48 and 72 hours post infection. 
 
Figure 5-3: RIPK3 expression leads to changes in the production of infectious viral particles 
HeLa Lzrs (Lzrs), HeLa RIPK3 D2 (RIPK3 D2) and HeLa RIPK3 E4 (RIPK3 E4) were infected with 
dl922-947 at MOI 10 over a time course of 72 hours. Viral titres were determined by TCID50 assay. 
Points represent mean +/- STDEV from one experiment performed in quadruplicate. 
 
Next I analysed if the expression of RIPK3 leads to differences in viral infectivity 
leading to an increase in virus-induced death. Therefore, HeLa Lzrs and HeLa 
RIPK3 clone D2 and E4 were infected with the E1 deleted non-replicating type 5-
adenovirus Ad-GFP, and infectivity determined 24 hours post-infection using flow 
cytometry. 
 
Figure 5-4 shows differences in infectivity between HeLa Lzrs and the HeLa 
RIPK3 clones D2 and E4. GFP positivity was the same at MOI 5 , while at MOI 50 
slight differences in infectivity could be observed at between Lzrs (97.3% GFP 
positive), HeLa RIPK3 D2 (97.2% GFP positive) and HeLa RIPK3 E4 (93.2% GFP 
positive). Table 13 summarises the percentage of GFP positive cells per 
condition as shown in figure 5-4. 
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Table 13: Percentage of GFP positive cells for each condition. 
 GFP positivity (%) 
Cell line Mock dl922-947 MOI 5 dl922-947 MOI 50 
HeLa Lzrs 0 68 97.3 
HeLa RIPK3 D2 0 67.4 97.2 
HeLa RIPK3 E4 0 67.3 93.2 
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Figure 5-4: HeLa clones expressing RIPK3 show no difference in infectivity  
A) HeLa Lzrs,  
B) HeLa RIPK3 D2 and 
C) HeLa RIPK3 E4 were either infected with dl922-947 or Ad-GFP at MOI 5 or MOI 50 for 24 hours 
in duplicate. After 24 hours, cells were prepared for flow cytometry analysis. Cells were analysed 
for GFP expression after 10,000 events were recorded. Shown are represented graphs from one 
experiment performed in duplicate. Orange lines indicated dl922-947, while green lines indicate 
Ad-GFP MOI 5 and purple lines indicate Ad-GFP MOI 50 infected samples. 		
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5.3 Investigating the assembly of a RIPK3-containing death complex 
during dl922-947 infection 
Since HeLa RIPK3 clones contain the normal and functional sequence of human 
RIPK3, I aimed to analyse the formation of the necrosome in HeLa RIPK3 
expressing cells. The necrosome consists of the proteins RIPK1, RIPK3 and MLKL 
(Vandenabeele et al. 2010b, Vandenabeele et al. 2010a).  
 
RIPK3 immunoprecipitation was performed in HeLa Lzrs and HeLa RIPK3 clone 
D2, to assess antibody specificity. As shown in figure 5-5 a RIPK3 pull-down was 
only detected in cells that express RIPK3. Further, a RIPK3 band was also 
detected in the supernatant, while no RIPK3 was seen in IgG-IP. As expected, no 
RIPK3 pull-down was seen in HeLa Lzrs cells. Interestingly, unspecific bands 
could be detected in non-IP samples. 
 
	
Figure 5-5: RIPK3 immunoprecipitation in HeLa RIPK3 clone D2 and HeLar Lzrs.                          
HeLa RIPK3 clone D2 and HeLa Lzrs samples were taken and prepared for immunoprecipitation 
with a RIPK3 or mouse IgG control antibody followed by western blot analysis. Samples were 
blotted IPK3 (57 kDa). One whole representative western blot from two experiments is shown. 
Arrow indicates RIPK3 band at 57kDa. 
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Co-immunoprecipitation of RIPK3 was performed on HeLa RIPK3 D2. Cells were 
either treated with TSZ for 1 or 2 hours (positive control) or infected with dl922-
947 at MOI 10 for 24 and 48 hours. Afterwards, samples were prepared for co-
immunoprecipitation of RIPK3 and analysed by western blot. 
 
As shown in figure 5-6, RIPK3 can be successfully pulled down in RIPK3 
expressing HeLa cells. MLKL was co-immunoprecipitated in cells treated with 
TSZ, which is in accordance with the known literature, and was also pulled-down 
in dl922-947 infected cells. However, no co-immunoprecipitation of RIPK1 was 
observed in either TSZ treated or dl922-947 infected cells. Interestingly, a 
strong band was detected in both dl922-947 infected samples at approximately 
45kDa, which was not seen in any of the other samples. 
 
Figure 5-6: RIPK3 co-immunoprecipitation during dl922-947 infection in Hela RIPK3 clone D2 
HeLa RIPK3 clone D2 cells were either treated with 20ng/mL TNF-α, 25µM Z.VAD.fmk and 1µM 
LCL-161 (smac mimetic) for 1 and 2 hours or infected with dl922-947 at MOI 10 for 24 and 48 
hours. Samples were taken and prepared for co-immunoprecipitation with a RIPK3 antibody 
followed by western blot analysis. Samples were blotted for RIPK1 (78 kDa), RIPK3 (57 kDa) and 
MLKL (54 kDa). One representative western blot from two experiments is shown. Arrows indicate 
RIPK1, RIPK3 or MLKL in accordance with staining shown. 	
It has been shown that several viruses encode proteins that are able to interfere 
with the necrotic machinery (Wang et al. 2014b) by interactions with RHIM 
domain of RIPK3 leading to a block in the induction of programmed necrosis in 
the host cell. Therefore, I wanted to investigate if viral proteins were co-
immunoprecipitated with RIPK3. I made use of an Anti-Adenovirus type 5 
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antibody that recognises several viral proteins including hexon and penton base 
as well as several adenovirus core proteins. Therefore, samples used in figure 5-
6 were re-run, and analysed for viral proteins using an Anti-Adenovirus type 5 
antibody. 
 
Figure 5-7 shows that RIPK3 co-immunoprecipitation lead to the pull-down of 
three viral proteins. The three bands that were co-immunoprecipitated in dl922-
947 treated cells were detected at an approximate molecular weight of 110 – 
150 kDa and a double band at around 60 - 80 kDa. They could be detected at 24 
as well as 48 hours post-infection. Further, pull-down of these viral proteins 
increased from 24 to 48 hours post-infection and was not due to changes in 
RIPK3 pull-down as shown in figure 5-6. Interestingly, the band observed at 
approximately 45kDa in figure 5-6 was observed when the anti-Adenovirus 
antibody was used, suggesting that it might not be a viral protein. 
 
Figure 5-7: RIPK3 co-immunoprecipitation during dl922-947 infection in Hela RIPK3 clone D2 
leads to the pull-down of adenoviral proteins 
HeLa RIPK3 clone D2 cells were either treated with 20ng/mL TNF-α, 25µM Z.VAD.fmk and 1µM 
LCL-161 (smac mimetic) for 1 and 2 hours or infected with dl922-947 at MOI 10 for 24 and 48 
hours. Samples were taken and prepared for co-immunoprecipitation with a RIPK3 antibody 
followed by western blot analysis. Samples were blotted anti-Adenovirus (14-110 kDa). One 
representative western blot is shown. Arrows indicate viral proteins that have been pulled down 
with RIPK3. 	
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5.4 RIPK3 overexpression reduces xenograft tumour growth in CD1 
nude mice  
To determine if RIPK3 expression affects tumour growth in CD1 nude mice, mice 
were injected with HeLa Lzrs or HeLa RIPK3 expressing cells. Tumour growth was 
monitored by external measurement. After tumours reached between 50-
100mm3 in volume, mice were randomly separated into two groups with one 
group receiving 50µL of PBS and the other one receiving 1x1010 particles of 
dl922-947 intra-tumourally. Mice were culled 48 hours post virus/PBS injection. 
 
Figure 5-8 shows tumour growth in mice over time frame of 19 days. As shown 
tumours start out at similar tumour volumes (HeLa Lzrs: 45mm3, HeLa RIPK3 D2: 
47mm3 and HeLa RIPK3 E4: 41mm3). Over time, two distinct growth patterns 
evolve with HeLa Lzrs tumours growing more rapidly over time in comparison to 
HeLa RIPK3 expressing tumours. At day of virus or PBS injection HeLa Lzrs 
tumours are significantly bigger in size than RIPK3 expressing tumours. At day of 
injection HeLa Lzrs tumours are 175mm3 in volume, HeLa RIPK3 D2 are 96mm3 
and HeLa RIPK3 E4 tumours are 78mm3 in volume. 
 
Figure 5-8: Tumour volume growth  
CD1 nude mice were injected subcutaneously with 5x106 cells per mouse and tumours were grown 
until they reached between 50-200mm3 in volume. Then mice were either injected intra-tumourally 
with 50µL PBS or 1x1010 particles of dl922-947. 48 hours after virus or PBS injection, mice were 
culled and tumours taken. Arrow indicates day of virus or PBS injection.                                            
P values are calculated using unpaired one tailed t-test, * shows p<0.05. 	
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5.5 HeLa RIPK3 cells retain RIPK3 expression after injection into CD1 
nude mice 
It has been shown recently, that in many cancers RIPK3 expression is repressed 
due to methylation-dependent mechanisms near its transcriptional start site, 
leading to greater resistance to death-induced by death receptor ligands and 
surprisingly to a greater resistance to chemotherapeutic agents (Koo et al. 
2015). Further, it has been shown that the microenvironment can alter 
epigenetic and gene expression profiles (Hamm et al. 2010) and that tumours 
themselves can induce alterations in genomic DNA-methylation in the 
microenvironment to aid tumour growth (Xiao et al. 2016). Therefore, the 
transplantation of human cancer cells into mice could lead to a change in the 
methylation status of RIPK3 to create a more tumorigenic microenvironment. 
 
To assess if tumours altered their RIPK3 expression after injection into CD1 nude 
mice, three random HeLa Lzrs and three random HeLa RIPK3 expressing 
subcutaneous tumours were taken for western blot analysis to confirm RIPK3 
protein expression. 
 
As shown in figure 5-9 HeLa RIPK3 cells injected into CD1 nude mice retain their 
RIPK3 expression in vivo.  
 
 
Figure 5-9: HeLa RIPK3 clones retain their RIPK3 expression after subcutaneous injection 
into mice 
Tumours of three mice injected with HeLa Lzrs and three mice injected with HeLa RIPK3 cells were 
prepared for western blot. Western blot confirmed that tumours of mice injected with HeLa’s that 
express RIPK3 retain their expression in an in vivo environment. Samples were blotted for β-actin 
(42 kDa) and RIPK3 (57 kDa). 
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5.6 RIPK3 expression in subcutaneous tumours does not affect 
adenovirus protein expression in vivo 	
Since tumours in mice were grown subcutaneously, direct injection of virus or 
PBS into the tumour site was chosen for delivery.  Expression of viral proteins in 
subcutaneous tumours was analysed by immunohistochemistry to evaluate 
distribution of dl922-947, 48 hours post-infection. 
 
 
As shown in figure 5-10 and figure 5-11 tumours injected with dl922-947 express 
E1A as well as adenoviral core and capsid proteins in comparison to PBS injected 
tumours, which don’t. Further, histoscoring on tumours using a programmed 
algorithm showed that there was no significant difference between the 
expression of adenoviral E1A or adenoviral capsid and core proteins in HeLa Lzrs 
and HeLa RIPK3 tumours in vivo. 
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Figure 5-10: RIPK3 expression does not increase E1A protein expression in vivo.  
A) HeLa Lzrs 
B) HeLa RIPK3 D2 and  
C) HeLa RIPK3 E4 expressing tumours were processed for E1A immunohistochemistry by the 
Histology service at the CRUK Beatson Institute. Pictures were taking using a light microscope. 
IgG controls were used as negative control to confirm specificity of the antibody.                            
D) E1A histoscores of dl922-947 injected tumours were analysed. No significant difference was 
observed between Lzrs and RIPK3 expressing cells.  
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Figure 5-11: RIPK3 expression does not increase the expression of viral core and capsid 
proteins in vivo 
A) HeLa Lzrs  
B) HeLa RIPK3 D2 and  
C) HeLa RIPK3 E4 expressing tumours were processed for α-Adenovirus immunohistochemistry 
by the Histology service at the CRUK Beatson Institute. IgG controls were used as negative control 
to confirm specificity of the antibody.                             
D) Anti-Adenovirus histoscores of dl922-947 injected tumours were analysed. No significant 
difference was observed between Lzrs and RIPK3 expressing cells. 
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5.7 RIPK3 expression increases adenovirus efficacy and necrosis in 
vivo 
Next, I wanted to investigate further if the expression of RIPK3 would increase 
the amount of necrosis induced by dl922-947. Unlike apoptosis, there are no 
validated biochemical or IHC markers of necrosis for use in vivo.  However, 
necrosis can be defined as regions within the tumour that lack nuclei. To 
measure the necrotic area, E1A positive slides were scanned and uploaded to 
slidepath. The desired files were opened and the draw-polygon tool was chosen. 
Using the draw polygon tool the necrotic area was outlined within the tumours 
and measured. The necrotic area was then normalized to the total tumour area 
and calculated at percentage of total tumour area. 
 
Figure 5-12A shows an example of how the necrotic area within a tumour section 
was measured. As shown in figure 5-12B, expression of RIPK3 leads to a 
significant increase in necrosis in dl922-947 infected cells in vivo in comparison 
to HeLa Lzrs tumours infected with dl922-947. 
 
Figure 5-12: Tumours expressing RIPK3 show an increase in adenovirus-induced necrosis 
in vivo  
A) shows an example of how necrotic area was measured using slidepath.  
B) The necrosis area in HeLa Lzrs and HeLa RIPK3 tumours treated with PBS or dl922-947 was 
measured using slidepath. Necrosis area is shown as a percentage of whole tumour section. 
 P values are calculated using unpaired t test, * shows p<0.05 and **p<0.01. 
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Since RIPK3 expression in dl922-947 infected cells lead to an increase in cell 
death in vitro, I next assessed if RIPK3 overexpression in a human xenograft 
model would increase dl922-947 efficacy in vivo.  CD1 nude mice were injected 
with HeLa Lzrs or HeLa RIPK3 expressing cells. Tumour growth was monitored by 
external measurement. After tumours reached between 50-100mm3 in volume, 
mice were randomly separated into two groups with one group receiving two 
doses of 50µL of PBS and the other one receiving two doses of 1x109 particles of 
dl922-947 intra-tumourally. Mice were monitored and tumour volume measured.  
 
Figure 5-13 shows dl922-947 efficacy in vivo. Figure 5-13A and B shows growth of 
HeLa Lzrs and HeLa RIPK3 tumours respectively. In the HeLa Lzrs mice, 
treatment with dl922-947 produced no significant reduction in tumour volume 
compared to PBS. By contrast, two intra-tumoural injections of dl922-947 
produced a significant reduction in HeLa RIPK3 tumour volumes. 
	
Figure 5-13: RIPK3 expressing increases dl922-947 efficacy in vivo                                               
24 CD1 nude mice were randomly separated into two cohorts of 12 each and 
A) either injected subcutaneously with 5x106 HeLa Lzrs cells per mouse. Tumours were grown until 
they reached between 50-200mm3 in volume. 23 days post-injection mice were again randomly 
separated into cohorts of six and either twice-injected intra-tumourally with 50µL PBS or 1x1010 
particles of dl922-947.                                                                                                                                       
B) 12 CD1 nude mice were injected with 5x106 HeLa RIPK3 cells. Tumours were grown until they 
reached between 50-200mm3 in volume. 28 days post-injection mice were again randomly 
separated into cohorts of six and either twice-injected intra-tumourally with 50µL PBS or 1x1010 
particles of dl922-947. Tumour growth was monitored every second or third day. Mice were either 
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killed when tumours reached 1.4cm3 in volume or if they showed signs of ill health. Arrows indicate 
days of PBS and dl922-947 injection. 
P values are calculated using unpaired one tailed t-test, *shows p<0.05. 
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5.8 RIPK3 expression does not alter macrophage and neutrophil 
migration in vivo 
Recent research has shown that the immune system plays an essential role in the 
efficacy of oncolytic virotherapy (Tong et al. 2012, Chiocca and Rabkin 2014), 
which lead to the development of viral strains that express factors like cytokines 
and chemokines that increase an anti-tumour response in clinical trials 
(Andtbacka et al. 2015, Cripe et al. 2015, Hemminki et al. 2015). Furthermore, 
research in reovirus has shown that a robust immune-dependent anti-tumour 
response was observed that was independent of viral replication and lysis 
(Prestwich et al. 2009). 
 
CD1 nude mice have a dysfunctional and rudimentary thymus leading to a great 
reduction in T cells. This allows the engraftment of many different types of 
tissues and tumours. Although CD1 nude mice have a greatly reduced number of 
T cells, they still produce normal Antigen presenting cells (APC), NK cells and 
cells of myeloid lineage. 
  
As shown above, RIPK3 expression leads to an increase in dl922-947 efficacy; to 
assess if the increase in efficacy was aided by an increase in immune cell 
infiltration, I aimed to investigate if RIPK3 expression and/or dl922-947 infection 
in tumours lead to changes in macrophage and neutrophil migration. 
 
First I analysed if RIPK3 expression would influence the infiltration of 
macrophages into xenograft tumours. Figure 5-14 shows F4/80 
immunohistochemistry performed on PBS and dl922-947 injected tumours. As 
shown in figures 5-14B and C, there was a non-significant trend towards reduced 
macrophage infiltration in dl922-947-treated tumours.  However, expression of 
RIPK3 made no difference to this in macrophage infiltration. 
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Figure 5-14: RIPK3 expression and/or dl922-947 infection does not alter macrophage 
migration                                                                                                                                              
A) HeLa Lzrs and RIPK3 expressing tumours were processed for F4/80 immunohistochemistry and 
pictures were taking using a light microscope. IHC staining for a PBS or dl922-947 treated tumour 
is shown.                                                                                                                                            
B) F4/80 histoscores of dl922-947 or PBS injected tumours.                                                              
C) Combined F4/80 histoscores from two independent experiments. Filled in symbols represent an 
experiment were CD1 nudemice were injected with HeLa Lzrs or HeLa RIPK3 expressing cells. 
Tumours were grown until they reached between 50-200mm3 in volume. Then mice were either 
injected intra-tumourally with 50µL PBS or 1x1010 particles of dl922-947. 48 hours after virus or 
PBS injection, mice were culled and tumours taken. Empty symbols represent tumours that have 
been grown exactly the same but tumours were injected with 5x1010 particles of dl922-947. 
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Figure 5-15A shows that dl922-947 infection leads to an increase in neutrophil 
infiltration in a xenograft model. Immunohistochemical analysis of HeLa Lzrs and 
HeLa RIPK3 expressing tumours showed that RIPK3 expression did not lead to a 
significant increase in neutrophil migration (Figure 5-15B), but interestingly 
dl922-947 infection lead to a significant increase in neutrophil migration. 
 
Figure 5-15: dl922-947 infection leads to an increase in neutrophil migration                             
A) HeLa Lzrs and RIPK3 expressing tumours were processed for NIMP immunohistochemistry and 
pictures were taking using a light microscope. Shown is IHC staining for a PBS or dl922-947 
treated tumour.                                                                                                                                     
B) NIMP histoscores of dl922-947 or PBS injected tumours.                                                               
C) Combined NIMP histoscores from two independent experiments. Filled in symbols represent an 
experiment were CD1 nude mice were injected with HeLa Lzrs or HeLa RIPK3 expressing cells. 
Tumours were grown until they reached between 50-200mm3 in volume. Then mice were either 
injected intra-tumourally with 50µL PBS or 1x1010 particles of dl922-947. 48 hours after virus or 
PBS injection, mice were culled and tumours taken. Empty symbols represent tumours that have 
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been grown exactly the same but tumours were injected with 5x1010 particles of dl922-947.              
P values are calculated using unpaired t test, *shows p<0.05 and ***p<0.001. 
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5.9 Discussion 
For a long time, necrosis was thought to be a form of unregulated cell death in 
response to accidental tissue injury.  However, recent research has shown that 
programmed necrosis is a regulated type of cell death that is distinguishable 
from apoptosis and autophagy. In the centre of this pathway is the protein 
RIPK3, which induces programmed necrosis when apoptosis is blocked or 
inhibited, allowing cells to die from an alternative pathway in response to 
stress, injury or infection. Recent research in programmed necrosis in cancer 
cell lines has shown that RIPK3 is often silenced due to methylation dependent 
mechanisms, giving cancerous cells a potential survival advantage (Morgan and 
Kim 2015, Koo et al. 2015), and analysis of RIPK3 expression in ovarian cancer 
cell lines has shown the same. Using HeLa cells, I aimed to generate another cell 
line with stable overexpression of human RIPK3 to assess the therapeutic value 
of RIPK3 expression during adenovirus infection.  
 
HeLa cells were retrovirally transduced and RIPK3 expressing cells selected by 
their zeocin resistance. Though a calculated MOI is used for transduction, often 
the MOI will vary from cell to cell within the same culture. This can lead to the 
integration of different copy numbers of the target gene into the host genome, 
therefore affecting the amount of protein expression and as shown by western 
blot, dilution cloning of HeLa RIPK3 expressing cells lead to the isolation of 
clones with slightly different levels of RIPK3 protein expression. Further 
characterization using TSZ showed that RIPK3 expressing cells were able to 
undergo programmed necrosis, while interestingly, clones varied in overall cell 
survival post TSZ treatment. This could be either due to the slight differences in 
RIPK3 expression or due to differences in the vector integration locus between 
the different RIPK3 clones. A different integration locus could potentially 
activate or inactivate other genes in the clones that are important for cell death 
induction and therefore lead to differences in cell death upon TSZ stimuli. 
During dl922-947 infection, RIPK3 expressing clones showed a higher sensitivity 
towards cell death compared to empty vector cells and this increase in cell 
death showed to be RIPK3-dependent, since the inhibition of RIPK3 using the 
RIPK3 specific inhibitor GSK’840B reversed the amount of cell death to similar 
levels of HeLa Lzrs cells.  
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Further analysis of RIPK3 expressing cells also showed that during dl922-947 
infection a RIPK3/MLKL-containing complex is formed 48 hours post-infection. 
Interestingly no association of RIPK1 was observed in this complex, which further 
shows that RIPK1 is redundant in dl922-947-induced death and necrosis can be 
RIPK1-independent as shown by others (Tomasella, Blangy and Brancolini 2014, 
He et al. 2011). The formation of RIPK3 containing complexes that induce 
programmed necrosis has been extensively described (He et al. 2011, Upton, 
Kaiser and Mocarski 2012). Especially in viral induced necrosis, it has been shown 
that RIPK3 can associate with viral gene products like HSV1 ICP6 (Huang et al. 
2015) or other cellular proteins like DAI (Upton et al. 2012) to inhibit, interfere 
or induce programmed necrosis. Interestingly, using an antibody that detects 
several viral core and capsid proteins showed the association of three viral 
proteins with RIPK3 during viral infection. This suggests that adenoviruses might 
also encode proteins that can manipulate the necrotic machinery. Further, 
previous data showing that RIPK1 and MLKL are dispensable for dl922-947 
induced cell death might be due to dl922-947 encoding proteins interfering with 
necrotic machinery. Also, data produced using TOV21G showed interesting, 
albeit partially contradictory results, about the involvement of RIPK3 in 
adenovirus-induced death leaving room for the involvement of viral proteins that 
encode inhibitors of necrosis. 
  
Next, RIPK3’s effects on viral infectivity, replication and expression of proteins 
were further assessed. Interestingly RIPK3 expression did not interfere with viral 
infectivity, but western blot analysis of viral E1A showed that E1A was up-
regulated in RIPK3 expressing HeLa cells at 24 hours post-infection. Proteins that 
are encoded by E1A are involved in the activation of viral transcription and in re-
programming cellular gene expression to aid viral replication, therefore up-
regulation of E1A in RIPK3 expressing cells might be a result of differences in 
those cellular events. Considering that it has been shown that the 
overexpression of RIPK3 alone can trigger cells to undergo programmed necrosis, 
cells expressing RIPK3 might change the expression of those proteins to avoid 
the induction of cell death. Interestingly, it has been shown that the over-
expression of E1A is able to induce apoptosis (Mymryk, Shire and Bayley 1994, 
Rao et al. 1992). If RIPK3 expression was to alter the expression of proteins 
involved in cell death, the up-regulation of E1A would not induce apoptosis in 
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those cells and rather benefit viral replication and analysis of viral replication 
showed that at 24 hours post-infection the same or a higher viral titre could be 
produced in RIPK3 expressing cells compared to non-RIPK3 expressing HeLa Lzrs. 
This observation was in line with research showing that E1A expression levels 
affect viral replication. Zheng, et al. observed that high levels of E1A could 
increase virus replication that resulted in higher viral titres (Zheng et al. 2005). 
Interestingly, Hela RIPK3 clone D2 was not able to reach similar titres to clone 
E4 or HeLa Lzrs and produced lower titres from 48 hours post-infection; this 
might be due to an early induction of cell death through necrosis. 
 
To further assess the therapeutic value of RIPK3 expression, a human xenograft 
model was used to evaluate whether RIPK3 expression would increase adenovirus 
efficacy in vivo. First, tumour growth of subcutaneous injected HeLa Lzrs and 
HeLa RIPK3 cells was assessed. Results suggested that expression of RIPK3 
slowed subcutaneous growth, as has been observed in previous research using a 
xenograft model with RIPK3 overexpressing KYSE410 cells (Xu et al. 2014), where 
they showed that differences in tumour growth were due to RIPK3-mediated 
necrosis. Once tumours reached between 50-200mm3, tumours were injected 
with PBS or 1x109 particles of dl922-947. IHC showed that there was no 
difference in E1A and adenoviral core and capsid protein expression between 
HeLa Lzrs and HeLa RIPK3 expressing tumours. Interestingly, while there was no 
difference in viral protein expression in tumours, tumours expressing RIPK3 
showed significantly higher amounts of virus-induced necrosis. Most importantly, 
my results indicated that RIPK3 expression significantly improved dl922-947 
efficacy in this subcutaneous HeLa xenograft model. 
 
Next I aimed to assess the effects of RIPK3 expression and dl922-947 infection on 
innate immune cell migration in human tumour xenografts. Infection with dl922-
947 appeared to decrease macrophage infiltration, albeit non-significantly. 
Research published by others also showed that infection with Ad5 showed a 
decrease in macrophage infiltration in a model of ovarian cancer (Thoma et al. 
2013) and work performed by others has further showed that Intravenous Ad5 is 
absorbed by liver Kupffer cells (Lieber et al. 1997) and IHC on livers of mice that 
have been injected intravenous with Ad5 showed a reduction in F4/80-positive 
staining (Khare et al. 2013). Also work published by Passaro, et al. showed that 
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dl922-947 infection impaired macrophage infiltration in an anaplastic thyroid 
carcinoma model (Passaro et al. 2016). Interestingly, dl922-947 infection lead to 
a significant increase in neutrophil infiltration compared to PBS treated 
tumours. For a long time it has been thought that necrosis is more pro-
inflammatory than apoptosis, but recent research has shown the opposite. 
Kearney, et al. have shown that TNF-induced necrosis suppresses the production 
of TNF-induced pro-inflammatory cytokines and chemokines through excessive 
cell death, thereby. Therefore showing that necroptosis can actually suppresses 
inflammation. When female mice were injected with LPS and LPS/Z.VAD.fmk, 
LPS treatment alone lead to an increase in splenic neutrophils, F4/80+ 
macrophages, eosinophils and B- and T-lymphocytes in mice while this effect 
was diminished in LPS/Z.VAD.fmk treated mice (Kearney et al. 2015).  
 
Concluding this chapter, I have been able to devise a RIPK3 overexpression 
model in HeLa cells for in vivo studies. I have shown that HeLa RIPK3 expressing 
cells undergo programmed necrosis, which can be rescued by common necrosis 
inhibitors. Further I have been able to show that RIPK3 expression increases viral 
cytotoxicity due to an increase in necrosis in vivo and that adenovirus infection 
stimulates the formation of a RIPK3 and MLKL death complex. Western blot 
analysis of this death complex showed the association of adenoviral proteins, 
which have not been characterised yet. 
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6 Final Discussion 
In 2005, H101 became the first approved oncolytic therapy in combination with 
chemotherapy for squamous cell cancer of head and neck or oesophagus in China 
(Garber 2006). Though it showed promising results in clinical and pre-clinical 
settings, it didn’t take long to discover its limitations, which lead to the 
exploration of other alternative viral vectors for oncolytic therapies. However, 
for successful use in clinical settings, oncolytic viruses have to fulfil certain 
criteria to allow for their safe use. They have to replicate selectively in a wide 
range of tumour cells while not affecting healthy tissues. Further they should be 
able to induce immunogenic cell death, a form of cell death that can stimulate 
anti-tumour immunity.  
 
Several adenoviruses have been used in clinical setting (Including ONYX-015, 
H101 and EnAd), all of which demonstrated their safety for use in patients. Many 
of those oncolytic adenoviruses have been genetically modified to ensure that 
they selectively replicate in cancerous cells. One of the most commonly Ad5-
based oncolytic adenoviruses carries a 24bp mutation in the E1A gene (E1AΔ24), 
which is involved in releasing E2F from the Rb/E2F complex to promote cell 
entry into S-phase for viral replication and due to this mutation E2F cannot be 
released from the RB/E2F complex, therefore oncolytic viruses carrying this 
mutation take advantage of cells that have high levels of free E2F for their 
replication leading to an increase in cancer cell specific lysis and in their safety.  
 
Besides the use of deletion mutants, adenoviruses with transgenes and other 
modifications are being developed to increase their efficacy or their ability to 
stimulate an immune-mediated anti-tumour response. Adenoviruses of the 
serotype 5 (Ad5) are commonly used for Ad-based vectors, but it has been shown 
that one of the big hurdles in using adenovirus serotype 5 (Ad5)-based vectors is 
that their primary entry receptor CAR is commonly down-regulated in several 
human tumours (Hulin-Curtis et al. 2016), although new research from the host 
lab has shown that in ovarian cancers, CAR expression is up-regulated in 
paclitaxel-resistant cells. This observation could have positive implications in 
future clinical use if it can be further validated and offer help to women that 
are resistant to paclitaxel (Ingemarsdotter et al. 2015). To further increase the 
transduction of Ad5-based vectors, the viral fiber can be modified by inserting 
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an RGD-motif. This modification can increase the interaction with integrins, 
which are highly expressed on some cancers and it also has been shown that the 
fiber itself can be replaced with other serotype fibers to use different receptors 
like CD46, which is used by adenoviruses of the serotype 35. Though CD46 is 
highly expressed on many cancers, this has to be taken with a grain of salt since 
Ad5 vectors bearing the Ad35 fiber knob proteins also down-regulate CD46. 
 
Though cancer cell specific lysis has been shown to be effective in vitro, 
xenograft models and certainly human solid tumours are considerably more 
complex systems, since they are heterogeneous structures that contain not only 
malignant cells but also cells such as fibroblasts, endothelial cells and immune 
cells, which make up the tumour microenvironment that helps promote tumour 
growth. Dense extracellular matrix (ECM), abnormal vasculature, cancer-
associated fibroblasts, increased fluid pressure and hypoxic areas within the 
tumour can hinder viral spread, therefore oncolytic adenoviruses that can target 
the extracellular matrix and angiogenesis are needed to increase anti-tumour 
efficacy. Over the past years oncolytic adenoviruses expressing molecules that 
disrupt the ECM (Lee et al. 2013, Vera et al. 2016), target abnormal vasculature 
(Thaci et al. 2013, Choi et al. 2015), target hypoxic environments (Cuevas et al. 
2003, Post et al. 2004), that modulate the immune status of the tumour to aid 
immune cell infiltration (Koski et al. 2010, Ranki et al. 2016, Vassilev et al. 
2015) or express cytokines (Hirvinen et al. 2015) to induce cell death or activate 
and stimulate immune cells (Manetti et al. 1993, Freytag, Barton and Zhang 
2013, Pesonen et al. 2012) have be generated and shown to increase viral spread 
in tumour models and reduce tumour formation and progression. But as research 
by others has shown, extensive research has to be put into those modified 
viruses since the insertion of target peptides can also change or alter viral 
tropisms (Lucas et al. 2015). 
 
Besides improving oncolytic viruses by using modifications, better understanding 
of viral infection, replication, spread and virus-induced killing can further help 
to improve their efficacy. In this thesis, I aimed to investigate how the Ad5 
deletion mutant dl922-947 induces cell death in ovarian cancer cells. A special 
emphasis was put on the involvement of programmed necrosis in dl922-947-
induced death in ovarian cancer, since research published by the host lab and 
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others showed that dl922-947 does not induce apoptosis and death rather 
resembled necrosis (Baird et al. 2008).  
 
I have been able to show that during infection cells undergo morphological 
changes that strongly resemble necrosis rather than what for a long time has 
been thought to be a death of an apoptotic nature. Interestingly, upon further 
characterisation it was observed that cell death induced by dl922-947 was 
independent of TNF-α, RIPK1 and MLKL, which form part of the major 
components of the classical programmed necrosis pathway. Also necrosis 
induced by the ripoptosome could be excluded since RIPK1 is a critical 
component of this pathway, but showed to be redundant in dl922-947-induced 
death. Further, using a RIPK3 overexpression model, I was able to show that 
RIPK3 expression significantly increases viral efficacy due to an increase in 
necrosis in vivo and further stimulates the formation of an RIPK3/MLKL 
containing complex that associates with unknown viral proteins. These results 
lead to my conclusion that cell death-induced by dl922-947 heavily depends on 
the cellular context and that upon viral infection several different cell death 
mechanisms can be induced. In the context of endogenous RIPK3 expression 
dl922-947 does not induce apoptosis as shown by the host lab (Baird et al. 2008) 
and by research showing that adenoviruses efficiently block apoptosis. 
Interestingly, during dl922-947 infection cells undergo morphological changes 
that resemble programmed necrosis even though death is RIPK1, MLKL and TNF-
α-independent and only partly RIPK3-dependent. The use of multiple parallel 
death pathway modalities by a cell could explain this and in the case of 
Influenza A virus, Nogusa et al, have shown that RIPK3 can activate parallel 
pathways of MLKL-driven necroptosis and FADD-mediated apoptosis (Nogusa et 
al. 2016). Another indicator is that adenoviruses do not encode any direct 
inhibitors of caspases or in the case of programmed necrosis; they do not encode 
a direct inhibitor of caspase-8, which is needed for successful induction of 
RIPK3, but upon inhibition of caspase-8, cells can efficiently induce programmed 
necrosis. Interestingly, cells do not undergo apoptosis even when they do not 
express RIPK3, which could be an indicator for the involvement of another cell 
death mechanisms other than apoptosis or classic programmed necrosis, but with 
necrotic morphology. In the case of RIPK3 overexpression, cells undergo RIPK3-
dependent cell death that involves the formation of a RIPK3/MLKL containing 
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death complex that associates with viral proteins and efficiently leads to 
necrosis. Figure 6-1 summarises the scenarios of death-induced by dl922-947 
depending on RIPK3 status in ovarian cancer cells. 
 
 
Figure 6-1: Cell death modalities induced by dl922-947 depending on RIPK3 status in 
ovarian cancer cells in vitro                                                                                                                
A) In the presence of endogenous RIPK3 levels cells undergo RIPK1, MLKL and TNF-α-
independent cell death that is partially RIPK3-dependent.                                                                                            
B) When RIPK3 is not expressed cell undergo cell death that resembles necrosis, but is RIPK1, 
RIPK3 and MLKL-independent but not apoptotic.                                                                                
C) When RIPK3 is overexpressed cells form a RIPK3/MLKL containing complex with unknown viral 
proteins that efficiently induces RIPK3-dependent necrosis in vitro. 	
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In addition to necrosis induced through TNF/TNFR and the ripoptosome, other 
pathways of programmed necrosis have been described in the recent years. One 
of those includes the induction of regulated necrosis through TLR3 and TLR4. 
Interestingly, it has been shown that necrosis induced by those TLR’s can be 
independent of RIPK1 and especially in the context of adenovirus infection, 
where TLR’s will be activated might be worth of further investigation. Of special 
interest here is necrosis-induced by TLR3. TLR3 is located at the endosome, 
where it detects PAMPs like dsRNA, which are produced as part of the viral 
replication cycle, while those RNA transcripts are common to RNA viruses, it has 
been suggested that DNA viruses might produce RNA transcripts that can engage 
TLR3 (Hoebe et al. 2003) as well. Therefore dl922-947 could also use an 
alternative form of programmed necrosis that has not been covered in this 
thesis. 
 
One of the main questions that remains, however, is if inducing necrosis in 
cancer cells is of therapeutic value. For a long time, it was thought that 
apoptosis does not induce inflammation. The reason behind this was that upon 
apoptosis cells undergo organised morphological changes that include cell 
shrinkage and the initial maintenance of their plasma integrity before they are 
being ingested by phagocytes. Necrotic cell death on the other hand has been 
associated with stimulating a strong host inflammatory response due to cell 
swelling and the rapid loss of membrane integrity, which leads to the release of 
damage-associated molecular patterns (DAMPS) and the attraction and 
infiltration of immune cells leading to immunogenic cell death. However, 
research has shown that things are more complicated than that and that 
apoptosis can be indeed of immunogenic nature while cells dying from necrosis 
can be less immunogenic. Kearney, et al. have shown that TNF-induced necrosis 
suppresses the production of TNF-induced pro-inflammatory cytokines and 
chemokines through excessive cell death, and showed that necroptosis can 
actually suppress inflammation. Further, the early and excessive induction of 
death can hinder viral replication and therefore reduce further infection of 
tumour cells. Therefore, though necrosis was thought to be favourable due to its 
fast acting dynamics and its association with the release of DAMP’s, the real 
benefits of inducing necrosis need to be further evaluated. Especially in a viral 
context this includes the characterisation and identification of DAMP’s that are 
		
187	
being released, how necrosis affects the production of inflammatory cytokines 
and chemokines, the production of viral titres and viral intra-tumoural spread 
and its importance towards inducing immunogenic cell death. 
 
In the past few years, oncolytic virotherapy has advanced considerably with the 
development of highly selective strains and the generation of strains that 
express therapeutic gene products that showed effective anti-tumour properties 
in pre-clinical models. One of those oncolytic adenoviruses is EnAd, which is 
currently undergoing several early phase clinical trials, one of which evaluates 
its use as a treatment for women with platinum-resistant ovarian cancer, making 
adenovirus-based oncolytic therapy an interesting and promising therapeutic 
approach for cancer. 
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